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2 Abbreviations and acronyms 
(v/v)   volume/volume percent 
(w/v)   weight/volume percent 
1D   1st dimension/one-dimensional 
2D   2nd dimension/two-dimensional 
5-HIAA  5-hydroxyindolacetic acid 
AA   amino acid 
Ala   alanine 
APCI   atmospheric pressure chemical ionization 
API   atmospheric pressure ionization 
ASA   acetylsalicylic acid 
Asn   asparagine 
Asp   aspartic acid 
AUC   area under the curve 
biol. tripl.  biological triplicate 
calib. tripl.  calibration triplicate 
CD   cyclodextrin 
CDW   cell dry weight 
CE   capillary electrophoresis 
corr.   corrected 
COW   correlation optimized warping 
csv   character separated value 
CVal   cross-validation 
Cys   cysteine 
đ   mean difference 
DDA   dodecanoic acid 
ECD   electron capture detector 
E. coli   Escherichia coli 
EDTA   ethylenediaminetetraacetic acid 
EI   electron ionization 
FAME   fatty acid methyl ester 
FC   fold change 
FDA   Food and Drug Administration 
 V
FDR   false discovery rate 
FID   flame ionization detector 
FPR   false positive rate 
GABA   γ-aminobutyric acid 
GC   gas chromatography 
GC×GC  comprehensive two-dimensional gas chromatography 
Gln   glutamine 
Glu   glutamic acid 
Glucose-6P  glucose-6-phosphate 
Gly   glycine 
GUI   graphical user interface 
HCA   hierarchical cluster analysis 
HepDA  heptadecanoic acid 
HexDA  hexadecanoic acid 
HPLC   high-performance liquid chromatography 
ID   internal diameter 
Ile   isoleucine 
IS   internal standard 
LB   Luria-Bertani 
LC   liquid chromatography 
Leu   leucine 
LLOQ   lower limit of quantification 
LMCS   longitudinal modulating cryogenic system 
LOD   limit of detection 
LOQ   limit of quantification 
LR   linear range 
Lys   lysine 
m/z   mass-to-charge ratio 
MCF   methyl chloroformate 
Met   methionine 
MS   mass spectrometry/mass spectrometer 
MS/MS  tandem quadrupole mass spectrometry 
MPS   multipurpose sampler 
MSTFA  N-methyl-trimethylsilyltrifluoroacetamide 
 VI
NA   nonanoic acid 
NAD+/NADH  nicotinamide adenine dinucleotide (oxidized and reduced form) 
NADP+/NADPH nicotinamide adenine dinucleotide phosphate (oxidized and 
reduced form) 
NDA   nonadecanoic acid 
NIST   National Institute of Standards and Technology 
NMR   nuclear magnetic resonance 
NPD   nitrogen phosphorus detector 
OD   optical density 
ODA   octadecanoic acid 
PARAFAC  parallel factor analysis 
PCA   principal component analysis 
PCDA   principal component discriminant analysis 
PCF   propyl chloroformate 
PDA   pentadecanoic acid 
Phe   phenylalanine 
PLS-DA  partial least squares - discriminant analysis 
Pro   proline 
PTV   programmed-temperature vaporization 
QC   quality control 
qMS   quadrupole mass spectrometry 
R   correlation coefficient 
R2   square of the linear regression coefficient R 
ROC   receiver operator characteristic 
RSD   relative standard deviation 
RT   retention time 
S/N   signal-to-noise ratio 
SC   Statistical Compare 
SD   standard deviation 
Ser   serine 
SIM   selected ion monitoring 
SPME   solid-phase microextraction 
TCA   tricarboxylic acid cycle/citric acid cycle 
TDA   tridecanoic acid 
 VII
 VIII
TE   technical error 
TeDA   tetradecanoic acid 
Thr   threonine 
TIC   total ion chromatogram 
TMS   trimethylsilyl 
TOF   time-of-flight 
TPR   true positive rate 
Tyr   tyrosine 
U   unique 
U-13C   uniform 13C labeled 
UDA   undecanoic acid 
ULOQ   upper limit of quantification 
Val   valine 
 
 3 Motivation 
The metabolome represents the quantitative complement of low molecular-weight 
metabolites present in a cell or body fluid under certain physiological conditions. It 
reflects the cellular processes and thus directly the biochemical phenotype of a living 
system. Metabolomics is defined as the systematic study of metabolites and their 
response to environmental, nutritional, genetic, and pathophysiological influences. 
The ultimate objective is the quantitative analysis of the entire metabolome in a 
single run. Currently, not a single method, but rather a combination of analytical 
techniques is required to accomplish this challenging task because of the greatly 
differing physicochemical properties of the hundreds to thousands of metabolites 
present in biological systems.1, 2 
Metabolomics data is typically tackled by employing either metabolic fingerprinting or 
metabolite profiling approaches. Metabolic fingerprinting assembles all the analytical 
information gathered from a sample and thus provides a snapshot of metabolism at a 
given state, while metabolite profiling focuses on the quantitative analysis of a 
metabolite class or metabolites associated with a selected biochemical pathway.2 
Gas chromatography coupled to mass spectrometry (GC-MS) has become a 
common tool for metabolomic investigations.3 Despite its excellent chromatographic 
resolution, one-dimensional (1D) GC cannot resolve the multitude of metabolites 
present in physiological fluids or tissue/cell extracts. Comprehensive two-dimensional 
gas chromatography (GC×GC) uses a thermal modulator incorporated between two 
columns with orthogonal separation characteristics and thus enables a multiplicative 
increase in peak capacity, enhanced resolution, lower limits of detection (LODs), and 
a structured separation space.4 Coupled to an electron ionization (EI) fast acquisition 
time-of-flight mass spectrometer (TOFMS) for the identification and quantification of 
analytes, GC×GC is perfectly suited for metabolic fingerprinting. 
Aim #1: Development of a data processing strategy for comparative metabolic 
fingerprinting by GC×GC-TOFMS 
Setup and validation 
The initial goal of this present work was the development and validation of an 
algorithm for the processing of GC×GC-TOFMS metabolic fingerprinting data for the 
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 comparative characterization of multiple samples and their constituents. To this end, 
initial data processing functions provided by the LECO ChromaTOF software, such 
as baseline correction, spectrum deconvolution, and peak detection, combine, 
integration, and identification, were adopted to generate a peak list for every sample 
analyzed. For a comparative analysis, identical peaks had to be recognized across 
all peak lists. Due to a lack of efficient solutions for data alignment, the Integrative 
Normalization and Comparative Alignment (INCA) module was developed that in a 
first step compensated for run-to-run retention time (RT) fluctuations before aligning 
the entire data from all peak lists into one final data matrix according to 1st dimension 
(1D) and 2nd dimension (2D) retention times as well as mass spectral information. 
The area integral of the m/z 73 ion trace of the trimethylsilyl (TMS) group was 
employed as a quantitative measure originating from the characteristic fragmentation 
behavior of silylated metabolites upon EI ionization. Statistical classification and 
testing strategies were used to visualize the data and to determine differences in 
metabolite abundance, respectively. The accuracy of peak detection and alignment 
of 1.1- to 4-fold changes in metabolite concentration was validated by a spike-in 
experiment. 
Application 
The GC×GC-TOFMS comparative metabolic fingerprinting strategy was applied to 
the metabolome analysis of two Escherichia coli (E. coli) strains which vary in 
glycolytic flux distribution. That the signal intensity of the m/z 73 ion reflected true 
differences in metabolite abundance was verified by absolute quantification of class-
distinguishing metabolites using compound-specific fragment ions and stable 
isotope-labeled standards in a separate metabolite profiling approach. 
The same procedure was utilized in 1D mode (GC-TOFMS) to determine differences 
between blood serum and plasma. 
Comparison 
Data acquired for the spike-in experiment and the comparative metabolic 
fingerprinting of E. coli strains were used to directly compare the performance of 
INCA versus the Statistical Compare (SC) alignment tool, which recently became 
commercially available as an add-on option for ChromaTOF version 4. Advantages 
and limitations of the two algorithmic data processing strategies were assessed. 
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 Aim #2: Performance evaluation and application of GC×GC-TOFMS metabolite 
profiling 
Another objective was the comprehensive evaluation of GC×GC-TOFMS in 
comparison to other GC-MS techniques for metabolite analysis. For this purpose, 
GC×GC-TOFMS was evaluated against GC-APCI-TOFMS, GC-EI-TOFMS, GC-CI-
qMS, and GC-EI-qMS in terms of reproducibility, dynamic range, and limits of 
detection and quantification using a mix of 43 metabolites from different chemical 
classes and metabolic pathways and 12 stable isotope-labeled standards. 
Further, a GC×GC-TOFMS metabolite profiling approach was established for the 
analysis of amino acid enantiomers (AAEs) as their methanol/methyl chloroformate 
derivatives (MeOH/MCF). The goal was to improve enantiomer resolution and 
quantification compared to a previously published 1D-GC-qMS approach with single 
ion monitoring (SIM) 5 by using a combination of a γ-cyclodextrin (CD) chiral 1D 
column (Rt-γDEXsa) and two different 2D columns. The method was applied to the 
analysis of sera of patients suffering from liver cirrhosis. 
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 4 Background 
An abbreviated version of this chapter was published in Analytical Bioanalytical 
Chemistry.6 Parts were also published in book chapters 7 and 8. 
4.1 Metabolomics 
Metabolomics or metabonomics, both terms are nowadays used interchangeably 9, is 
an intrinsic part of systems biology, which focuses on the study of molecular 
components (genes, transcripts, proteins and metabolites) in a biological system and 
the complex interactions of these constituents. The transcriptome, proteome, and 
metabolome all reflect the physiological status of a cell, tissue, or organism and their 
response differs upon both genetic and environmental (age, diet, disease, drug, 
lifestyle) influences (Figure 4.1). 
 
Environment
Figure 4.1. Complex interactions of constituents from all functional levels and the 
environment generate the phenotype. Based on its downstream position the metabolome 
represents the most immediate measure of the biological phenotype. Modified from 10. 
Alterations at the metabolite level (concentration and flux) tend to be more 
pronounced than at the transcript or protein level as the metabolome is positioned 
farthest downstream of gene expression and closest to the biological phenotype. 
Additionally, primary metabolism is a highly dynamic system. Opposed to turnover in 
the proteome and transcriptome (minutes to hours), metabolic flux operates on time 
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 scales of seconds. The study of the metabolome, whether applied individually or in a 
more integrated way, is a sensitive and rapid phenotypic measure for detecting 
altered physiological states.11-14 
4.1.1 The fundamentals of metabolomics 
Metabolomics is the systemic study of metabolite profiles, their composition and 
dynamics as influenced by genetic modifications, physiological stimuli, 
environmental, nutritional or other factors. Metabolites are low molecular-weight 
organic (or inorganic 15, 16) compounds (< 1,500 Da) that are formed by the numerous 
biosynthetic and catabolic pathways within a biological system (endogenous) or 
originate from host-specific microbes and the consumption of food nutrients and 
pharmaceuticals (exogenous). The ultimate ambition in metabolomics studies is the 
global detection and quantification of all metabolites in a single analysis. Although the 
number of metabolites in most organisms is estimated to be lower than that of genes 
and proteins, a holistic analysis by a single analytical platform may remain 
technologically infeasible due to the great chemical diversity of metabolites present 
over a wide concentration range.17-20 
Compared to the chemically very similar nucleotides in genomics and transcriptomics 
and amino acids in proteomics, the metabolome consists of various substance 
classes, including alcohols, ketones, carbohydrates, amino and organic acids, lipids, 
nucleotides, polyols, and others. Metabolites can therefore vastly differ in molecular 
weight, size, charge, volatility, acidity, polarity or hydrophobicity. Due to this broad 
chemical space, special branches, such as lipidomics and glycomics, have 
developed within the field of metabolomics.21-23 
The number of metabolites is organism and sample type dependent. While 
prokaryotes, like E. coli, hold approximately 750 metabolites 24, the number for 
eukaryotic systems can range from around 1100 in yeast 25 to many thousands in 
humans 26, 27 and up to tens or hundreds of thousands in plants 28, 29 and fungi 30. In 
higher organisms multiple metabolomes (specific cell, tissue, biofluid, and 
microbiomes of the gastrointestinal tract) coexist that vary distinctly in number and 
types of metabolites present. To date metabolic databases only contain a fraction of 
all metabolites, lacking many lipids, xenobiotics, their metabolites, and metabolites 
emerging from interacting metabolomes.31-33 
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 4.1.2 Strategies in metabolomics studies 
Albeit the terminology differs among related publications, commonly two 
experimental strategies are applied to metabolomic research, targeted (metabolite 
profiling and metabolite target analysis) and untargeted studies (metabolic 
fingerprinting and metabolic footprinting). Examples are shown in Figure 4.2. 
 
Figure 4.2. The most common strategies in metabolomics research. Reproduced from 6. 
Metabolite profiling focuses on the analysis of a limited number of (generally known) 
metabolites associated with a selected biochemical pathway (e.g. TCA cycle) or a 
specific class of compounds (e.g. amino acids, fatty acids).34 Metabolite target 
analysis is a more specific approach, which concentrates on selected analytes only, 
e.g. biomarkers of disease. Both strategies are classically hypothesis-driven and 
mostly provide absolute quantification of metabolite concentrations with high 
accuracy and precision, and low detection limits. On the other hand, metabolic 
fingerprinting is a non-biased hypothesis-generating approach with the experimental 
goal to gather analytical information on an extensive range of intra-cellular 
metabolites directly yielding a snapshot of metabolism at a given time.35, 36 The 
metabolic fingerprints are screened comprehensively for signals that distinguish 
populations. Such global studies are typically carried out on analytical platforms with 
fast acquisition rates. Due to extremely large datasets chemometric or comparative 
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 visualization techniques are often required. The equivalent to metabolic fingerprinting 
at the extracellular level is called metabolic footprinting.37, 38 In contrast to targeted 
analyses the simultaneous detection of hundreds to thousands of metabolites in a 
single analysis is usually accompanied by limited metabolite information (lots of 
unknowns are detected) and a lack of absolute quantitative data. A targeted follow-up 
study with a directed sample preparation is recommended to verify interesting 
identifications. 
4.2 Experimental preparation 
A metabolomics study is divided into sample collection and preparation, data 
acquisition and processing, bioinformatic analysis, and interpretation. In addition, 
method optimization and validation, and an appropriate quality control play an 
essential role. Various parameters determine a well-thought-out experimental design. 
Depending on the biological system that is being studied an adequate number of 
samples per group need to be obtained. The more complex the metabolome the 
more samples are recommended. However, sample sizes can be reduced if certain 
factors (age, gender, etc.) are controlled or a time-series experiment on the same 
individuals is performed. During sample preparation artificially introduced variability 
has to be kept at a minimum to avoid compositional changes of the metabolome. 
That is usually facilitated by standardized quenching, extraction, and derivatization 
protocols. 
4.2.1 Quenching and extraction 
Quenching, the process of decreasing or completely inhibiting enzymatic activity, can 
be accomplished by freezing in liquid nitrogen, acid treatment or by using cold-
buffered methanol solutions.39, 40 The subsequent extraction of metabolites can vary 
according to the experimental strategy. More extensive extraction techniques are 
typically performed for targeted analyses, whereas extraction in untargeted studies is 
optimized towards detecting as many metabolites as possible. 
Solvent and solid-phase extractions are established extraction techniques, but some 
sample types demand additional procedures. Tissue specimens (brain, kidney, etc.) 
require homogenization and mechanical or chemical lysation of cell walls followed by 
liquid–liquid extraction to release and extract intracellular metabolites.41, 42 The high 
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 protein content of serum and plasma specimens requires the precipitation of proteins 
during the extraction process.43, 44 Urine may require urease treatment as high 
concentrations of urea are unfavorable especially for GC-MS analyses.45 Variable 
fluid intake affects the comparison of urinary metabolite patterns. Adjusting sample 
volumes, e.g. based on the creatinine concentration, is advisable. 
4.2.2 Derivatization 
Only few metabolites are naturally volatile (e.g. alcohols, esters, monoterpenes). The 
majority lacks sufficient volatility and, therefore, requires chemical derivatization to 
expand the capacity of metabolites amenable to GC-based methods. There are many 
derivatization techniques that have been tailored for particular metabolite classes, 
such as alkyl chloroformates for amino/organic acids 46, 47 or esterification for fatty 
acids 48. A frequently-used derivatization method is silylation 49 as it modifies a 
diversity of functional groups (hydroxyl, carboxylic acid, amine, amide, imine, thiol, 
phosphate) and, hence, is perfectly suited for untargeted approaches. The 
derivatives generally become less polar, more volatile, and thermally more stable. 
Two-step derivatization, which involves (m)ethoximation forming stable derivatives 
with carbonyl moieties, followed by trimethylsilylation, is a highly versatile procedure 
50 that is routinely used in GC×GC based metabolomics studies (Figure 4.3). 
1. Methoximation
2. Silylation
-OH
-COOH
-SH
-NH
-NH2
-POH
-SOH
+
+
- HCl, -H2OO-Methylhydroxylamine
hydrochloride
MSTFA
(N-methyl-N-trimethylsilyl-
trifluoroacetamide)
-O-Si(CH3)3
-COO-Si(CH3)3
-S-Si(CH3)3
-N-Si(CH3)3
-NH-Si(CH3)3/ N-[Si(CH3)3]2
-PO-Si(CH3)3
-SO-Si(CH3)3
CF3 N
O
CH3
Si
CH3
CH3
CH3
CH3 O NH2 *HCl
R1 R2
O
R1 R2
N
O
CH3
 
Figure 4.3. Example of a two-step derivatization procedure (primarily used in this work). 
Reproduced from 7. 
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 After derivatization a single metabolite can be represented by more than one product 
(feature) and vice versa. While E-Z isomerism of methoxyamines can form two 
signals, partial silylation can form numerous ones for certain metabolites, e.g. amino 
acids. In addition, steric hindrance, degradation or rearrangement reactions can take 
place.49, 51 
4.3 Analytical techniques for metabolome analysis 
An assortment of analytical tools has been used to cope with the complex information 
space in metabolomics research. Nuclear Magnetic Resonance (NMR) spectroscopy 
52, 53, GC-MS 54 and liquid chromatography (LC) – MS 55 are the major techniques in 
use today, but many others have been applied including capillary electrophoresis 
(CE) – MS 56 and infrared/Raman spectroscopy.57 All of these methods can be 
applied to broad metabolite classes, but each one has its distinct advantages and 
disadvantages regarding detection limits, throughput, sensitivity, interferences, and 
the kind of information that is provided. In the end, maximum coverage of the 
metabolome can only be obtained by a combination of analytical platforms (and 
sample preparation techniques).58, 59 
This chapter highlights the analytical techniques that were mainly employed in the 
course of this thesis. 
4.3.1 Comprehensive two-dimensional gas chromatography – time-
of-flight mass spectrometry 
Gas chromatography is an excellent technique for the qualitative and quantitative 
analysis of volatile compounds or analytes that can be derivatized to obtain a 
sufficient vapor pressure. The one-dimensional separation process provides 
adequate resolution for various analytical tasks. However, conventional 1D-GC does 
not suffice to globally resolve the numerous components present in extracts of 
physiological fluids and tissues resulting in many co-elutions. 
There are multiple ways to cope with these co-elutions. Selective sample preparation 
or pre-fractionation is rather suited for the targeted analysis of (also low abundant) 
metabolites than for metabolic fingerprinting, where sample preparation should be 
kept to a minimum to afford coverage of as many metabolites as possible. 
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 Incorporating selective detectors, such as a nitrogen/phosphorus (NPD) or electron 
capture detector (ECD), is another alternative, but again is only advisable if selected 
components are analyzed. A mass spectrometer is a rather universal detector for 
both compound identification and quantification (for more details see chapter 4.4.1). 
Capillary GC in combination with MS has thus become a widely used tool for 
metabolomic investigations.50 However, as current mass spectral deconvolution 
algorithms are only effective to a certain extent and are not helpful in case of 
overlapping isomers, improvement of chromatographic resolution is still desirable. 
Another strategy is to change selectivity, e.g. stationary phase, or to improve column 
efficiency, using for instance a longer column. Since resolution increases only with 
the square root of the column length, changing the selectivity is often more 
appropriate. On the other hand, a different stationary phase may result in baseline 
separation of a given peak pair but can cause co-elutions in other parts of the 
chromatogram. The concept of multidimensional GC (MDGC, GC-GC), which has 
been presented several decades ago 60, serially couples two columns with different 
selectivity. However, in the heart-cut technique at best only few chromatographic 
bands (unresolved peaks) can be selected for further separation on the second 
column rendering the technique unsuited for across-the-board screening of 
metabolites. The introduction of comprehensive two-dimensional gas 
chromatography overcame this limitation. 
4.3.1.1 Fundamentals 
In 1991, Phillips and coworker introduced comprehensive two-dimensional gas 
chromatography, which enables the separation of the complete sample in both 
dimensions.61 Two columns with orthogonal separation characteristics are connected 
in series by a modulator resulting in enhanced resolution, a multiplicative increase in 
peak capacity, and a structured separation space.62 The modulator is located 
between the columns to accumulate/focus the effluent from the first column and 
periodically transfer it to the second column in small concentrated segments.63 In 
case of thermal modulation (see chapter 4.3.1.2) the focusing effect carries the 
additional benefit of creating narrow second dimension peaks and, thereby, 
increasing peak heights that in turn enhance detection sensitivity.64 Due to its 
superior chromatographic resolving power, GC×GC is particularly suitable for the 
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 separation of low molecular-weight analytes in complex samples.61, 65 A picture and 
scheme of the GC×GC setup utilized in this work is shown in Figure 4.4. 
 
Modulator
Hot jets
Cold jets
PTV
Column 1
TOFMS
Column 2
A B
Figure 4.4. (A) Actual and (B) schematic setup of a GC×GC-EI-TOFMS. A thermal modulator 
is used to alternately cool and heat the incoming analytes and to release them periodically in 
packages onto the 2nd dimension column. PTV, Programmed Temperature Vaporizer. 
Reproduced in part from 7. 
4.3.1.2 Modulators 
For a true two-dimensional separation it is necessary to maintain the 
chromatographic resolution achieved in the first dimension. Therefore, at least three 
modulations per peak are required.64 While one fraction of an analyte is separated on 
the second dimension column the next fraction is already sampled in the modulator. 
With peak widths of 6 to 25 seconds in the first column and 3 to 4 required 
modulations the separation in the second column can only last 2 to 8 seconds. 
Consequently, short narrow columns are used for fast analysis in the 2D, because 
the separation on the second column must be finished before the next fraction is 
transferred. Otherwise so-called wrap-around effects can occur. Due to an analysis 
time of 2 – 8 seconds, separations in the 2D are basically isothermal. 
A number of modulators are available.66 They can be divided into flow modulators 
and thermal modulators. Although improvements have been made regarding flow 
modulation 67, thermal modulators have become more prevalent. They use a 
localized temperature difference to create the required retention/release.68, 69 The 
earliest modulators, like the sweeper, have applied heat.61, 70 It consists of a 
modulator capillary that connects the columns and a rotating slotted heater, which 
periodically rotates over the modulator capillary to desorb, spatially compress and 
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 release fractions. Simultaneously, modulators were developed that alternately cool 
and heat one or two segments of the GC capillary (or transfer line) and thus were 
able to achieve a wider volatility range. The first cryo-modulator was the longitudinal 
modulating cryogenic system (LMCS, Figure 4.5).71, 72 The LMCS uses expanding 
liquid carbon dioxide for analyte trapping. It needs no additional heat source as the 
trap after a fixed time interval is moved mechanically to an upstream position in order 
to expose the focused fraction to the GC oven air temperature. 
 A B
Figure 4.5. Schematic diagram of (A) a GC×GC setup using a LMCS and (B) the 
corresponding trap assembly. Modulation is accomplished by pneumatic movement of the 
trap. Liquid CO2 is supplied through a restrictor allowing the liquid to expand. A secondary 
flow of N2 prevents ice build-up at the ends. Taken from 73. 
Today jet-based modulators with either carbon dioxide or (liquid) nitrogen for cooling 
are applied. The main benefit here is the absence of moving parts. In our studies a 
dual-stage four jet modulator is used that consists of two cold jets operating with cold 
nitrogen and two hot jets using hot air (Figure 4.6). The jets are used in alternating 
fashion. The first stage of modulation starts with cooling the eluate. The focused 
fraction is released by a stream of hot air and then trapped again in the second stage 
(cold jet on). Finally, the cold jet in the second stage is turned off and the hot jet 
turned on to transfer the fraction onto the second column. While the fraction is 
released the cold jet in the first stage is turned on again to trap the next fraction. With 
this dual-stage setup one stage is always cold to prevent analyte breakthrough 
during the heating phase. The focusing effect achieved during modulation creates 
very narrow peaks in the range of 50 – 200 ms in the 2nd dimension. Consequently, 
fast detectors are needed to appropriately describe the peaks. 
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Figure 4.6. Simplified representation of a modulation process using a dual-stage four-jet 
modulator. Reproduced from 8. 
4.3.1.3 Detectors 
Acquisition of at least 15 data points across a typical 2D GC peak 100 ms in width 
requires a data acquisition rate of 150 Hz, which can be delivered for example by 
modern generation flame ionization detectors (FIDs) 74 or ECDs 75. However, the 
detection method of choice for metabolomics studies is MS. A mass spectrometer 
provides structural information, which can be used for elucidation of unknowns, and 
high selectivity throughout the chromatogram. While rapid scanning quadrupole mass 
spectrometers suitable for GC×GC are available, most metabolomics studies to date 
have used fast acquisition time-of-flight mass spectrometers with nominal mass 
resolution. GC×GC coupled to an EI-TOFMS is predestined for the characterization 
of metabolic fingerprints taking the entire available (also non-targeted) information 
from all experiments into account for subsequent statistical analysis. TOFMS 
instruments like LECO´s (Corporation, St. Joseph, MI, USA) Pegasus IV are able to 
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 acquire up to 500 mass spectra per second (at unit-mass resolution), which is highly 
suitable for proper reconstruction of the very narrow 2D peaks and reliable 
deconvolution of overlapping peaks. 
4.3.1.4 Data visualization 
GC×GC data are commonly visualized as contour plots. However, the detector 
records a continuous chromatogram. The raw chromatogram is cut into a series of 
individual chromatograms based on the modulation time. These short 2D 
chromatograms are then stacked to each other, creating a three dimensional plane, 
with 1D retention time as x-axis, 2D retention time as y-axis, and peak intensity as z-
axis. The peaks are represented as contour plots or in a 3D view with color coding as 
abundance measure (see Figure 4.7). 
Retention time
S
ig
na
l
S
ig
na
l
2nd dimension 
retention time
Three dimensional representation.
Contour plot.
 
Figure 4.7. Visualization of GC×GC data. The raw GC chromatogram is cut into a series of 
2nd dimension chromatograms whose duration is defined by the modulation time. The 
individual chromatograms are than stacked to each other creating a three dimensional plane. 
Reproduced from 8. 
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 4.3.2 Gas chromatography – atmospheric pressure chemical 
ionization – time-of-flight mass spectrometry 
In 1973, Horning et al. introduced atmospheric pressure chemical ionization (APCI) 
as a soft ionization technique for coupling GC to MS.76, 77 Over the years the 
technique hardly attracted attention until recently, when both Schiewek et al. and 
McEwen and McKay modified an atmospheric pressure ionization (API) source for 
simultaneous operation in LC and GC mode.78, 79 These APCI sources were recently 
made commercially available. They enable hyphenation of GC to high-resolution 
mass spectrometers. 
APCI is widely employed for ionization of small, semi-polar to polar metabolites. The 
soft-ionization technique mainly generates quasi-molecular ions. Fragmentation is 
thus substantially reduced in comparison to hard ionization methods, like EI. A 
corona discharge needle provides electron ionization of the surrounding nitrogen gas. 
The subsequent plasma formation leads to an ion/charge transfer to water vapour. 
The hydronium ion-water clusters then produce the protonated molecular ions. 
Overall, GC-APCI-TOFMS offers high chromatographic resolution and peak capacity 
of volatile compounds in addition to a promising ionization sensitivity and mass 
accuracy for the quasi-molecular ions. The high-resolution accurate mass 
measurement can be utilized to generate a sum formula. Considering in addition the 
isotopic pattern of a feature 80 as well as chemical and heuristic rules 81 will further 
facilitate the determination of unknown analytes. GC-APCI-TOFMS is particularly 
suited for the analysis of complex mixtures, but has only been applied to date in a 
few targeted studies for pharmaceutical research 82, analysis of foodstuff 83, and 
metabolomics 84, 85. 
4.4 From raw GC×GC data to relevant biological information 
A prerequisite for statistical data analysis is an unbiased and reproducible data 
processing. There are two ways of handling the acquired analytical raw data. The 
raw data are either converted to a specific format (typically NetCDF, network 
common data format) and exported for external work-up or processed in situ using 
the vendor software of the instrument manufacturer. In GC×GC-TOFMS based 
metabolomics the main data processing methods applied to raw data include 
 15
 background correction, deconvolution, peak picking, peak integration, and peak 
merging of modulations belonging to one compound. The performance of each 
processing step has an influence on the quality of the final data and, ultimately, on 
the value of biological information extracted from the data. When using vendor 
software typically a peak table is obtained for each sample that typically comprises 
hundreds to thousands of features and their characteristics (1D and 2D retention 
time, mass spectrum, peak area, etc.). A comparative analysis of entire profiles 
requires reliable and automated data alignment to recognize identical metabolites in 
every sample. Data evaluation is achieved by using univariate or multivariate 
statistics. This chapter discusses method development for data processing, 
alignment and analysis and their implementation in metabolomics studies. A general 
overview is given in Figure 4.8. 
Peak alignment
Msort, INCA, 
DISCO, Guineu
ChromaTOFdata processing
- Automated peakdetection
- Spectrum deconvolution
- Peak combine
- Peak identificationPreprocessingtools
- DotMap
- PCA
- Fisher ratio
- S-ratio
RT alignment
Export peak lists
- Including peak true spectra
ChromaTOF
Statistical Compare
Export aligned
peak tablePARAFAC
- Deconvolution
- Quantification Data matrix
- Normalization
- Transformation
- Impute missing values
- Removal of artifacts
Statistical analysis
Validation  
Figure 4.8. Possible routes that have been proposed in GC×GC based metabolomics 
studies to handle raw data. Reproduced from 6. 
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 4.4.1 Data processing 
Deconvolution is a mathematical operation that exploits differences in mass spectral 
information to separate overlapping peaks thereby enhancing the analytical 
resolution even further. It is particularly suited for the complex and large-scale 
datasets generated by the GC×GC-TOFMS instrument. It also yields a “pure” mass 
spectrum for each feature for mass spectral matching, compound identification and 
quantification. Two software packages are commonly used for deconvolution of 
GC×GC-TOFMS raw data, the commercial ChromaTOF software by LECO 
Corporation (St. Joseph, MI, USA) and parallel factor analysis (PARAFAC).86 A third 
software solution that merits mentioning is GC Image.87, 88 However, so far it has only 
been employed in GC×GC-based metabolomics for the processing and construction 
of the GC×GC contour plots of data from FAMEs of various bacteria.89 
4.4.1.1 Deconvolution using ChromaTOF 
ChromaTOF, like other commercial software packages, was originally intended for 
data acquisition and processing of 1D data, but was modified accordingly to handle 
data from 2D separations. ChromaTOF´s most important features besides data 
acquisition certainly are true signal deconvolution®, peak find, second dimension 
peak combine via spectral matching, peak integration and identification (based on 
mass spectral similarity to library spectra), classification, peak table compilation, 
quantification (semiquantitative or based on calibrations), data visualization (3D 
landscape or 2D color plots), and export. Koek et al. (2010) quantitatively evaluated 
the efficiency of the ChromaTOF software in terms of non-targeted GC×GC-TOFMS 
data processing.90 A set of mouse liver specimens and pooled quality controls thereof 
were measured by GC×GC-TOFMS (Figure 4.9) and GC-qMS, and data processing 
results were compared. Targeted GC-qMS data processing involved inspection and, 
if necessary, manual correction of the integration of all quantified metabolites. For 
GC×GC-TOFMS, a target table was constructed manually and missing values across 
the samples were filled by lowering the mass spectral match threshold in a separate 
processing run; the rest (deconvolution, peak find/integration/identification, 2D peak 
combine) was fully automated. Individual peak list entries were quantified based on 
unique masses determined by the ChromaTOF software. 
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 RSDs of the MS response of target compounds found by both GC methods were 
compared. For 70 % of these analytes accurate peak areas could be obtained with 
ChromaTOF. The inaccuracy of the remaining peak areas originated mostly from 
poor deconvolution, which caused errors in combining peaks from the same 
metabolite in the second dimension. 
 
Figure 4.9. Contour plot of a GC×GC-TOFMS total ion chromatogram (TIC) of a pooled 
mouse liver sample. Taken from 90. 
Although the data processing strategy pursued in this paper was very time-
consuming and recommended for studies of 30-50 samples only, the work clearly 
illustrated the need for improvement of existing deconvolution algorithms 
implemented in commercial software (here ChromaTOF). 
4.4.1.2 PARAFAC 
The evolution of PARAFAC 
The PARAFAC algorithm resolves and quantifies target analytes in higher order (3 
and greater) data arrays. More dimensions can be obtained by adding analytical 
dimensions and/or combining multiple samples. For third order instrumentation, like 
GC×GC-TOFMS, only a single sample profile is needed due to the extra dimension in 
chemical selectivity. Sinha et al. (2004) were the first to apply PARAFAC to GC×GC-
TOFMS based metabolomics data. PARAFAC initiated by trilinear decomposition 
(TLD) was used to deconvolute isomers on three overlapping species of possibly 
isomeric monosaccharide derivatives in a chromatographic subregion of a Huilmo 
grass metabolite extract.91 
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 Initially, PARAFAC algorithms always required input on the specific number of factors 
in order to create the deconvolution model, which made it a semi-automated rather 
than a completely automated method. A solution was presented by Hoggard and 
Synovec (2007), who complemented TLD-initiated PARAFAC with an alternating 
least square (ALS) method.92 This improved PARAFAC version automatically 
selected the adequate number of factors by starting off with a one-factor model for 
each sample and maximizing the number of factors (multi-factor model) until 
overfitting (i.e. “splitting” of the analyte signal) occurred. The mass spectral loadings 
of first and second column profiles of each model were matched against the mass 
spectrum of the target analyte. Overfitting was indicated by more than one factor in 
the same model showing match values above a user-defined mass spectral 
threshold. To avoid excessive computation times, the number of factors tested had to 
be limited. 
In 2008, PARAFAC was successfully applied to a respective subsection of different 
GC×GC-TOFMS chromatograms (amongst others a yeast cell extract, Figure 4.10) in 
an automated way without requiring assumptions about analyte identities.93 This non-
targeted method was stated to be applicable to an entire chromatogram by 
individually analyzing all its subsections. However, the time needed to process a 
single sample was estimated to take tens of hours. The samples were spiked with 
compounds yielding known signals to qualitatively validate the performance of the 
method, but no quantitative data was shown. 
 
Figure 4.10. (A) Grayscale TIC 2D separation of the derivatized metabolite raw data 
subsection, loadings on the first (B) and second (C) separation dimension of the selected 
factors; orn, ornithine; cit, citric acid; 4-keto, 4-ketoglucose; arg, arginine; tet, tetradecanoic 
acid; UDP, UDP glucose fragment. Adapted from 93. 
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 In order to find metabolites of interest in the raw data and particularly those that differ 
between samples or sample classes, multivariate analysis tools were employed. 
Deconvolution was then applied only to the interesting regions, which demanded 
considerably less computation time than conventional deconvolution of an entire 
chromatogram. 
PARAFAC preprocessing tools 
In 2004, the DotMap algorithm was developed to quickly locate candidate analytes 
among other sample components by using a weighted mass spectral similarity metric 
to scan all observed mass spectra.94 This dot-product mass spectral matching 
algorithm was applied to find derivatized target metabolites in time segments of raw 
GC×GC-TOFMS data from human infant urine. In case of interference by other 
components respective regions were deconvoluted by TLD-initiated PARAFAC to 
provide pure profiles of the respective target metabolite. 
In 2006, Pierce et al. introduced two approaches to determine natural chemical 
differences between classes of complex samples without a priori knowledge of 
particular target regions. First, a PCA was used prior to PARAFAC deconvolution to 
quickly capture differences between chromatograms (based on the two selective 
mass channels m/z 73 and 217) of organic acid extracts of plant samples.95 Raw 
chromatographic data were translated into lower-dimensional principal components 
(PCs), which were retained and further evaluated when covering a relevant portion of 
the total variance (here PC1 and PC2). Mohler et al. (2006) proceeded similarly to 
identify 26 class-differentiating metabolite peak locations between yeast cell extracts 
grown on different carbon sources. Data from m/z 73, 205, and 387 were subjected 
to PCA, normalized to the summed TIC, and mean centered. Most variable 
metabolites were quantified using an in-house developed PARAFAC graphical user 
interface (GUI).96 In the second approach by Pierce et al. (2006) an automated 
Fisher ratio method was incorporated as a front end tool.97 Contrary to PCA, the 
Fisher ratio technique was supervised and thus more robust against within-class 
variation in discriminating samples. The Fisher ratio method was applied to entire 4D 
datasets (all mass channels were scanned providing another dimension) by using a 
point-by-point indexing scheme (considers each point in the separation space 
independently) for feature selection to discover potential regions with biological 
significance. The method was evaluated by means of a spike-in experiment and 
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 applied to urine specimens from pregnant and non-pregnant women to detect 
unknown differences in organic acid metabolite composition. 
Mohler et al. (2007) 98 took advantage of the progress made in the development of 
chemometric software by applying the Fisher ratio algorithm 97 with the automated 
PARAFAC GUI 92 and a Students´ t-test to the previously analyzed yeast metabolite 
data from cells grown under fermenting and respiring conditions (Figure 4.11). The 
number of group-distinguishing metabolite peaks could be nearly tripled employing a 
Fisher ratio threshold just above the noise level. In addition, Mohler et al. (2008) 
established the signal ratio (S-ratio) method to analyze sample differentiating 
locations of GC×GC-TOFMS data in 24 time interval measurements (injected in 
triplicate) from yeast cells grown under continuous, nutrient-limited conditions.99 The 
S-ratio method was specifically developed to cope with the oscillatory behavior of the 
yeast metabolome as PCA and Fisher analysis were ill-suited for such a large 
number of sample classes and similar metabolite concentrations of contiguous time 
intervals. The phase delay of the cycling metabolites alternated widely in relation to 
the oxygen consumption cycling pattern. The S-ratio captured the amplitude (depth-
of-modulation) of the cycles at each m/z based on the strongest (Smax) and the 
weakest (Smin) signal intensity for each metabolite. Finally, the most selective m/z 
ions for a given metabolite were retained to find locations of those metabolites that 
showed periodic patterns. 
 
Figure 4.11. GC×GC-TOFMS contour plots at m/z 73 of (A) fermenting and (B) respiring 
yeast cells. (C) The sum of Fisher ratios plot for m/z 73-500. The signals in the plot provide 
the locations of chromatographic peaks that differentiate the classes (A) and (B). The 
streaking in (C) originates from trehalose, which is present in excess in (B). Taken from 98. 
For all of the between-species metabolite profiling approaches presented in this 
section relative abundances based on TIC chromatographic peak volumes were 
given for the highly significant component peaks. A prerequisite for proper 
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 implementation of the PCA, Fisher ratio, and S-ratio preprocessing tools, besides a 
sufficient sampling of the first dimension slices to reconstruct a column 1 peak profile, 
was a precise retention time alignment between samples to eliminate retention time 
variations. The next chapter takes a closer look at different alignment algorithms for 
both raw and already processed data. 
4.4.2 Alignment 
Accurate and preferably automated retention time alignment is essential for 
comparative characterization of multiple samples or sample classes. Identical 
metabolites have to be recognized over many GC×GC-TOFMS runs. Alignment of 
metabolic fingerprinting analyses poses a great challenge. The entire available 
information from all experiments has to be taken into account in order to maximize 
the possibility of detecting novel biomarkers. Numerous solutions have been 
presented in recent years for the alignment of GC×GC-TOFMS data. 
In 2005, the first application of GC×GC-TOFMS to a metabolomics study was 
described analyzing tissue extracts from spleens of obese and lean mice.100 In a 
subsequent publication, the same authors applied several univariate analysis 
strategies to the same dataset.101 Chromatogram subtraction, averaging routines, 
weighting factors, Student’s t-test, and automated peak comparison using the 
Compare function implemented in the LECO ChromaTOF software were employed to 
directly compare GC×GC metabolite fingerprints against a reference chromatogram. 
Because not all signals were found in all chromatograms, each sample had to serve 
as reference leading to computing-intensive comparisons. 
In the PARAFAC community, algorithms have been proposed to compensate for run-
to-run variations 102, 103, but they are only applicable to small segments of the 2D 
chromatogram. A retention time correction of the entire chromatogram in both 
separation dimensions was accomplished by Pierce et al. 104 (2005) using an 
indexing scheme with a piecewise RT alignment algorithm and by Zhang et al. 105 
(2008) employing a correlation optimized warping (COW) algorithm. Whereas the 
piecewise alignment algorithm only accepts simple scalar shifts, the COW algorithm 
interpolatively stretches and compresses local regions to maximize the correlation 
between the warped and the reference chromatogram. The COW alignment 
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 mechanism was demonstrated on chromatograms of standard mixtures (Figure 4.12) 
and two serum replicates that had been recorded 5 months apart. 
Homogeneous samples (of the same origin or replicates) could be directly aligned 
based on their TIC chromatograms, while for heterogeneous samples selected ion 
count (SIC) chromatographic profiles were required to determine adequate warping 
parameters. Most approaches presented so far use raw instrument data without 
considering any global data processing functions (automated baseline correction, 
mass spectral deconvolution, peak picking, integration, library search, and 
signal/noise filtering). Therefore, data alignment was primarily based on 1D and 2D 
retention times ignoring the additive information given by a metabolite´s characteristic 
fragment ion mass spectrum. 
 
Figure 4.12. Alignment of two TIC chromatograms of a standard mix using the COW 
algorithm. Taken from 105. 
Oh et al. (2008) were the first to use the data processing options provided by the 
ChromaTOF software to create peak tables for subsequent alignment by their own 
developed MSort® software.106 MSort® works with 1D and 2D RTs, the linear 
correlation (Pearson coefficient) of fragment mass spectra, and, optionally, the peak 
name as assigned by ChromaTOF for peak merging and sorting. Ultimately, a new 
peak table representing all peaks in all chromatograms was generated. The software 
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 was tested on standard metabolite mixtures and human serum specimens spiked 
with the standard mixture. A disadvantage of the software is the utilization of a user-
defined RT window, whose fixed size in both RT dimensions affects the software´s 
reliability and efficiency. Furthermore, the algorithm can only handle small and linear 
RT distortions and needs considerable computational power for larger datasets. 
In 2009, we developed a retention time correction and data alignment tool called 
INCA for comparative metabolic fingerprinting based on peak lists generated by 
ChromaTOF as a starting point.107 The accuracy of processing, alignment, and 
detection of fold changes in metabolite concentration was validated by a spike-in 
experiment. In a proof-of-principle study we applied the metabolic fingerprinting 
strategy to quantitatively discriminate metabolomes of mutant and wild type E. coli 
strains. Further details are presented in chapter 6. 
In a follow-up study, the peak lists generated from the spike-in and E. coli 
experiments were utilized to evaluate and directly compare the performance of INCA 
and the Statistical Compare (SC) alignment module, which had been made 
commercially available in 2010 as an add-on to ChromaTOF software version 4.108 
Enhancements and limitations of the two algorithms are discussed in chapter 7. 
Wang et al. (2010) proposed a distance and spectrum correlation optimization 
(DISCO) algorithm to manage large nonlinear RT shifts.109 DISCO used peak lists 
generated by ChromaTOF as input. After z-score transformation of metabolite RTs, 
DISCO selected a set of so-called landmark peaks from a specific number of 
samples based on Euclidean distances of two-dimensional retention times and mass 
spectrum similarity via Pearson correlation coefficient. RT variation of the landmark 
peaks was assumed to reflect those of all other metabolite peaks in the same 
sample. The two-dimensional RT space was divided into numerous subsections 
containing landmark peaks. A local partial linear fitting function in each RT dimension 
was applied to adjust RT shifts followed by metabolite peak alignment of all samples 
using a progressive RT map searching method based on the optimized Euclidean 
distance and mass spectrum similarity. The algorithm enabled alignment of data 
acquired under various experimental conditions (shown in Figure 4.13). 
The method was claimed to be suitable for metabolomics; but instead of assessing 
its performance on metabolites, a mixture of saturated n-alkanes and the 8270 
MegaMix from Restek containing mostly cyclic and polycyclic aromatic hydrocarbons 
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 were used. Hence, the claim has been supported insufficiently to date. Also, the 
performance of DISCO was evaluated on five out of (only) six deuterated semivolatile 
internal standards spiked into derivatized extracts from rat plasma and no 
quantitative data was shown. 
 
Figure 4.13. Performance of the DISCO algorithm in detecting landmark peaks from data 
acquired under different experimental conditions. Temperature programs were ramped at (a) 
5, (b) 7, and (c) 10°C/min, respectively. Blue circles are landmark peaks in sample S51 and 
red squares are corresponding landmark peaks in sample S52 (a), S71 (b), and S101 (c). Taken 
from 109. 
Recently, Castillo et al. (2011) presented a data analysis platform named Guineu for 
large GC×GC-TOF-MS datasets.110 Like previously described algorithms, Guineu 
uses peak lists generated by vendor software (e.g. ChromaTOF) as input and aligns 
data based on retention times and mass spectral information (eventually 
identification). The freely available open source software package offers in addition 
data normalization, numerous filtering tools, the use of retention indices, and a tool 
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 for group-type identification of compounds. Mainly peak areas from total ion 
chromatograms were used for quantification purposes. Concentrations of selected 
compounds were separately determined using ChromaTOF and characteristic m/z 
ions. In 440 serum specimens acquired over a period of 20 days the average RSD 
was under 10 % for the internal standards. Equally good was the day-to-day 
repeatability for the quantitative analysis of amino and carboxylic acids in control 
serum samples over a period of 3 months. 
4.4.3 Data analysis and validation 
Prior to statistical analysis, data are often pretreated, e.g. normalized, transformed, 
missing values are imputed, and artifacts are removed. The strategy for statistical 
analysis, e.g. univariate or multivariate, regression and classification techniques, 
should be selected according to experimental setup and the hypothesis under 
testing. The main statistical methods used in each study are given in the last column 
of Table S1. Unsupervised approaches, such as principal component analysis (PCA), 
and supervised approaches, such as partial least squares - discriminant analysis 
(PLS-DA) and Fisher ratio analysis were among the most popular multivariate 
methods, but others, including principal component discriminant analysis (PCDA) or 
hierarchical cluster analysis (HCA) can be also found. 
In most cases, metabolomics datasets contain more variables than samples. 
Simultaneous testing of thousands of variables may yield small p-values by chance 
resulting in false positives. Thus, p-values must be corrected for multiple testing. The 
family-wise type I error rate can be controlled by conservative correction algorithms 
such as Bonferroni 111 or Westfall and Young’s step-down adjusted p-values 112. 
Another way of correcting for multiple comparisons is the estimation of the false 
discovery rate (FDR).113 The FDR of a list of features is the expected relative 
frequency of false positives in it. These approaches have been introduced to the 
metabolomics field in 2006 114 and are now commonly used. 
In terms of validation, figures of merits including LOD, linear range, lower limit of 
quantification (LLOQ), accuracy, and precision are determined for metabolite 
profiling. For metabolic fingerprinting, class prediction and cross-validation (CVal) 
methods have been adopted to reduce the probability of obtaining correlations by 
chance. 
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 4.5 GC×GC based metabolome analysis 
This chapter focuses on targeted and non-targeted approaches in GC×GC based 
metabolomics studies. The GC×GC based applications are categorized based on 
biological matrices and briefly summarized in Table S1 in the appendix. 
4.5.1 Biofluids 
Biofluids can be obtained non-invasively by excretion (urine, sweat), secretion 
(breast milk, bile), or invasively by needle (blood, cerebrospinal fluid, cyst fluid). To 
date GC×GC-based studies have been focused almost exclusively on the 
metabolomes of blood and urine. 
The analysis of whole blood is not common; rather serum or plasma is used. Both 
are isolated from whole blood in separate preparation steps. Serum is obtained as a 
supernatant after centrifugation of clotted blood. Plasma represents the liquid phase 
of blood after treatment with anticoagulants like citrate, EDTA or heparin. Serum and 
plasma are among the most complex biofluids requiring at least the removal of 
proteins as described in chapter 4.2.1. Urine may be used directly, but adjustment for 
urine concentration differences and removal of urea are recommended. 
4.5.1.1 The blood metabolome 
By way of comparison, more studies employing GC×GC-TOFMS have been 
published on the analysis of the serum/plasma than the urine metabolome. 
Suomalainen and colleagues applied GC×GC-TOFMS to the measurement of amino 
acids in serum 115 and skeletal muscle specimens 116 collected from a mouse model 
of progressive late-onset mitochondrial myopathy. In comparison to wild type 
animals, mice carrying mutant mtDNA helicase Twinkle had increased serum levels 
of most amino acids.115 In skeletal muscle, in contrast, only the levels of serine and 
alanine were significantly increased in affected mice.116 Feeding a ketogenic, high-fat 
diet normalized the aberrant amino acid levels. 
Asiago et al. (2010) studied 257 retrospective serum specimens obtained from 56 
breast cancer patients using both GC×GC-TOFMS and NMR.117 An aliquot of 200 µL 
serum was subjected to protein precipitation by the addition of 400 µL methanol and 
centrifugation, the protein pellet was further washed with chloroform, the combined 
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 extracts were dried and derivatized using MTBSTFA (N-methyl-N-(tert-
butyldimethylsilyl)trifluoroacetamide). Four metabolite markers, namely glutamic acid, 
N-acetyl-glycine, 3-hydroxy-2-methyl-butanoic acid, and nonanedioic acid were 
selected from the GC×GC-TOFMS data and used together with NMR data to build a 
predictive model for early detection of recurrent breast cancer. 
Lankinen et al. (2011) analyzed plasma samples to study the effects of rye bread 
consumption.118 In total 231 metabolites, including organic acids, sterols, and 
alcohols, were identified in the plasma samples. Rye bread consumption over eight 
weeks resulted in increased levels of ribitol, indoleacetic acid, and ribonic acid. 
Beckstrom et al. (2011) studied perinatal asphyxia in a non-human primate model by 
analyzing heparinized blood specimens.119 The abundance of ten metabolites was 
significantly changed in comparison to control animals. While the known biomarkers 
lactate and creatinine could be confirmed, new metabolites were identified as 
potential markers including succinate, malate, and arachidonic acid. Li et al. (2009) 
performed a biomarker discovery study by analyzing plasma (the anticoagulant used 
was not reported) specimens from 48 type 2 diabetes mellitus patients and 31 
healthy controls.120 The study yielded five potential biomarkers including glucose (to 
be expected), 2-hydroxyisobutyric acid, linoleic acid, palmitic acid, and phosphate. 
GC×GC-TOFMS and lipidomics were used in a longitudinal metabolome study in 
children to detect changes in the serum metabolome preceding the onset of diabetes 
mellitus type 1. The GC×GC-TOFMS metabolomics dataset comprised 75 
metabolites that had been measured in 419 samples.121 Reduced serum 
concentrations of succinic acid and altered lipid profiles were observed at birth for 
children who progressed to diabetes. In 2011, Oresic et al. used the same analytical 
platforms to study the serum metabolome associated with schizophrenia and other 
psychotic disorders.122 
Velagapudi et al. (2009) compared the serum metabolome and the lipidomes of 
serum, adipose tissue, and liver, respectively, of conventionally raised and germ-free 
mice to investigate the effect of gut microbiota on host energy and lipid 
metabolism.123 Analysis of the serum metabolome was performed by GC×GC-
TOFMS resulting in the identification of 185 metabolites. A clear segregation of the 
metabolic fingerprints based on colonization status of the gut microflora was 
observed. Increased levels of microbially derived metabolites, including 3-
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 hydroxyphenylpropionic acid, hydrocinnamic acid, and rhamnose, were found in 
addition to changes in serum levels of endogenous sugars, amino acids, fatty acids, 
and metabolites involved in energy metabolism and phase II metabolism. 
GC×GC-TOFMS has not only been used for global metabolome investigation but 
also for metabolite profiling of selected compound classes, such as elucidation of the 
plasma fatty acid profile 124 and the analysis of amino acids 116, 125. Waldhier et al. 
(2011) demonstrated improved enantiomer resolution and quantification of free D- an 
L- amino acids in serum and urine by GC×GC-TOFMS compared to 1D-GC-qMS.126 
Further details are presented in chapter 8. 
A number of publications used serum or plasma as a model sample for method 
development and optimization. A differential metabolomics approach applying stable 
isotope labeling for quantification by GC×GC-TOFMS was investigated by Huang and 
Regnier (2008).127 Samples were either derivatized with deuterium labeled or 
unlabeled derivatization agent, then mixed and analyzed. For derivatization N-
methyl-N-tert-butyldimethylsilyl-trifluoroacetamide (MTBSTFA) was used, because 
derivatives are less prone to hydrolysis and label scrambling. Initial studies were 
performed using amino acid, fatty acid, and organic acid standards to test the 
efficacy of comparative quantification by isotope ratio analysis and the method was 
then applied to human serum. Compared to fatty acids, inferior average accuracies 
and precisons were obtained for isotope ratios of amino and organic acids. One 
drawback of this approach is that deuterium labeled compounds generally elute at 
lower retention times than their non-labeled analogs. The retention time gap 
increases with the number of deuterium atoms in the derivative and, consequently, 
with the number of derivatizeable functional groups per compound, which proved 
unfavorable for the quantification efficiency using this approach. Another 
disadvantage is the size of MTBSTFA. Derivatization is not always possible, 
particularly when target compounds contain sterically hindered sites.128 O’Hagan et 
al. (2007) used closed-loop optimization, in which the complete process of parameter 
setting, GC run performance, and data analysis was automated and iterated to obtain 
a method that yielded the maximum number of peaks detected in serum 
specimens.129 Gröger and Zimmermann (2011) employed parallel computing to 
accelerate data processing and analysis proceedings.130 The setup was tested on a 
dataset obtained from plasma specimens of male Sprague–Dawley rats exposed to 
side stream cigarette smoke. 
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 A common problem in metabolomics studies is the wide concentration range of 
metabolites in biological matrices. Koek et al. (2008) addressed the issue of mass 
loadability by using a wider bore column (0.32 mm ID) in the second dimension.131 
Mass loadability was improved 10-fold compared to a conventional narrow bore 
second dimension column (0.10 mm ID) at the expense of a 40 % decrease in peak 
capacity. The setup was used to analyze 15 fetal bovine serum specimens 
demonstrating better peak shapes for metabolites eluting close to high abundant 
compounds in case of the wider bore column combination (exemplified in Figure 
4.14). 
 
Figure 4.14. Total ion chromatograms of fetal bovine serum samples using a conventional 
setup (left) compared to a high loadability setup (right). 1, serine; 2, threonine; 3, urea. 
Reproduced from 131. 
4.5.1.2 The urinary metabolome 
The application of GC×GC-TOFMS to urine specimens has focused mainly on the 
analysis of inborn errors of metabolism. Wojtowicz et al. (2010) developed an 
automated data processing strategy for the detection of 21 target metabolites that are 
indicative of 6 defects of metabolism including thymidine phosphorylase deficiency, 
mevalonic aciduria, hawkinsinuria (also called 4-alpha-hydroxyphenylpyruvate 
hydroxylase deficiency), aromatic L-amino acid decarboxylase deficiency, propionic 
acidaemia, and medium-chain acyl-CoA dehydrogenase deficiency (an example is 
shown in Figure 4.15).132 Sample preparation consisted of direct ethoximation in 
urine, followed by extraction with ethyl acetate. The organic phase was dried and 
further extracted using a methanol/acetone mixture. The extract was dried and 
trimethylsilylation was performed. The method was applied to analyze six patient 
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 samples. Automated data processing resulted in the correct annotation of all 
pathological markers, which was superior over 1D-GC-MS. 
 
Figure 4.15. GC×GC-TOFMS contour plot zoom-in section of urine from a patient with 
thymidine phosphorylase deficiency. Dihydrouracil 2TMS, glutaric acid 2TMS, and tartronic 
acid 3TMS are resolved from thymine 2TMS. Thymine 2TMS is identified with a NIST 
spectral match of 912. Taken from 132. 
Kouremenos et al. (2010) studied the urinary profiles of 5 patients with different 
inborn errors of metabolism.133 The study included the comparison of two column 
combinations (nonpolar/polar versus polar/nonpolar) with the polar/nonpolar column 
combination making better use of the 2D separation space. The quantification 
capabilities of GC×GC-TOFMS using stable isotope-labeled internal standards were 
demonstrated for five metabolites. Furthermore, a novel urinary metabolite, crotonyl 
glycine, was identified that might serve as a diagnostic marker for mitochondrial 3-
hydroxy-3-methylglutaryl CoA synthase deficiency. Urine specimens were diluted to a 
fixed creatinine concentration, followed by methoximation, extraction with ethyl 
acetate, and derivatization with BSTFA (bis-(trimethylsilyl)trifluoroacetamide) 
containing 1% TMCS (trimethylchlorosilane). Microwave assisted derivatization was 
performed as previously optimized by Kouremenos et al. (2010) employing a mix of 
standard compounds (amino acids, organic acids, sugars, sugar alcohols, and fatty 
acids).134 Sinha et al. (2004) used GC×GC-TOFMS to analyze metabolites in a 
human infant urine specimen to demonstrate the applicability of their DotMap 
algorithm (see chapter 7.1.2.2).94 
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 4.5.2 Cell culture and tissue extracts 
Pasikanti et al. (2010) performed a metabolic footprinting study comparing the 
metabolite pattern in cell culture media from tumorigenic and nontumorigenic 
uroepithelial cells.135 A culture media aliquot of 200 µL was used and protein 
precipitation with methanol was performed. The SC tool from LECO (presented and 
evaluated in chapter 7) was used for data analysis. Twenty metabolites, including 
glucose, other sugars, sugar alcohols, and malic acid, were identified that differed 
significantly between the two cell types. 
Mucosal biopsies from the ascending colon were investigated using both lipidomics 
and GC×GC-TOFMS based metabolomics to study the pathophysiology of irritable 
bowel syndrome.136 Tissue samples for GC×GC-TOFMS were extracted using 
methanol. A total of 107 metabolites were identified in the GC×GC chromatograms 
and used for further analysis. The most prominent change with an almost 14-fold up-
regulation in patients compared to controls was observed for 2(3H)-furanone. 
Kleemann et al. (2010) studied the pathogenesis of insulin resistance in male 
ApoE3Leiden transgenic mice that were fed a high-fat diet.137 Liver tissue samples 
were freeze-dried overnight, homogenized, and extracted using 80 % (v/v) methanol 
in water. GC×GC-TOFMS analysis revealed significant changes in the concentrations 
of glucose, gluconeogenesis and Krebs cycle metabolites, and branched amino 
acids. The samples were used by Koek et al. (2010) to evaluate commercially 
available software for non-target processing of GC×GC-TOFMS data.90 
Mervaala et al. (2010) investigated metabolic profiles in angiotensin II–induced 
cardiac hypertrophy by analyzing heart tissue specimens from transgenic and control 
rats, respectively.138 The GC×GC-TOFMS dataset comprised 247 metabolites, of 
which 112 showed significant differences. Further applications of GC×GC-TOFMS 
include a biomarker discovery study in spleen tissue extracts of obese NZO mice 100 
and the analysis of L-β-methylamino-alanine in mouse and human brain tissues 139. 
4.5.3 Bacteria and yeast 
GC×GC studies on the metabolomes of bacteria and yeast were mainly performed by 
the Lidstrom group and Synovec and colleagues, respectively, both at the University 
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 of Washington in Seattle, using PARAFAC and associated preprocessing tools. 
Details about the methodologies are given in chapter 4.4.1.2. 
4.5.3.1 Bacteria 
The Lidstrom group focused their GC×GC-TOFMS analyses exclusively on 
Methylobacterium extorquens AM1, a facultative methylotroph capable of generating 
energy and assimilating carbon from reduced one-, two-, or four-carbon substrates 
such as methanol, ethylamine, or succinate, respectively.140-142 It presents an 
attractive model system for the application of novel metabolomics-related techniques 
because of the in-depth understanding of its genetics and biochemistry. 
In 2008, Guo and Lidstrom investigated metabolite profiles of 
methoximated/trimethylsilylated extracts from cells grown on either methanol or 
succinate.140 Absolute quantification of amino acids and major intermediates of 
central C1 and multicarbon metabolism was accomplished by spiking different 
amounts of standard mixtures into cell cultures. In addition, Fisher ratio analysis at 
m/z 147 determined thirty-six differentially expressed metabolites. Thirteen could be 
identified by matching to library mass spectra. PARAFAC GUI was used for peak 
deconvolution and calculation of normalized peak volumes from reconstructed 3D 
peaks (Figure 4.16). The completely overlapping peaks of 3-hydroxyisobutyrate and 
3-hydroxybutyrate were successfully deconvoluted, which allowed for the detection of 
differences in abundance of both isomers between cells grown on methanol and 
succinate, respectively. Further, increased concentrations of methylfumaric and 
methylmalic acid in C1 metabolism indicated an active glyoxylate regeneration cycle. 
Yang et al. (2009) utilized the complementary nature of LC- and GC-based methods 
by applying liquid chromatography – tandem quadrupole mass spectrometry (LC-
MS/MS) and GC×GC-TOFMS with PARAFAC data analysis to compare 
concentrations of 39 targeted metabolites involved in central carbon metabolism of 
M. extorquens AM1 grown on ethylamine (C2) and succinate (C4), respectively.141 
The abundance of twenty intermediates changed between differentially grown cells 
reflecting the pathways linked to C2 and C4 metabolism. Agreement of the two 
methods and quantification accuracy were verified for seven metabolites that had 
been detected by both methods. 
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Figure 4.16. Demonstration of using PARAFAC for peak quantification. (A) TIC contour plot 
of a derivatized methanol chemostat culture extract analyzed by GC×GC-TOFMS. (B) 2D 
plot of the boxed region in (A) at m/z 73, 147, 189. The peak with an arrow on top is 
identified as glyceric acid, triTMS. (C) Glyceric acid, triTMS (solid lines) was completely 
separated from four overlapping components (dashed and dotted lines) on both column 1 (C) 
and column 2 (D). (E) The 3D reconstruction of the glyceric acid, triTMS peak. Reproduced 
from 140. 
In 2010, Okubo et al. determined the capability of M. extorquens AM1 mutants to 
grow on C2 compounds in the absence of malyl-CoA/β-methylmalyl-CoA lyase and 
malate synthase activity, respectively.142 The extensive study included a 13C labeling 
experiment, microarray gene expression analysis, enzyme activity assays, and 
metabolite determination by means of LC-MS/MS and GC×GC-TOFMS using the in-
house developed signal ratio method to detect differences between mutants. One of 
the major findings of the study was the identification of an alternative route for 
glyoxylate consumption in M. extorquens AM1, in which glyoxylate is converted to 
intermediates of central metabolism via a part of the serine cycle coupled to the 
glycine cleavage system. This alternative pathway complements the malate synthase 
reaction, which is a bottleneck in M. extorquens AM1 cultivated on C2 compounds. 
Methyl esters of fatty acids from Brevundimonas diminuta, Chryseobacterium gleum, 
and Stenotrophomonas maltophilia, respectively, were analyzed by David et al. 
(2008) using the commercial Sherlock Microbial Identification System, GC×GC-FID, 
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 and GC-MS in electron impact and positive chemical ionization mode.89 The 
enhanced selectivity and group type separation of GC×GC allowed a more complete 
elucidation of the fatty acids in the microorganisms (Figure 4.17). 
 
Figure 4.17. Structured separation space of FAMEs from Stenotrophomonas maltophilia 
using GC×GC-FID. Taken from 89. 
4.5.3.2 Yeast 
The Synovec group covered most of the GC×GC-TOFMS based metabolomic 
research on yeast. Mohler et al. (2006) compared metabolite extracts isolated from 
yeast cells grown on either glucose (fermentation) or ethanol (respiration).96 PCA on 
three selective mass channels combined with PARAFAC and LECO ChromaTOF 
could locate and identify 26 class-distinguishing metabolites. 
A Fisher ratio/PARAFAC GUI approach on the same dataset raised the number of 
identifications nearly three-fold.98 A Student´s t-test with a 95 % confidence limit 
determined 54 metabolites to be statistically changing. In 2008, Mohler et al. 
developed the S-ratio/PARAFAC GUI method, another multivariate classification 
analysis tool geared specifically to time-interval experiments. In 24 time-point 
measurements of yeast cells, 44 identified unique metabolites were located that 
exhibited cycling with a depth-of-modulation amplitude of greater than three.99 
Humston et al. (2008) employed the same method to detect time-dependent 
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 metabolite changes in wild type and snf1Δ mutant yeast cells under repressing and 
depressing conditions.143 In a follow-up study, GC×GC-TOFMS and LC-MS/MS were 
used to investigate metabolite differences between wild type and four mutant strains 
(snf1Δ, adr1Δ, cat8Δ, and adr1Δcat8Δ) grown in fermentable synthetic complete 
medium containing 5 % glucose.144 For this study, metabolite levels were correlated 
with RNA data for pathways comprising statistically significant metabolites (TCA 
cycle, glyoxylate cycle, and gluconeogenesis). 
Cooper et al. (2010) developed a high-throughput profiling technique to quantify 
primary amine-containing metabolites in the Saccharomyces cerevisiae yeast 
deletion collection by means of capillary electrophoresis coupled to a laser-induced 
fluorescence detector (CE-LIF) of cell extracts labeled with 4-fluoro-7-nitro-2,1,3- 
benzoxadiazole (NBD-F).145 Amino acid peak identities were verified by spike-in 
experiments and parallel quantification of trimethylsilylated amino acids by means of 
GC×GC-TOFMS. Comparison of data obtained for four samples showed that 12 out 
of 13 amino acids measured by both CE-LIF and GC×GC-TOFMS were correlated at 
R2 >0.7 (6 out of 13 had R2 >0.9). Glutamine yielded a low correlation, as it did not 
separate from valine by CE. 
4.5.4 The plant kingdom 
An array of analytical strategies has been proposed for plant metabolomics.146 GC-
MS has proven the most popular among these. In recent years GC×GC-TOFMS 
approaches have emerged. 
In 2005, Hope et al. first optimized the GC×GC-TOFMS separation space for the 
analysis of TMS derivatives of amino and organic acids and then applied the method 
to two extracts of common lawn grass samples.147 Pierce et al. (2006) employed PCA 
data mining on entire GC×GC-TOFMS chromatograms to discover differences 
between organic acid extracts of basil, peppermint, and the sweet herb stevia.95 
Kusano et al. (2007) combined GC-TOFMS and GC×GC-TOFMS for comprehensive 
non-targeted metabolite profiling of brown rice seeds from the world rice core 
collection (WRC), a representative set of Asian rice cultivars.148 1D-GC-TOFMS was 
used for high-throughput profiling of all rice cultivars, followed by GC×GC-TOFMS for 
a detailed analysis of a representative subset. Since the WRC covered most of the 
DNA polymorphisms, metabolite phenotyping provided an insight into the metabolite 
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 diversity of rice natural variants and facilitated the selection of nutritionally useful rice 
varieties. 
Following publication of the genome sequence of the green alga Chlamydomonas 
reinhardtii in 2007 149, May et al. (2008) employed GC×GC-TOFMS based 
metabolomics and LC-MS based shotgun proteomics profiling technologies 
complemented with in silico genome annotation methods to characterize the 
molecular repertoire of this model organism under reference conditions.150 
Computational metabolic modeling revealed new putative genes, pathways, and 
enzymatic links. In 2009, Kempa et al. proposed a workflow for flux analysis 
incorporating GC×GC-TOFMS, ChromaTOF deconvolution, and an algorithm for 
batchwise data processing to study the 13C-pattern in C. reinhardtii.151 Doebbe et al. 
(2010) reported a differential GC×GC-TOFMS analysis of metabolite profiles between 
a high H2-producing C. reinhardtii strain and the corresponding wild type before and 
during the H2 production phase.152 In contrast to GC-MS, the number of resolved 
peaks could be increased by an order of magnitude. Remarkable differences were 
detected in anaerobic pathways of starch degradation, fatty acid and lipid synthesis, 
and formate/ethanol production that provided potential targets for metabolic 
engineering to further enhance substrate supply for the hydrogenase(s) in the 
chloroplast. 
As part of the META-PHOR project (METAbolomics for Plants Health and 
OutReach), Allwood et al. (2009) presented an extensive GC-TOFMS ring 
experiment based on major differential metabolite features of melon, broccoli, and 
rice sample extracts for short-term inter-laboratory reproducibility.153 During the 
course of the study conventional GC-TOFMS was also compared to GC×GC-
TOFMS. 
Finally, Johanningsmeier and McFeeters (2010) described a non-targeted solid-
phase microextraction (SPME) GC×GC-TOFMS approach for discriminative analysis 
of fermented cucumber volatiles before and after anaerobic spoilage making use of 
the Reference and Compare function of the ChromaTOF software.154 A composite 
sample that comprised equal volumes of aliquots from each treatment served as 
reference. Analysis of variance (ANOVA) of analyte log peak areas detected 33 
metabolites that changed significantly in concentration after spoilage. 
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 4.5.5 Miscellaneous 
This chapter takes a brief look at GC×GC studies of metabolites in milk, beverages, 
invertebrates, and feces. 
Hyötyläinen et al. (2004) tested four column combinations (see Table S1) by 
GC×GC-FID to find optimal conditions for the separation of dietary milk derived fatty 
acids as their methyl ester derivatives.155 Best results, in particular for C18 fatty 
acids, were obtained with a nonpolar 100% dimethylpolysiloxane HP-1 column 
coupled to a polar narrow-bore (0.05 mm ID) Carbowax column as the second 
dimension column. Vlaeminck et al. (2007) utilized the superior separation efficiency 
of GC×GC for the analysis of milk fatty acid profiles from dairy cows fed a control 
versus a ration diet supplemented with marine algae.156 FAMEs were separated 
using both nonpolar/polar and polar/nonpolar column combinations. The well-ordered 
structure in the 2D contour plot facilitated identification of known and unknown 
compounds. 
Mayadunne et al. (2005) compared two different column sets, low-polarity/polar and 
polar/nonpolar, for the separation of amino acids as their propyl chloroformate 
derivatives.157 Standards were characterized by GC-MS, GC×GC-FID, and GC×GC-
TOFMS. A selection of samples (wines, beer, and honey) was analyzed by GC×GC-
FID using the favored column combination comprising a polar 30 m × 0.25 mm ID × 
0.25 µm SolGel-WAX and a nonpolar 1.5 m × 0.1 mm ID × 0.1 µm BP-1. Junge et al. 
(2007) applied GC×GC to the separation of amino acid enantiomers as their ethyl 
chloroformate derivatives in samples of beer by coupling a Chirasil-L-Val column with 
a low-polarity column in the second dimension.158 In addition, a chiral/polar column 
combination and various derivatization techniques were tested. 
In further GC×GC-TOFMS studies, Ralston-Hooper et al. (2008 & 2010) employed 
MSort® (for details see chapter 4.4.2) to examine metabolomic changes among 
distinct populations of aquatic invertebrates 159, 160, while Aura et al. (2010) used an 
anaerobic in vitro colon model combined with a global metabolomics approach to 
identify novel metabolites synthesized by the fecal microbiota.161 
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 5 Experimental section – Material, methods and 
instrumentation 
5.1 Chemicals 
Metabolite standards, Luria-Bertani (LB) broth, odd-numbered saturated straight 
chain fatty acids (C9-C19), methoxylamine hydrochloride, isooctane, pyridine, MCF, 
norvaline, all solids of L and D configured amino acids (AAs), racemates of 
proteinogenic AAs, [2H7]-trans-cinnamate, [2,2,4,4-2H4]citrate, [U-13C]glucose, and [U-
13C]β-hydroxybutyrate were purchased from Sigma-Aldrich/Fluka (Taufkirchen, 
Germany). Glycerol was from BDH Prolabo (VWR International, Vienna, Austria), [U-
13C]lactose from Omicron Biochemicals (South Bend, USA), methanol (LC-MS grade) 
and chloroform (HPLC grade) were from Fisher Scientific GmbH (Ulm, Germany), [U-
13C]fumarate, [U-13C]lactate, [U-13C]pyruvate, [U-2H]succinate, and a [U-13C, U-15N] 
cell free amino acid mix from Eur-isotop (Saint-Aubin Cedex, France), DL-[2,3,3-
2H3]malate and [4,6,7-2H3]5-hydroxyindole-[2H2]acetate from CDN Isotopes Inc. 
(Quebec, Canada), and N-methyl-N-trifluoroacetamide (MSTFA) from Macherey-
Nagel (Dueren, Germany). The water was purified using a PURELAB Plus system 
(ELGA LabWater, Celle, Germany). 
5.2 Sample preparation 
5.2.1 Automated methoximation/silylation 
Automated methoximation/silylation was carried out in metabolic fingerprinting 
experiments in capters 6 and 7 and in the quantitative analysis of β-hydroxybutyrate, 
glucose, and intermediates of the citrate cycle in chapter 9. 
After sample evaporation, the vials were closed with magnetic crimp caps and placed 
in a cooled tray (5 °C) for automated handling using the MPS-2 Prepstation sample 
robot (Gerstel, Muehlheim, Germany). Fifty microliters of 10 mg/mL methoxylamine 
hydrochloride in pyridine were added and incubated at 60 °C for 60 min. Prior to 
trimethylsilylation, 10 µL of internal standard solution containing odd-numbered, 
saturated straight chain fatty acids (C9–C19) at a concentration of 1 mM were added 
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 to the sample residue. Then, 50 μL MSTFA were added and incubated at 60 °C for 
60 min. Samples were vortexed continuously at 500 rpm during incubation in the 
agitator. For analysis, a sample volume of 1.5 µL was injected in splitless mode. 
5.2.2 Derivatization with methyl chloroformate 
Methanol/methyl chloroformate derivatization was used for quantitative analysis of 
amino acid enantiomers (chapter 8) as described by Waldhier et al.5  
Magdalena Waldhier (Institute and Chair of Functional Genomics, University of 
Regensburg) optimized the derivatization steps and performed in part the sample 
preparation together with Nadine Nürnberger (Institute and Chair of Functional 
Genomics, University of Regensburg). 
5.2.3 Derivatization with propyl chloroformate 
Propyl chloroformate (PCF) derivatization was employed for quantitative analysis of 
amino acids (chapter 9) according to Kaspar et al.162 
Briefly, AAs were derivatized directly in the aqueous biological sample, 20-50 µL of 
which were transferred together with 20 µL of the stabilization reagent to a 2-mL 
autosampler vial (Gerstel). The vial was closed with a magnetic crimp cap to allow 
automated handling by the MPS-2 Prepstation sample robot (Gerstel) in all the 
following steps. First, the sample was diluted with water up to 225 µL, followed by 
addition of 10 µL of a norvaline solution (200 µM) and 10 µL of internal standard mix. 
A mixture of uniformly 13C, 15N-labeled alanine, glycine, valine, leucine, isoleucine, 
threonine, serine, proline, asparagine, aspartate, methionine, glutamate, 
phenylalanine, glutamine, lysine, histidine, tyrosine, and tryptophan, as well as [2,5,5-
2H3]α-aminoadipic acid, were used as internal standards with a concentration range 
from 0.0438 to 1.4175 mM. To increase the pH of the solution, 120 µL of 0.33 M 
sodium hydroxide solution were added, followed by 50 µL of picoline in propanol, 
which acts as a catalyst for the derivatization reaction (solution provided by 
Phenomenex Inc., Torrence, CA, USA). The vial was moved to an agitator and the 
solution was mixed at 750 rpm for 0.2 min at 35 °C. Fifty µL of propyl chloroformate 
in chloroform were added to the sample, the solution was mixed for 0.2 min (750 
rpm, 35 °C), equilibrated for 1 min and again mixed for 0.2 min. To extract the 
derivatives, 250 µL of isooctane were added and the vial was vortexed for 0.2 min 
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 (750 rpm, 35 °C). For analysis, an aliquot (2.5 µL) was taken from the upper organic 
phase and injected at a split ratio of 1:15. 
5.3 Instrumentation 
5.3.1 Metabolic fingerprinting/quantitative analysis of selected 
metabolites 
A LECO (Corporation, St. Joseph, MI, USA) Pegasus 4D GC×GC-TOFMS instrument 
was used comprising an Agilent Technologies Model 6890 GC (Agilent, Palo Alto, 
CA, USA), a dual-stage, quad-jet thermal modulator, a secondary oven coupled to a 
fast-acquisition time-of-flight mass spectrometer providing unit mass resolution, a 
PTV injector (Gerstel), and a MPS-2 Prepstation sample robot (Gerstel) for 
automated sample derivatization and handling. The robot was equipped with two 
agitators for sample incubation and two syringes of different volumes. A 10-µL 
syringe was used for internal standard addition and sample injection, while reagents 
were added by means of a 250-µL syringe. Between adding steps, the syringes were 
washed at least 3 times with isooctane. Samples were kept in a cooled tray at 5 °C. 
The GC×GC column set consisted of a Rxi®-5ms column (30 m × 0.25 mm ID × 0.25 
µm film thickness) from Restek (GmbH, Bad Homburg, Germany) equipped with a 5 
m × 0.25 mm ID deactivated pre-column (Agilent) as the first dimension column and 
a Rtx®-1701 (2 m × 0.1 mm ID × 0.1 µm film thickness, Restek) as the second 
dimension column. The oven temperature was initially held at 50 °C for 0.2 min, 
raised at 8 °C/min to 265 °C, and held for 10 min. A positive offset of 5 °C was used 
for the second dimension column and a 15 °C offset relative to the first dimension 
column for the modulator. The column flow (constant) was 1 mL He/min. The 
temperature of the PTV Injector was set at 50 °C for 0.5 min and ramped at 12 °C/s 
to 250 °C over 1 min. A chemically inert SILTEC liner (Gerstel) was used. For 
GC×GC analyses a 4 s modulation period was used (0.6 s hot pulse time and 1.4 s 
cool time). Mass spectra were acquired from m/z 40-600 at a rate of 200 spectra/s. 
For 1D-GC-TOFMS analysis the modulator was turned off and mass spectra were 
collected at 50 spectra/s. The solvent delay was always 8 min. 
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 5.3.2 Quantitative analysis of amino acid enantiomers 
The GC×GC-TOFMS instrument described in chapter 5.3.1 was used. Following 
settings were altered: an Rt®-γDEXsa column (30 m × 0.25 mm ID × 0.25 µm film 
thickness, Restek) protected by a 5 m × 0.25 mm ID fused silica deactivated guard 
column (Agilent) was emloyed as the first dimension column, while an Rtx®-1701 (2 
m × 0.1 mm ID × 0.1 μm film thickness, Restek) or a ZB-AAA (2 m × 0.25 mm ID × 
0.1 µm film thickness, Phenomenex) column was employed as the second dimension 
column. The helium flow-rate was set at 1.9 mL/min (constant flow). The solvent 
delay was kept at 19 min. Temperature programs are detailed in chapter 8. 
5.3.3 Quantitative analysis of amino acids 
Quantitative analysis of AAs was performed as previously described.162 An Agilent 
Technologies Model 6890 GC equipped with a 5975 Inert XL MSD, a PTV injector 
(Gerstel), and a MPS-2 Prepstation sample robot (Gerstel) was used. The syringes 
were washed with propanol after adding aqueous solutions and with chloroform and 
propanol after addition of organic solutions. 
The GC column was a ZB-AAA (15 m × 0.25 mm ID × 0.1 µm film thickness, 
Phenomenex). The oven temperature was initially held at 70 °C for 1 min, raised at 
30 °C/min to 300 °C, and held for 3 min. The column flow was 1.1 mL He/min. The 
temperature of the PTV Injector was set at 50 °C for 0.5 min and ramped at 12 °C/s 
to 320 °C (5 min). A chemically inert SILTEC liner (Gerstel) was used. The transfer 
line to the mass spectrometer was kept at 310 °C. The MS was operated in scan 
(m/z 50-420) and SIM mode. For SIM, appropriate ion sets were selected and two 
characteristic mass fragments of the derivatized amino acids were used for almost all 
amino acids, except for the labeled amino acids. 
5.3.4 Miscellaneous 
Solvent evaporation was performed on a Combi Dancer Infra-Red Vortex-Evaporator 
(Hettich AG, Baech, Switzerland). 
Shake flasks for cultivation of E. coli were incubated in an Innova 4430 Incubator 
Shaker (New Brunswick Scientific GmbH, Nuertingen, Germany). 
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 Optical density (OD) measurements were performed on an Ultrospec 3100 pro 
UV/VIS Spectrophotometer (Amersham Biosciences, Buckinghamshire, UK). 
For the sterilization of all materials utilized for the cultivation and preparation of 
bacterial samples a steam sterilizer (Varioklav, Thermo Fisher Scientific Inc., 
Waltham, MA, USA) was used. 
5.4 Software 
Analysis of the acquired raw data generated on the GC×GC-TOFMS instrument was 
performed using the LECO ChromaTOF software versions 3.34 to 4.32. For 
metabolic fingerprinting, regions of the 2D chromatogram containing excessive noise 
were excluded. Baseline correction, deconvolution, and peak picking were 
performed. Signals exceeding a predefined S/N were selected and combined in the 
second dimension separation using a spectral matching factor. The definition of a 
separate S/N for 2nd dimension subpeaks was an improvement of ChromaTOF 
version 4 over earlier versions. An override of the allowed 2nd dimension retention 
time shift was set to improve the separation of closely eluting peaks with an identical 
1D retention time and a similar 2D RT. For compound identification, commercial 
standards were run individually and EI spectra were matched against both an in-
house library (for details see Table S2 in the appendix) and the NIST 05 library. After 
data processing a corresponding peak table was obtained for each sample. Various 
characteristics per feature, such as name, retention times, area, similarity, S/N, quant 
mass, and unique mass were set. Note that unique mass refers to a metabolite-
specific unique m/z ion trace, which exhibits the least amount of interferences 
compared to other m/z ion traces available in a compound’s fragment spectrum. 
Quant mass represents an assigned m/z ion trace to calculate a compound’s peak 
area/height. 
5.5 Validation Methods 
5.5.1 LOD and LOQ 
The LOD was defined as the concentration producing an S/N of at least 3:1. The 
linear range was determined by the lower (LLOQ) and the upper limit of quantification 
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 (ULOQ), which were defined as the lowest and highest point of the calibration curve 
with an accuracy between 80 % and 120 %, in agreement with the FDA Guide for 
Bioanalytical Method Validation.163 In addition, peaks had to exceed an S/N of 8:1 in 
case of the LLOQ. 
5.5.2 ROC curve 
Receiver operator characteristic (ROC) curves were used to graphically present the 
compromise between the false positive and false negative rates. The plots show the 
false positive rate on the x-axis and the true positive (1-false negative) rate on the y-
axis. A discrimination of different abundance levels is good if a small false positive 
rate and a small false negative rate are obtained. A ROC curve can be quantified by 
determining the area under the curve (AUC). The closer the AUC is to 1, the better is 
the differentiation of the various levels. 
5.5.3 Bland-Altman plot 
Bland-Altman plots were applied to assess the agreement between different 
methods.164 The Bland-Altman analysis is a graphical model, also known as Tukey 
mean difference plots, which displays for each sample the concentration difference yn 
between data obtained by two analytical methods or sampling techniques a and b (y 
= ca - cb) against the average xn of the two concentrations (xn = (xa + yb)/2). Every 
Bland-Altman plot includes three horizontal lines that mark the mean difference and 
the upper and lower limits of agreement which are defined as mean difference ± 1.96 
times SD of the difference (đ ± 1.96 SD). An ideal agreement between two datasets 
is observed, if the absolute mean difference is zero. 
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 6 Development of an alignment tool for GC×GC-TOFMS 
comparative metabolic fingerprinting 
6.1 Introduction 
As described in chapter 4.2.2, comparative analysis of metabolic fingerprints requires 
a reliable and preferentially automated data alignment to recognize identical 
metabolites across many samples. Initial algorithms for GC×GC-TOFMS data 
alignment have been developed, but were either based on raw data using retention 
times only or limited to a fixed retention time window. Furthermore, the methods were 
computationally intensive and lacked quantitative information rendering a global 
discriminative study impossible. 
This project was performed in cooperation with Inka Appel (Institute of Functional 
Genomics, Chair of Statistical Bioinformatics, University of Regensburg), who as part 
of her Ph.D. thesis focused on the bioinformatics work and, in particular, the 
development of an algorithm for normalizing retention times and aligning GC×GC-
TOFMS data with the goal of combining multiple measurements into one data matrix 
for subsequent multivariate statistical analysis. The author of the present thesis, on 
the other hand, performed all experiments related to the validation and biomedical 
application of the algorithm. Their equal contributions to this body of research are 
documented in two joint first authorships in Analytical Chemistry 107 and the Journal 
of Chromatrography A 108. 
Starting point were the data processing functions provided by the LECO ChromaTOF 
software, such as baseline correction, mass spectral deconvolution, peak picking, 
signal/noise filtering, peak integration, and library search. They were used to 
generate peak lists for each sample. Retention time variations in the complete series 
of measurements were compensated by fitting linear models to each retention time 
plane in every sample. In a subsequent step, the peak lists were aligned in one data 
matrix based on 1D and 2D retention times as well as spectral information (number of 
fragment ions and relative intensities). The final data matrix contained peak 
intensities of the universal m/z 73 ion for all features as a quantitative measure. 
Multivariate analysis and testing strategies were used to visualize the data and 
determine differences in metabolite abundance. 
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 The accuracy of peak alignment and detection of 1.1- to 4-fold changes in metabolite 
concentration were validated by a spike-in experiment. The tools were further applied 
to the comparative metabolic fingerprinting of a wild type versus a double-mutant 
strain of E. coli lacking the transhydrogenases UdhA and PntAB, which play 
important roles in NADPH metabolism. Finally, the data obtained were also 
compared with previously published CE-TOFMS data.165 
This chapter was published in 107. 
6.2 Material and Methods 
6.2.1 Sample preparation 
6.2.1.1 Spike-in experiment 
Hundred microliters of an aqueous-methanolic E. coli BL21 extract were transferred 
to a 2-mL glass vial with a 0.2-mL glass insert, followed by the addition of a mixture 
of 20 metabolites: 2-hydroxybutyrate, 3-hydroxybutyrate, 2-hydroxy-3-methylbutyrate, 
3-methyl-2-oxovalerate, malonate, nicotinate, phenylacetate, dimethylsuccinate, 
decanoate, mandelate, adipate, erythritol, phenyllactate, triethanolamine, 
dodecanoate, suberate, xylitol, vannilate, mannitol, and eicosanoate. 
Blank samples containing only E. coli extract and seven spike levels were generated 
with 0.25, 0.275, 0.3125, 0.375, 0.5, 0.625, and 1.0 nmol absolute of each analyte. 
Each sample was prepared in six replicates. Samples were evaporated and 
derivatized as described in chapter 5.2.1. In total, 42 spiked and six blank samples 
were measured in random order by GC×GC-TOFMS. 
6.2.1.2 Bacterial strains and growth conditions 
The E. coli wild type strain MG1655 and the mutant UdhA-PntAB (MG1655 ∆Udh-
∆PntAB) were cultured at 37 °C in 250-mL shake flasks containing 30 mL of LB and 
harvested after reaching stationary phase growth. Cell dry weight (CDW) was 
determined by vacuum filtration of 10 mL medium containing cells at different optical 
densities. The filters were dried at 120 °C and weighed empty and with dried cells. 
Cells were harvested by fast filtration as previously described.165 Briefly, 2-10 mL of 
cell suspension (depending on OD) were filtrated by vacuum filtration using 
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 polyethersulfonate (PESU) filters (0.45 μm pore size, 25 mm, Sartorius AG, 
Göttingen, Germany). The filters were then washed with an identical volume of NaCl 
solution (0.9 % (w/v), room temperature), before they were submersed in 3 mL of 
quenching/extraction solution in 50-mL Falcon tubes (Fisher Scientific, PA, USA). 
The extraction solution consisted of 80 % (v/v) methanol in water at -20 °C and 
contained the extraction standards [U-13C]lactate, [U-13C]pyruvate, [U-2H]succinate, 
[2,3,3-2H3]malate, [U-13C]glucose, [2H7]cinnamate, and norvaline at 1 mM each. The 
tube was vortexed for 60 s; the filter was removed and checked visually for complete 
dissolution of cells. Falcon tubes were transferred to liquid nitrogen for 3 min, thawed 
in an ice bath for 15 min, and briefly vortexed. This freeze-thaw cycle was repeated 
three times for complete cell disruption. The sample was centrifuged at 4 °C and 
3,375 xg for 5 min and the supernatant transferred to a new tube. Pellets were re-
extracted twice with 0.5 mL of 80 % (v/v) methanol at -20 °C and the extracts were 
combined. The extracts were concentrated in a vacuum evaporator, transferred into a 
2-mL glass vial with a 0.2-mL glass insert, and evaporated and derivatized as 
described in 5.2.1. The metabolic fingerprints of the E. coli wild type MG1655 and the 
E. coli MG1655 double-mutant ∆Udh-∆PntAB were compared by cultivating each 
strain in three separate flasks and by filtrating each culture in triplicates. In total, nine 
samples per strain and three medium blanks were measured in random order using 
GC×GC-TOFMS. 
6.2.1.3 Calibration 
Calibration was performed using metabolite standard solutions in methanol. One 
hundred μL of different calibration levels were transferred to a glass vial with glass 
insert and 20 μL of the surrogate solution containing [U-13C]lactate, [U-13C]pyruvate, 
[U-2H]succinate, [2,3,3-2H3]malate, [U-13C]glucose, [2H7]trans-cinnamate, and 
norvaline (1 mM each) were added. The standards were dried and derivatized as 
described in 5.2.1. In total, twelve calibration points were generated over a 
concentration range of 0.5-1000 μM. 
6.2.2 Data processing 
Raw data were processed with the LECO ChromaTOF software version 3.34. 
Regions of the 2D chromatogram containing excessive noise were excluded. 
Baseline correction, deconvolution, and peak picking were performed. Signals with a 
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 predefined S/N of ≥500 were selected and combined in the second dimension 
separation using a spectral matching factor of 700. An override of the allowed 2nd 
dimension retention time shift was set at 0.150 s early and 0.050 s late. For 
compound identification, commercial standards were run individually and EI spectra 
were matched against both an in-house library and the NIST 05 library. Every sample 
was processed as described above and a corresponding peak table was generated. 
As a quantitative measure the peak area of the m/z 73 ion trace was integrated. For 
each chromatogram the peak list was exported in a character separated value (csv) 
file format containing peak names, 1D and 2D retention times, area integrals for m/z 
73, similarity values of EI spectra to the mass spectral libraries, and the deconvoluted 
mass spectra containing only fragment ions with a relative intensity ≥5 % of the base 
peak. 
6.2.3 Scaling 
To account for shifts in retention times, linear models were fitted to the series of 
measurements. For 1D and 2D retention time two independent linear models for 
each measurement were learned separately. To that end, retention times for odd-
numbered fatty acids included as derivatization standards in each measurement 
were extracted. A given linear model consists of a scaling factor and an offset, which 
best correlate the observed retention times for the standards in the corresponding 
measurement to the median across all measurements. The fatty acids used as 
standards typically had well separated peaks that occurred uniformly over the entire 
separation space except for the early part of the chromatogram, where smaller odd-
numbered fatty acids could not be included as standards because of their natural 
occurrence in E. coli. This ensured that the linear models were well supported across 
a wide range of retention times. By applying the scaling parameters to the 
corresponding retention times of all peaks, possible shifts were compensated. The 
code was implemented in the statistical computing package R (http://www.r-
project.org).166 
6.2.4 Alignment 
After retention time scaling, the peak lists were aligned in one data matrix based on 
1D and 2D retention times as well as spectral information. In spite of scaling, small 
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 shifts in retention times remained. Similarly, EI spectra varied in the number of m/z 
ions detected and relative signal intensities over time. These were taken into account 
by four user-defined tolerance parameters, one for each retention time, number of 
fragment ions with a relative intensity ≥5 % of the base peak, and relative intensities 
of the respective fragment ions. The generated matrix contained areas detected for 
m/z 73 and had one column per measurement and one row per feature, where a 
feature corresponded to a set of aligned peaks. Each feature was characterized by 
the average and interval of 1st and 2nd dimension retention times and its EI spectrum 
consisting of m/z ions with scaled ion abundances. Ion abundances of spectra were 
always scaled so that the highest abundance was 999. 
To generate the alignment matrix, all the peak lists for each measurement were read 
into a raw peak list and this list was then sorted according to retention times. Peaks 
of the complete peak list were added one by one into the alignment matrix. A raw 
peak was aligned to a feature in the alignment matrix, if all tolerance parameters 
were satisfied. Otherwise a new feature containing the peak’s retention times and 
spectrum was generated. A retention time was considered close enough, if its 
distance from the entry’s corresponding mean of interval boundaries was smaller 
than the corresponding tolerance parameter. Two spectra were defined as similar if 
their fragment ions had a sufficient overlap and the difference in ion abundances of 
the overlapping ions was small. Upon successful alignment, a new union set of 
fragment ions and respective relative abundances was generated. Finally, the 
appropriate area detected for m/z 73 was stored into the aligned data matrix. In this 
matrix, entries that corresponded to undetected features were set to zero. The peak 
alignment module was implemented in R and could be accessed via the shell. The 
pseudocode can be found in Figure S1 in the appendix. 
The module for retention time scaling and peak alignment was implemented by Inka 
Appel and therefore named INCA – Integrative Normalization and Comparative 
Analysis. 
6.2.5 Normalization, testing and validation 
During measurements, small variations in the amount of sample injected might be 
caused by a number of environmental effects such as humidity or temperature. To 
compensate for such fluctuations, we used the area integral of the m/z 271 trace of 
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 tridecanoic acid, which had been added to all samples as an internal derivatization 
standard of known concentration (1 mM), to normalize all peak areas prior to log-
transformation. 
Spectral features distinguishing the wild type from the mutant E. coli strain were 
selected using a t-test with equal variances. Since thousands of features were tested 
simultaneously, small p-values occurred by chance and false positive features were 
expected. The false discovery rate of a list of features was the expected relative 
frequency of false positives in it. False discovery rates were estimated according to 
Benjamini and Hochberg 113 using the R package MULTTEST.167 
Metabolic fingerprinting aims to decide, whether a biological sample belongs to one 
of two predefined classes (e.g. wild type vs. mutant), exclusively based on a vector of 
metabolite abundances. The problem is embedded into the realm of supervised 
machine learning. Hence, the nearest shrunken centroid learning algorithm was used 
which originally had been developed for gene expression fingerprinting by means of 
DNA microarrays.168 The inputs of this method are vectors of metabolite abundances 
from both sample classes, the so-called metabolic fingerprints; the output is a 
metabolic signature. The signature is a rule converting fingerprints into class 
predictions. In order to evaluate fingerprinting performance objectively, a leave-one-
out cross-validation scheme was applied. In turn, each sample was excluded from 
the data, a signature was learned from the remaining data, and the excluded sample 
was predicted. The resulting error rate estimated fingerprinting accuracy in practice. 
Testing and validation was performed by Inka Appel using the statistical computing 
software R. 
6.3 Results 
6.3.1 Method validation via spike-ins 
INCA was validated by spiking twenty standard compounds into an E. coli wild type 
strain extract at seven different concentration levels, each of which was prepared in 
six replicates and measured in random order by GC×GC-TOFMS. The total number 
of features available for optimizing and testing the retention time correction and 
alignment tools was 800 after exclusion of two runs because of technical problems.  
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 A series of steps were performed to compile a metabolic fingerprint from the raw data 
in a single peak list (Figure 6.1). Using the LECO ChromaTOF software, first the 
regions of the 2D chromatogram containing excessive noise were excluded, thereby 
cutting on average the number of features per sample in half. In a second step, the 
ChromaTOF software was used for baseline correction, the merging of peaks 
generated in the second dimension separation using spectral matching, and the 
exclusion of signals not exceeding a predefined S/N of ≥500. 
 
Figure 6.1. Workflow of the various processing steps. Reproduced from 107. 
The EI spectra of trimethylsilyl derivatives showed a typically abundant ion with m/z 
73 that corresponded to the trimethylsilyl cation [(CH3)3Si]+, while derivatives with at 
least two TMS groups always yielded a strong signal at m/z 147 corresponding to the 
pentamethyldisiloxane cation [C5H15Si2O]+.49 This characteristic fragmentation 
behavior was exploited for data analysis by using only the area integrals for m/z 73 
as a quantitative measure for all peaks in the peak lists. A compound-specific unique 
m/z ion could not be used, as the ChromaTOF software was unfortunately unable to 
constantly assign the same abundant unique mass to an identical compound in the 
different peak lists. Deconvoluted spectra with a mass threshold of ≥5 % were used 
accordingly. After exporting the peak lists of each sample, the similarity measure was 
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 used to automatically locate the odd-numbered fatty acid standards in the peak list, 
which always showed similarities of >95 %. 
Prior to alignment, retention times were normalized by fitting linear models separately 
al tolerance parameters were 
Table 6.1. Parameters and associated tolerances tested for feature alignment. t_1st and 
Parameter Tolerance 
to the first and second dimension retention times using the odd-numbered fatty acids 
as reference points. Afterwards, peak alignment was carried out using consecutively 
first dimension retention time, second dimension retention time, m/z values, and 
relative ion intensities of EI spectra as sorting criteria. 
In order to apply the peak alignment effectively, optim
determined by testing a total of 288 parameter combinations on the 20 standard 
compounds that had been spiked into an E. coli wild type extract (Table 6.1). Sixteen 
of the parameter settings were able to align the 20 standard compounds in a single 
row each, yielding 800 out of 800 true positives. The number of true positives 
depended more on the tolerance parameters chosen for spectra than for retention 
times. 
t_2nd correspond to first and second dimension retention time, while t_ol and t_rate 
correspond to relative overlaps of fragment ions and their relative signal intensities for a 
given feature. 
t_1st [s] 4, 8, 12 
t_2nd [s] 0.025, 0.05, 0.075, 0.1, 0.125, 0.15 
 
t_ol 1.0, 0.9, 0.8, 0.7 
t_rate 0.1, 0.2, 0.3, 0.4 
 
he optimal parameter setting chosen for subsequent analysis of features was 8 s T
and 0.1 s for 1st and 2nd dimension retention time, respectively, and 90 % and 40% 
overlap of m/z values and relative ion intensities, respectively. Using this setting, a 
total of 4,726 features remained of the GC×GC-TOFMS spike-in data. However, 
some features were not detected in all samples, possibly indicating noise. Therefore, 
only features detected in at least 50 % of all samples were selected for further 
analysis. This feature reduction resulted in 517 features with a maximum of 17 % 
zero values. This was highly compatible with multivariate analysis according to Gika 
et al., who had suggested that up to 50 % zero values might be tolerated.169 Zero 
values were set to the minimum area count assuming that peaks were missing 
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 because they fell below the background noise. The peak areas of the features were 
then normalized with the area integrals of tridecanoic acid at m/z 271 and subjected 
to a log transformation for further validation. 
The spike-in dataset allowed for the comprehensive evaluation of the ability of 
c
GC×GC-TOFMS together with INCA to detect fold changes. When comparing two 
groups of samples with different spike-in levels, only features spiked into the matrix 
should vary. Pairwise t-tests of each spike-in level with the biological background 
data were performed to detect differential features assuming equal variance in both 
groups. Sorting the list of features in decreasing order according to the absolute 
value of the t-statistics put differential features on top of the list that should ideally be 
represented by the spike-in metabolites. For each rank of the t-statistic, true positives 
and negatives, and respectively false positives and negatives could be determined by 
comparing the features up to the respective rank to the actual list of spike-ins. The 
efficiency across all thresholds is illustrated in ROC curves. Here the false positive 
rate (FPR, or 1-specificity) is plotted versus the true positive rate (TPR, or sensitivity) 
for all possible t-statistic ranks (Figure 6.2). While it proved impossible to discriminate 
a 1.1-fold change from the background, higher fold changes yielded increasing 
empirical accuracies (92 % and 96 % for the 2- and 4-fold change, respectively). This 
matches accuracies reported for gene expression data.170 
Hence, genuine changes in metabolite concentration ould be detected against a 
background of thousands of spectral signals subject to random measurement 
fluctuations that arise in the analysis of complex biological matrices. Next, we asked 
whether fold changes could be reproduced quantitatively. Linear dependencies 
between expected and observed fold changes were observed. However, the slope 
and offset of regression lines differed from metabolite to metabolite. Figure 6.3 
exemplifies the spike-in data for 2-hydroxybutyrate. Thereby, all possible pairwise 
fold changes were plotted. Corresponding figures for the entire spike-in dataset can 
be found in Figure S2 in the appendix. Reproducibility of fold changes was assessed 
using univariate linear regression on the integrals of both the universal m/z 73 
fragment ion trace (Fig. 6.3A) and the analyte-specific fragment ion trace (Fig. 6.3B) 
for each of the 20 different spiked analytes investigated over the fold changes. 
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Figure 6.2. ROC curves for different fold changes. Sensitivity and 1-specificity improve with 
increasing fold change. Reproduced from 107. 
Regression equations, regression coefficients, and relative standard deviations 
(RSDs) are given in the figures. The correlation between observed and spiked-in fold 
changes increased when integrating a unique mass trace rather than the m/z 73 
fragment ion trace. The ranges of regression coefficients and RSDs improved from 
0.630 – 0.985 and 7.8 – 52.9 % to 0.874 – 0.993 and 5.0 – 19.3 %, respectively. In 
summary, fold changes could be reproduced up to linear transformations. 
 
Figure 6.3. Linear dependency between expected and observed fold changes of 2-
hydroxybutyrate for both (A) the universal m/z 73 fragment ion trace and (B) the analyte-
specific fragment ion trace m/z 205. All possible pairwise fold changes are plotted. 
Reproduced from 107. 
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 6.3.2 Comparison of E. coli strains 
Figure 6.4 shows a comparison of a 1D total ion chromatogram of the mutant E. coli 
strain (Fig. 6.4A) with 2D total ion chromatograms of the mutant (Fig. 6.4B) and the 
respective wild type strain (Fig. 6.4C). 
 
Figure 6.4. (A) TIC chromatogram of mutant ∆UdhA-∆PntAB E. coli MG1655 strain using 
1D-GC-TOFMS. (B) TIC chromatogram of the same mutant strain sample using GC×GC-
TOFMS. (C) GC×GC-TOFMS separation of the wild type E. coli MG1655 strain. Major 
metabolites are labeled and the added internal standards are italicized. Selected 
compounds, in particular leucine and glycerol, are shown in the small windows D, E, and F. 
Even without data analysis, the comparison of mutant and wild type sample shows an 
apparent difference in the abundance of citrate (B vs. C). Enhanced separation is achieved 
by using GC×GC (E, F) instead of 1D-GC (D). Furthermore, retention time shifts are 
observed that require scaling (E vs. F). Reproduced from 107. 
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 The advantage of GC×GC over conventional 1D-GC is exemplified for the separation 
of glycerol and leucine. In 1D-GC-TOFMS, the two compounds could only be 
resolved by MS on the basis of the characteristic EI fragment ions of m/z 147 and 
158 for glycerol and leucine, respectively (Fig. 6.4D). In contrast, glycerol and leucine 
are baseline separated in the second dimension of GC×GC-TOFMS (Fig. 6.4E and 
F). Since ChromaTOF failed to deconvolute the signals of glycerol and leucine 
consistently in the 1D-GC-TOFMS spectra, the latter method failed, in contrast to 
GC×GC-TOFMS, to detect the significant difference in leucine abundance between 
the two strains. 
Following exclusion of peaks with S/N <500 and retention time scaling, peak 
alignment was carried out using 1D and 2D retention times and the deconvoluted 
mass spectra as sorting criteria. After alignment, a total of 2,259 features remained 
(Table 6.2). Only features that had been detected in at least 50 % of all samples (9 
out of 18) were further analyzed. This arbitrary cut-off was selected with respect to 
the group-size of 9 to ensure that features not present in one group but in the other 
were not excluded from the list. A total of 398 features with a maximum of 25 % zero 
values remained. 
Table 6.2. GC×GC-TOFMS data for comparison of the E. coli strains. Reproduced from 107. 
Total features 2259 
Reduced features1 398 
Significant features2 48 
Metabolites identified 
that distinguished the 
two E. coli strains 
pyruvate, citrate, cis-aconitate, succinate, α-ketoglutarate, 
fumarate, malate, glucose, glucose-6-phosphate, myo-
inositol, indole, GABA, glycine, proline, lysine, leucine, 
isoleucine, valine, pyroglutamate, putrescine, itaconate, 
aminoadipate, tartrate, orotate, furoate, caproate, sucrose 
1 Features exceeding S/N ≥500 in 9 out of 18 samples. 
2 Metabolites that differed significantly (FDR <0.05) in abundance between the 
strains. 
 
Zero values might result from (i) peaks that were actually not present, (ii) signals 
falling below predefined S/N thresholds, (iii) features not matching the alignment 
parameters, (iv) ineffective deconvolution of raw mass spectra, and (v) peaks that 
were not identified according to initial data processing settings. Especially, if values 
for almost a whole group, like a fold change level, are missing no inference can be 
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 made about the mean and variance of that group. Zero values were problematic for 
subsequent statistical analysis and were thus set to the minimum area count 
assuming that peaks were missing because they fell below the background noise. 
The features were then normalized with the area integrals of tridecanoic acid at m/z 
271, subjected to a log transformation and a PCA (Figure 6.5). A clear segregation of 
the two E. coli strains and the blanks was obtained. Moreover, the variability among 
the E. coli strains was notably higher than the variability among the blanks indicating 
that the metabolic fingerprints captured true biological variation. 
 
Figure 6.5. PCA of a randomly aligned dataset of E. coli mutant and wild type strains. 
Feature reduction yielded 398 features present in at least 50 % of samples within one group. 
PC1 accounted for 33 % of the variance, PC2 for 16 %. Reproduced from 107. 
A t-test with equal variances identified a list of 48 features that differed significantly 
between the two strains with an estimated false discovery rate of <0.05, indicating 
significance also after correction for multiple testing. In other words less than 3 false 
positives were expected among the 48 identified features. It should be noted that a 
feature does not necessarily equal a metabolite. Several amino acid signals were 
identified in the chromatograms corresponding to a single amino acid. It is well 
known that partial silylation can result in more than one signal for an amino acid. 
Also, certain metabolites such as those containing a carbonyl group, e.g. glucose, 
glucose-6-phosphate, and α-ketoglutarate, form two isomers upon methoximation 
 57
 that are separated by GC. In addition, steric hindrance, degradation, or 
rearrangement reactions can occur and cause multiple possible analyte structures of 
the same metabolite.49, 51 Thus, a metabolite can be represented by more than one 
feature and vice versa a feature can represent more than one metabolite. Twenty-
seven metabolites were identified accounting for 33 of the 48 features (Table 6.2). 
Significant features do not imply that metabolic fingerprinting is possible. In order to 
verify that strains can be correctly classified into wild type vs. mutant through their 
metabolic fingerprints, we learned metabolite signatures using the shrunken centroid 
classifier by Tibshirani et al.168 In a leave-one-out cross-validation procedure 100 % 
of the metabolic fingerprints were classified correctly. Most of the compounds were 
intermediates of the citrate cycle as expected from our previous analysis of the two 
E. coli strains employing CE-TOFMS.165 Importantly, the latter method also 
confirmed, that the additional significant features discovered by GC×GC-TOFMS 
were true positives. 
6.3.3 Comparative quantification using metabolite profiling 
Selected metabolites, including pyruvate, succinate, fumarate, malate, α-
ketoglutarate, cis-aconitate, citrate, myo-inositol, and glucose-6-phosphate, were 
quantified using their respective unique mass in a metabolite profiling approach. A 
calibration was performed using a custom-made metabolite standard solution with 
different calibration levels. The linear calibration range was 0.5 – 250 µM. Results are 
depicted in Figure 6.6. A significant increase of TCA cycle intermediates in the 
mutant compared to the wild type E. coli was observed, thus confirming the GC×GC-
TOFMS quantitative data based on the universal m/z 73 fragment ions. 
Analytes and standards are listed in Table 6.3. First and second dimension retention 
times, correlation coefficients, linear calibration ranges, calibration parameters, 
relative standard deviations of one calibration triplicate, and the average RSDs of 
biological triplicates are presented. In addition, the average RSDs of biological 
triplicates using m/z 73 is shown. The calibration triplicates of the internal standards 
were normalized by using the area integrals of tridecanoic acid at m/z 271. Utilizing 
the m/z 73, the RSDs of the analytes varied from 13.2 to 26.3 %. In contrast, using 
the respective unique mass, the RSDs of the analytes ranged from 7.4 to 24.5 % for 
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 metabolite extraction and GC×GC-TOFMS analysis. The RSDs for calibration 
replicates varied from 7.0 to 15.2 %. 
Table 6.3. Figures of merit for the metabolite profiling of significant compounds.1 Reproduced 
from 107. 
Compounds 1D, 2D 
retention 
time 
[s] 
r Linear equation RSD 
calib. 
tripl. 
(%) 
RSD  
biol. 
tripl. 
m/z 73 
(%) 
RSD 
biol. 
tripl. 
m/z U 
(%) 
Analytes 
Pyruvate 661, 1.995 0.999 y= 0.200 x 0.008 7.5 16.7 7.4 
Succinate 929, 2.225 0.992 y= 0.106 x 0.008 9.9 19.9 16.2 
Fumarate 957, 2.220 0.991 y= 0.102 x 0.017 11.0 21.8 19.7 
Malate 1101, 2.165 0.992 y= 0.059 x 0.010 7.0 17.8 16.5 
α-Ketoglutarate2 1153, 2.320 0.997 y= 0.001 x -4.0e-005 10.3 19.0 14.3 
α-Ketoglutarate2  1177, 2.270 0.998 y= 0.015x -0.001 11.6 23.5 18.6 
cis-Aconitate 1317, 2.330 0.999 y= 0.020 x 0.001 9.8 19.2 18.4 
Citrate 1385, 2.190 0.998 y= 0.078 x 0.012 13.0 13.2 17.5 
Myo-inositol 1589, 2.085 0.997 y= 0.067 x 0.013 15.2 26.3 24.5 
Glucose-6P2 1757, 2.770 0.999 y= 0.015 x -0.001 12.5 19.6 12.2 
Glucose-6P2  1773, 2.870 0.999 y= 0.003 x -4.8e-005 9.5 24.2 16.6 
Internal extraction standards 
[U-13C]Pyruvate 661, 1.995  na3 na 4.3 16.7 14.4 
[U-13C]Lactate 673, 1.960 na na 7.1 18.8 16.6 
Norvaline, OTMS 721, 2.155 na na 3.1 14.9 18.7 
Norvaline, N-, 
OTMS 
857, 2.015 na na 8.2 12.6 20.1 
[U-2H]Succinate 925, 2.250 na na 4.7 7.5 7.2 
[2,3,3-2H3]Malate 1097, 2.145 na na 7.7 14.4 11.6 
[2H7]trans-
Cinnamate 
1149, 2.465 na na 9.5 13.8 15.9 
[U-13C]Glucose2 1453, 2.025 na na 9.8 13.5 10.5 
[U-13C]Glucose2 1469, 2.020 na na 10.7 17.1 22.0 
Internal derivatization standards 
Nonanoate 973, 2.060 na na 2.4 15.2 8.6 
Undecanoate 1153, 2.140 na na 2.3 9.5 6.3 
Tridecanoate4 1317, 2.185 na na na na na 
Pentadecanoate 1465, 2.220 na na 1.7 7.4 6.4 
Heptadecanoate 1601, 2.275 na na 2.6 12.4 9.0 
Nonadecanoate 1737, 2.725 na na 4.7 11.0 10.0 
1 linear calibration range was 0.5 – 250 µM.  
2 form isomers upon methoximation. 
3 na, not applicable. 
4 used to normalize internal standards. 
 59
  
Figure 6.6. Absolute quantification of a selected set of metabolites, whose abundance 
differed significantly (FDR of <0.05) between E. coli mutant and wild type strain using their 
respective unique mass. Reproduced from 107. 
6.3.4 Comparison of GC×GC-TOFMS and CE-TOFMS data 
GC×GC-TOFMS data obtained were compared with CE-TOFMS data reported 
previously by Timischl et al. 165 for the same E. coli strains. In total, Timischl et al. 
made 58 high-confidence identifications of anionic metabolites in the two E. coli 
strains grown in LB medium and harvested in the stationary phase. Out of the 58 
metabolites, 37 showed significant differences in abundance between the strains 
based on a Student´s t-test (p <0.05) without correction for multiple testing. Eighteen 
of the 37 metabolites were also found by GC×GC-TOFMS to differ significantly with 
an FDR of <0.05 (see Table S3 in the appendix). Alanine, aspartate, benzoate, 
glucosamine-6-phosphate, glucuronate, glycerolphosphate, octanoate, pantothenate 
phosphoenolpyruvate, phosphoglycerate, and glutamate (a total of 11) showed no 
significant difference by GC×GC-TOFMS, but had been found to differ significantly by 
CE-TOFMS. However, glutamate is known to partly lose H2O and rearrange to 
pyroglutamate, which is also formed from glutamine through loss of NH3.51 This 
explains why pyroglutamate differed significantly between the strains in the GC×GC-
TOFMS analysis. Finally, GC×GC-TOFMS failed to detect 8 metabolites, namely 
UMP, UDP, UDP-glucose, CMP, dTMP, AMP, glutathione, and maltose. The majority 
of those compounds are nucleotides that are not amenable to GC analysis. In 
 60
 contrast to CE-TOFMS, GC×GC-TOFMS found α-ketoglutarate and tartrate to differ 
significantly between the strains. Finally, we were able to detect significant 
differences for glycine, indole, myo-inositol, and putrescine, which had not been 
detected by CE-TOFMS, and for GABA and furoate, which had not been confirmed 
by a commercial standard in the CE analysis. A complete comparison between 
GC×GC-TOFMS and CE-TOFMS is given in Table S3 in the appendix. 
6.4 Discussion 
6.4.1 Metabolic fingerprinting 
The GC×GC-TOFMS based metabolic fingerprinting approach presented in this 
chapter, in combination with classification and testing algorithms, provides an 
effective and simple means to classify samples according to metabolite abundances, 
potentially making it a valuable tool in many application areas, such as medical 
diagnosis and prognostication. The retention time correction and peak alignment 
algorithm INCA facilitates the comparison of fingerprints by (i) fitting retention times of 
unknown features to linear models using the homologous series of odd-numbered 
fatty acids as reference points, and by (ii) combining peak lists into a single data 
matrix based on first and second dimension retention times and spectral information. 
The algorithm further capitalizes on the characteristic fragmentation behavior of 
silylated metabolites upon EI ionization yielding a true mass spectrum, which can be 
used in library searches for identification purposes. In addition a trimethylsilyl cation 
with a characteristic m/z 73 ion is obtained, the integral of which can be used as a 
quantitative measure for all features detected above a predefined S/N. 
INCA particularly benefits from gathering the complete information from all peak lists. 
Thereby no data is lost and the decision about further data handling is left to the 
user. Furthermore, INCA is capable of automatically selecting optimal alignment 
tolerance parameters based on spiked-in compounds for any biological matrix, which 
proves to be a further user-friendly attribute.  
It must be pointed out that INCA, like MSort®, or the later developed DISCO or 
Guineu (for details see chapter 4.4.2) use automatically processed data by vendor 
software as input and, therefore, rely on the quality and transparency of the provided 
data. Alignment as well as quantification can suffer from well-known problems like 
 61
 ineffective deconvolution, peak picking, peak merging and peak integration, or 
signals falling below the predefined S/N threshold. This results in missing values 
which need to be handled carefully for subsequent statistical analysis. 
A disadvantage of ChromaTOF, in particular, is the lack of quantification options for 
metabolic fingerprinting. A compound-specific unique m/z ion could not be exploited 
for external data alignment due to the inability of the ChromaTOF software to 
constantly assign the same abundant unique mass to an identical compound across 
all peak lists. However, as shown in this chapter, while use of the universal m/z 73 
fragment ion for all compounds in a sample matrix might yield increased variance 
compared to the use of compound-specific unique m/z ions, it has proven sufficiently 
reliable for quantification purposes and, therefore, represents a reasonable 
alternative. 
The E. coli mutant versus wild type experiment was repeated together with Christian 
Wachsmuth (Institute and Chair of Functional Genomics, University of 
Regensburg).171 Extracts were analyzed by both GC×GC-TOFMS and GC-APCI-
TOFMS. Thirteen metabolites could be confirmed significant by both methods 
including all TCA cycle intermediates and the related itaconate. As a group, those 
analytes had been regulated most significantly (for more details see Table S4). Six 
metabolites, namely thymine, dihydroorotate, ornithine, N-acetylaspartate, N-
acetylneuraminate, and N-acetylputrescine, were assigned using the GC-APCI-
TOFMS data and a de novo identification approach.171 These six metabolites were 
not identified by the initial GC×GC-TOFMS study. The identification of derivatives of 
dihydroorotate, N-acetylneuraminate, and N-acetylputrescine proved difficult as their 
characteristic EI spectra were contained in neither the NIST 05 nor the Fiehn 
metabolite library. N-acetylaspartate had already been identified as significantly 
different using CE-TOFMS metabolic fingerprinting.165 
6.4.2 Metabolite profiling 
The performance of GC×GC-EI-TOFMS for metabolite profiling was comprehensively 
evaluated and within the scope of the master thesis of C. Wachsmuth compared to 
GC-EI-TOFMS, GC-APCI-TOFMS, GC-EI-qMS, and GC-CI-qMS in terms of 
reproducibility, dynamic range, limit of detection and quantification using a standard 
mixture of 43 metabolites from different chemical classes and metabolic pathways 
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 and 12 stable isotope-labeled standards (for details see Table S5 in the appendix). 
The results were published in Wachsmuth et al.171 
The standard mixture was prepared from separate stock solutions by C. Wachsmuth. 
It included each compound at a concentration of 1 mM in methanol and was serially 
diluted covering 31 points over a concentration range of 0.002 – 3000 μM. GC×GC-
EI-TOFMS raw data were processed with the LECO ChromaTOF software v4.32 
according to chapters 6.2.2 and 7.2.1, respectively. 
For calibration, compounds were normalized by the corresponding stable isotope-
labeled standard or by the closest eluting or structurally similar internal standard 
compound. A characteristic fragment ion was selected as quantifier for each 
compound according to Table S5 in the appendix. Calibration curves were obtained 
for every standard by plotting the response as a function of the absolute amount of 
standard in nmol. Whenever a certain analyte gave two peaks, e.g. cis-trans isomers 
of methoximated compounds or partly silylated amino acids, only the more intense 
one was used. 
In Table 6.4, linear ranges and RSDs of calibration replicates are given for the 43 
analytes and the five techniques. R square values were classified in three groups (R² 
>0.995, 0.990<R²<0.995, 0.980<R²<0.990) and the respective group is indicated for 
each analyte and technique. The exact R2 values are given in Table S6 in the 
appendix. Linear regression analysis revealed overall excellent R2 values exceeding 
0.995 for more than 70% of analytes in case of GC×GC-EI-TOFMS, GC-APCI-
TOFMS, and GC-EI-qMS, and for almost half of all compounds in case of GC-EI-
TOFMS and GC-CI-qMS. R2 values below 0.99 were only observed for Ile-2TMS 
employing GC×GC-EI-TOFMS, and GABA-3TMS, erythritol, and phenylacetate for 
GC-EI-TOFMS. Based on our results and literature data 84, 172, distinct improvements 
in linearity are attributed to the use of twelve stable isotope-labeled internal 
standards, because analytes with a corresponding stable isotope-labeled internal 
standard performed overall better than the other analytes. 
Evaluation of quantification ranges (Table 6.4) highlighted GC×GC-EI-TOFMS as the 
most powerful among the tested techniques due to its ability to measure 
concentration levels over three orders of magnitude down to LLOQs in the sub-
micromolar range. Compared to 1D-GC-EI-TOFMS, thermal refocusing of analytes 
eluting from the first column yielded narrow peaks and, consequently, lower LLOQs. 
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 Table 6.4. Linear ranges and RSDs for derivatization replicates (n=5) for master mix 
compounds analyzed with the five different techniques. Exact R² values are given in Table 
S6 in the appendix. The degree of silylation is only indicated for metabolites forming more 
than one derivative. Reproduced from 171. 
Compound    GC-APCI- 
   TOFMS 
GC×GC-EI-
TOFMS 
    GC-EI- 
    TOFMS 
       GC-CI- 
      qMS 
    GC-EI- 
    qMS 
 LR 
[µM] 
RSD
(%)b 
LR 
[µM] 
RSD
(%)b
LR 
[µM] 
RSD
(%)b
LR 
[µM] 
RSD 
(%)c 
LR 
[µM] 
RSD
(%)c
Ala-2TMS 1.95-250(2) 7.6 0.98-250(1) 6.7 7.81-500(2) 12.0 46.88-2000(2) 10.7 15.63-750(1) 6.5 
Val-2TMS 0.49-125(1) 2.5 0.12-500(1) 3.3 7.81-750(2) 11.1 11.72-1500(2) 8.3 3.91-1500(1) 3.2 
Leu-2TMS 0.49-250(2) 8.6 3.91-375(2) 3.8 15.63-250(2) 6.0 11.72-1000(1) 1.8 31.25-750(2) 4.0 
Ile-2TMS 0.49-187.5(1) 6.5 3.91-375(3) 3.7 31.25-250(2) 7.7 23.44-750(2) 10.6 46.88-2000(1) 4.3 
Pro-2TMS 7.81-1000(2) 5.4 7.81-750(1) 4.7 46.88-250(2) 5.1 62.5-1000(2) 6.8 46.88-500(2) 4.0 
Gly-3TMS 0.49-93.75(1) 3.2 0.12-750(1) 7.2 23.44-750(2) 6.7 15.63-500(2) 2.4 11.72-3000(1) 3.8 
Putrescine-4TMS 0.98-93.75(1) 2.5 11.72-750(2) 7.5 62.5-750(2) 7.3 15.63-500(2) 8.7 1.95-3000(1) 2.0 
GABA-3TMS 1.95-62.50(2) 8.7 0.98-500(2) 3.8 23.44-250(3) 5.9 15.63-375(2) 17.3 7.81-3000(1) 4.0 
Lactatea 1.95-750(2) 4.9 0.12-750(1) 1.2 3.91-750(1) 2.3 62.5-2500(1) 1.6 15.63-2000(1) 4.0 
2-OH-butyrate 0.24-187.5(1) 6.3 0.12-250(1) 2.3 7.81-750(1) 5.0 62.5-3000(1) 8.0 15.63-3000(1) 3.2 
3-OH-butyratea 0.06-187.5(1) 4.9 0.06-750(1) 1.4 3.91-750(1) 2.4 15.63-3000(1) 5.1 3.91-3000(1) 3.7 
Me-malonate 0.06-125(1) 3.5 0.24-750(1) 6.2 15.63-250(1) 7.7 7.81-2000(1) 0.9 7.81-2000(1) 3.4 
Glycerol 3.91-46.88(2) 3.9d 1.95-750(1) 3.2 7.81-125(1) 2.9 7.81-500(1) 3.2 3.91-2000(1) 3.0 
Succinatea 0.24-93.75(1) 2.5 0.12-187.5(1) 1.5 7.81-250(2) 1.8 31.25-1000(2) 2.1 7.81-3000(1) 1.9 
Glycerate 0.06-62.50(1) 4.8 0.06-750(2) 4.6 7.81-750(1) 4.5 31.25-1000(1) 3.1 7.81-2000(1) 2.8 
Fumaratea 0.49-250(1) 2.9 0.12-750(1) 2.0 0.49-750(1) 2.1 3.91-3000(1) 0.9 1.95-3000(1) 2.0 
Malatea 3.91-62.50(1) 3.8 0.03-750(1) 3.0 3.91-750(1) 3.2 23.45-1000(1) 6.1 1.95-2000(1) 2.4 
Adipate 3.91-93.75(1) 2.7 0.12-375(2) 9.3 15.63-750(1) 8.9 62.5-1500(2) 0.4 7.81-3000(1) 2.6 
Erythritol 3.91-93.75(2) 5.4 0.06-93.75(1) 1.2 3.91-500(3) 8.4 46.88-1000(2) 4.0 3.91-3000(1) 2.1 
cis-Aconitate 0.12-62.50(1) 1.7 0.06-375(1) 2.2 15.63-750(1) 1.9 46.88-1000(2) 10.4 3.91-1500(1) 5.2 
Citratea 1.95-62.50(1) 2.9 0.12-500(1) 2.1 3.91-375(2) 2.9 11.72-2000(2) 7.9 0.98-1000(1) 2.9 
Pyruvatea 0.24-500(1) 4.7 0.06-750(1) 2.1 15.63-750(1) 3.2 23.44-3000(1) 4.9 3.91-3000(1) 3.5 
2-Ketobutyrate 1.95-375(1) 2.1 0.12-250(2) 6.5 31.25-750(2) 14.4 62.5-1000(2) 6.9 7.81-3000(1) 4.2 
3-Me-2-oxovalerate 0.24-125(1) 5.0 0.49-375(1) 2.1 15.63-750(1) 2.1 62.5-750(2) 2.2 62.5-1500(2) 4.4 
4-Me-2-oxovalerate 3.91-187.5(1) 5.1 0.12-750(2) 3.2 3.91-250(1) 3.7 46.88-500(2) 4.4 7.81-750(1) 1.3 
α-Ketoglutarate 0.06-93.75(2) 4.8 0.98-750(1) 4.0 15.63-250(2) 8.0 46.88-750(1) 5.0 7.81-1500(2) 5.3 
Phenylacetate 3.91-125(1) 2.0 0.24-750(1) 2.4 23.44-375(3) 2.2 46.88-2000(2) 4.1 31.25-1000(2) 3.2 
Phenylpyruvate 0.49-93.75(1) 4.2 3.91-750(1) 4.2 15.63-187.5(2) 4.6 23.44-750(1) 1.7 62.5-3000(2) 2.7 
OH-phenylacetate 0.24-62.50(1) 5.4 0.06-375(1) 3.8 0.98-750(2) 11.8 11.72-1500(1) 2.0 7.81-1500(1) 3.6 
Homovanillate 3.91-62.50(1) 0.4 0.98-500(2) 3.3 1.95-750(2) 10.6 23.44-2500(1) 2.0 3.91-1500(2) 6.0 
Hippurate-1TMS 0.49-93.75(1) 3.3 93.75-750(1) nd 93.75-750(2) nd 31.25-750(1) 1.1 46.88-2000(1) 4.6 
Homogentisate 0.98-46.88(1) 5.7d 0.24-93.75(1) 1.9 3.91-750(2) 11.2 11.72-1000(1) 2.4 7.81-1500(1) 3.8 
OH-phenylpyruvate 0.49-93.75(1) 1.9 7.81-750(2) 5.3 15.63-250(2) 9.9 31.25-250(2) 10.2 7.81-250(2) 2.2 
5-HIAA-2TMSa 0.98-187.5(1) 3.7 0.12-500(1) 1.7 23.44-250(1) 2.0 31.25-750(1) 1.9 62.5-3000(1) 7.6 
Phenyllactate 1.95-93.75(1) 1.9 0.12-500(1) 3.9 1.95-750(1) 9.6 46.88-750(1) 1.9 7.81-3000(1) 2.7 
Nicotinate 1.95-62.50(1) 2.3 0.98-750(1) 9.6 0.98-750(1) 10.5 3.91-2000(1) 2.0 3.91-2000(1) 2.4 
Glycerol-1-P 1.95-93.75(1) 1.1 3.91-750(1) 3.2 3.91-250(2) 3.4 46.88-1500(2) 6.5 7.81-250(2) 1.3 
3-P-glycerate 1.95-62.50(1) 1.4 15.63-375(2) 3.4 46.88-375(2) 3.5 46.88-2000(1) 3.9 7.81-250(2) 1.8 
Glucose-6P 1.95-125(1) 5.4 23.43-750(2) 6.3 46.88-750(2) 10.7 62.5-1500(2) 8.5 3.91-500(1) 1.9 
Lactosea 3.91-125(2) 8.2 0.03-750(1) 1.8 3.91-750(1) 2.7 7.81-3000(1) 3.1 1.95-3000(1) 2.5 
Myo-Inositol 1.95-93.75(1) 1.4 0.24-93.75(1) 1.4 0.98-250(2) 0.6 23.44-2000(2) 10.8 7.81-2500(1) 3.6 
Glucosea 0.06-250(1) 3.3 0.03-750(1) 0.7 0.98-750(1) 2.6 23.44-3000(2) 5.7 3.91-3000(1) 3.5 
Fructose 0.98-93.75(1) 1.6 0.12-750(1) 1.6 7.81-750(2) 2.3 23.44-1500(2) 9.2 7.81-2000(1) 1.9 
a Compounds with a corresponding internal standard, b conc. = 62.5 µM n=5, c conc. = 500 µM n=5,  
d Standard conc. above ULOQ.  
(1) R² >0.995, (2) 0.990<R²<0.995, (3) 0.980<R²<0.990; nd, not detected. 
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 Overall, due to a higher ion transmission, LLOQs were lower for TOF mass 
analyzers. However, because of detector saturation, signals did not scale linearly up 
to the highest measured concentration for most metabolites, as it was the case for 
quadrupole mass analyzers. GC×GC-EI-TOFMS was superior to all other techniques 
yielding an average linear range of more than three orders of magnitude. LLOQs 
were in the range of 0.03 to 93.75 µM. GC-APCI-TOFMS showed an average linear 
range of about one order of magnitude less in concentration with LLOQs ranging 
from 0.06 to 7.81 µM. GC-EI-qMS and GC-CI-qMS had LLOQs in the range of 0.98 
to 62.5 µM and 3.91 to 62.5 µM, respectively. In the case of hippurate and 
compounds with a phosphate group (glycerol-1-phosphate, 3-phosphoglycerate, and 
glucose-6-phosphate) the LLOQs for methods with EI were surprisingly high and soft 
ionization at atmospheric pressure proved favorable for those analytes. 
LODs were also compared (see Table S6 in the appendix) and they were in the sub-
micromolar range in case of TOF mass analyzers (except GC×GC-EI-TOFMS) and in 
the lower micromolar range when quadrupole mass analyzers had been used. While 
GC×GC-EI-TOFMS showed outstanding low LODs in the nanomolar range, GC-
APCI-TOFMS performed best among the remaining techniques. Overall, trends for 
LODs were comparable to LLOQs. 
Finally, RSDs for calibration replicates (fivefold derivatized, see Table 6.4) and 
technical replicates (fivefold injected, see Table S6 in the appendix) of a calibration 
point were compared to assess the precision of the analytical procedure. For a better 
method comparison a standard concentration well in the linear range of the 
respective method was chosen, i.e. 500 μM and 62.5 μM for techniques employing 
quadrupole and TOF mass analyzers, respectively. As can be seen from Table 6.4, 
GC-EI-qMS showed the best performance with RSDs below 8 % for all compounds. 
These values are better than those reported in literature172, especially in case of 
amino acids, which is probably due to the utilization of more appropriate internal 
standards. RSDs were below 10 % for GC×GC-EI-TOFMS and GC-APCI-TOFMS 
and below 12 % for GC-EI-TOFMS and GC-CI-qMS with the exception of 2-
ketobutyrate (14.4 %) in case of GC-EI-TOFMS and GABA (17.3 %) in case of GC-
CI-qMS. RSDs for technical replicates were in total lower than those for calibration 
replicates and for more than 80 % of the compounds below 5 %. However, regarding 
repeatability, amino acids performed worst irrespectively of the GC-MS method 
employed, because silylation is not an appropriate derivatization method for this 
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 class of compounds as previously reported 172 and more suitable methods should be 
used.53, 173, 174 For other chemical groups there was no bias noticed towards high or 
low RSDs. In case of compounds with a corresponding stable isotope-labeled 
internal standard, RSDs were distinctly lower. 
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 7 Comparison of two algorithmic GC×GC-TOFMS data 
processing strategies for metabolic fingerprinting 
7.1 Introduction 
The SC option for GC×GC-TOFMS data was introduced in 2010 by LECO as an add-
on software package to ChromaTOF version 4. SC provides peak alignment, 
statistical information on various peak properties, and a Fisher ratio calculation 
module. 
Raw data acquired in chapter 6.2.1 for the spike-in experiment and the comparative 
metabolic fingerprinting of a wild type versus a double-mutant E. coli strain were 
used to evaluate the performance of SC and to compare it to our in-house developed 
retention time correction and data alignment algorithm INCA. Starting with identical 
peak lists generated by LECO’s ChromaTOF software, the accuracy of peak 
alignment and detection of 1.1- to 4-fold changes in metabolite concentration was 
assessed by means of differentially spiked E. coli extracts (analogous to Chapter 
6.3.1). To provide the same quality input signals for both alignment routines, the 
universal m/z 73 ion trace of the trimethylsilyl group was used as a quantitative 
measure for all features. 
Since SC operates as part of the ChromaTOF software, the feasibility of employing 
the signal intensities of metabolite-specific unique m/z ions for quantification instead 
of m/z 73 ions was studied. 
Multivariate statistical analyses were performed in order to evaluate the respective 
enhancements and limitations of the two algorithmic data processing strategies. 
This work was performed together with Inka Appel (Institute of Functional Genomics, 
Chair of Statistical Bioinformatics, University of Regensburg). The results in this 
chapter were published in 108. 
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 7.2 Methods 
7.2.1 Data processing 
Raw data were processed with the ChromaTOF software version 4.32. Parameters 
were chosen according to chapter 6.2.2. A separate S/N for 2nd dimension subpeaks, 
which was set at ≥50, was an improvement of ChromaTOF v4 over previous 
versions. 
7.2.2 Data alignment 
7.2.2.1 Statistical Compare 
In the SC feature of ChromaTOF the processed samples were added to a sample 
table and assigned to their respective groups. The alignment processing method 
provided two parameters for retention time and mass spectral matching, respectively. 
RT match criteria were taken into account by a maximum RT difference and a 
maximum number of modulation periods between peaks. For spectral matching, a 
mass threshold and a minimum similarity match were defined. Besides a separate 
S/N for peaks not found by the initial peak finding, thresholds for analytes to be kept 
for statistical evaluation (minimum number of samples or minimum percent of 
samples in a class that contain the analyte) could be defined. Optionally, it was 
possible to fill the table with zero values in case that an analyte was not found in a 
specific sample. 
The alignment parameters for retention time and mass spectral matching were 
chosen in accordance with the optimal parameter setting determined for INCA (see 
chapter 7.3.1). The maximum RT difference was set at 4 s, the maximum number of 
modulation periods at 2. A minimum similarity mass spectral match of 80 % was 
chosen. Further, in the deconvoluted mass spectra only m/z ions with relative base 
peak intensities ≥10 % were considered for alignment. The separate S/N for peaks 
not found by the initial peak finding was set at ≥50. Maximum data output for 
statistical analysis was obtained by setting the minimum number of samples 
containing the analyte and the minimum percent of samples in a class that contain 
the analyte at relatively low values of 1 and 10 %, respectively. Peak alignment was 
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 consequently carried out using 1st and 2nd dimension retention times and mass 
spectra as sort criteria. 
Pairwise sample comparisons for all samples analyzed are made peak by peak. 
Peaks across samples that are within the retention time window specified in the data 
processing method and share the best spectral match are grouped together. The 
spectral match uses the NIST match algorithm, the same as employed in library 
searches. Following the pairwise comparisons, common peaks are linked from 
sample to sample to create groups of common analyte peaks. During the grouping 
conflicts may arise due to the parameters specified in the data processing method 
(RT window and mass spectral match threshold) and/or variability in peak 
interferences and RT shifts. The software takes various steps encoded in non-
accessible source code to resolve these conflicts. Failure to resolve conflicts results 
in the exclusion of peaks from the final table. 
Each peak is assigned a peak quality based on the peak shape of the extracted 
unique mass ion chromatogram and the quality of the deconvolution. The peak that 
represents the best quality within a group of aligned peaks is selected to conduct a 
library search for that group of peaks and the name of the matching library compound 
appears in the compound table. 
Deconvolution performed during data preprocessing may yield different unique 
masses for identical compounds in different samples. Nonetheless, SC has to 
choose a consistent mass for quantification from the unique masses. This quant 
mass is selected according to the most common unique mass for a specific peak 
across all samples. The remaining alternating masses are adjusted according to this 
predominant mass, provided that the peak profile is good. If the peak profile is poor 
and thus does not allow the extraction of a unique m/z ion due to interferences, the 
ratio of the quant mass to the available unique mass will be determined to calculate 
peak height and peak area. Alternatively, a quant mass may be assigned by 
manually replacing the prevalent unique m/z ion trace for a feature across all peak 
lists by the m/z ion trace of choice, e.g. m/z 73. 
The aligned peak table was exported in a csv file format. The table was transformed 
to obtain a suitable data matrix for multivariate statistical analysis, which had one 
column per measurement and one row per feature. A feature was characterized by 
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 peak name, average of 1D and 2D retention times, area count, the unified quant 
mass, and the respective area integrals for each measurement. 
7.2.2.2 INCA 
For INCA, it was not possible to exploit a compound-specific unique m/z ion, as the 
algorithm worked outside LECO´s proprietary software and, therefore, had no access 
to the raw data during alignment. INCA instead relied on the characteristic EI 
fragmentation behavior of trimethylsilyl derivatives by using only the area integrals of 
the m/z 73 ion traces as a quantitative measure.  
A peak list in csv file format was exported for each chromatogram containing peak 
name, 1D and 2D retention times, area count of m/z 73, and the deconvoluted mass 
spectra containing only m/z ions with a relative intensity ≥10 % of the base peak. The 
implementation of a separate S/N for 2nd dimension subpeaks in ChromaTOF v4 
enabled more accurate peak integration compared to previous versions, but also 
increased the overall background noise. Hence, the intensity threshold for m/z ions 
relative to the base peak had to be raised from ≥5 to ≥10 % (compared to chapter 
6.2.2). Retention time scaling and peak alignment was performed in the same way as 
in chapter 6.2.3 and 6.2.4 to yield the aligned data matrix. 
7.2.3 Normalization and testing 
See chapter 6.2.5. 
7.3 Results 
INCA and SC were evaluated based on the spike-in dataset (for details see chapter 
6.2.1.1 and 6.3.1). To ensure direct comparability, INCA alignment was repeated with 
ChromaTOF software version 4.32. For SC exactly the same preprocessing steps 
were chosen to compile metabolite fingerprints from the raw data (schematically 
shown in Figure 7.1). The performances of the alignment routines SC and INCA were 
directly compared by manually selecting the universal m/z 73 ion trace of the 
trimethylsilyl group as the same quality input signal. 
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 7.3.1 Statistical Compare with m/z 73 versus INCA 
A total of 887 features were extracted from the GC×GC-TOFMS spike-in data using 
SC with m/z 73 as quant mass. However, some features were not detected in every 
sample causing missing values. Reasons for missing values were already addressed 
in chapter 6.3.2. Additionally, only features detected in at least 50 % of all samples 
were selected for further analysis removing primarily those features, which could not 
be aligned to other peaks at all. This strict feature reduction resulted in 458 features 
with a maximum of 14 % zero values. 
1. ChromaTOFTM Classification
Exclusion of chromatographic
noise regions
3. ChromaTOFTM Statistical Compare
- Generate classes
- Add samples to classes
- Peak alignment using 1D RT, 2D RT 
and mass spectra as sort criteria
2. ChromaTOFTM Processing
- Deconvolution
- Peak combine
- Peak detection 
above given S/N
- Integration of subpeaks4. Export
- Aligned peak table
in csv file format
Peak Mass RT1_mean RT2_mean Count Spike1a Spike1.1a Spike1.25a Spike1.5a Spike2a Spike2.5a Spike4a Spike1b Spike1.1b
Analyte 9 81 601.80 1.944 40 -3.518 -4.728 -4.557 -3.667 -3.775 -3.687 -3.837 -4.309 -4.105
Analyte 14 113 610.50 2.670 40 -5.161 -4.756 -4.182 -4.909 -4.486 -4.690 -3.404 -4.038 -3.833
Analyte 17 73 614.50 1.860 40 -1.882 -2.394 -2.168 -2.269 -2.245 -2.140 -1.621 -1.707 -1.698
Analyte 19 102 629.90 1.847 40 -3.081 -4.343 -0.994 -3.456 -2.284 -2.619 0.392 -0.398 -0.341
*Ethanolamin 174 630.70 1.802 40 -4.255 -4.185 -4.093 -4.283 -4.262 -4.192 -3.795 -4.690 -4.173
Analyte 24 131 634.30 1.784 40 -3.766 -4.112 -4.536 -4.191 -4.073 -3.816 -3.330 -4.732 -3.814
Lactic acid -d 117 637.80 1.789 40 -2.821 -2.626 -2.791 -3.075 -3.199 -3.648 -2.638 -2.467 -2.729
Analyte 37 207 641.70 1.713 40 -3.692 -3.208 -3.709 -3.780 -3.348 -3.816 -3.101 -3.423 -3.305
Analyte 43 152 642.60 1.967 40 -1.772 -1.754 -1.236 -1.836 -1.576 -1.497 0.024 -0.549 -0.790
Analyte 47 174 655.10 1.989 40 -2.881 -2.938 -2.760 -2.980 -2.918 -2.751 -2.428 -2.455 -2.556
*Malonic acid 147 658.70 1.842 40 -4.949 -5.147 -4.945 -5.081 -5.077 -4.906 -4.204 -4.732 -4.603
Analyte 55 207 659.90 1.724 40 -3.496 -3.243 -3.827 -3.724 -3.374 -3.589 -2.742 -3.237 -2.980
Lactic acid -d 117 667.00 1.935 40 -2.140 -1.856 -2.223 -2.077 -2.058 -1.987 -1.575 -2.029 -2.015
Analyte 69 178 671.10 2.148 40 -5.760 -6.601 -5.555 -5.801 -5.892 -5.563 -4.549 -5.044 -5.272
Analyte 70 89 673.10 2.211 40 -3.803 -3.836 -3.290 -3.234 -2.912 -2.561 -1.390 -3.763 -3.577
*Hexanoic aci 173 674.80 1.963 40 -5.778 -5.691 -5.759 -5.931 -6.154 -6.100 -5.488 -5.388 -5.560
5. Data conversion
- Feature selection
- Normalization with IS
- Log transformation
 
Figure 7.1. Schematic workflow of the various data processing steps. Reproduced from 108. 
Missing values were set to the minimum area count assuming that peaks were 
missing, because they had fallen below the background noise. The peak areas at m/z 
73 of the remaining features were then normalized against the peak area at m/z 271 
of tridecanoic acid and subjected to a log transformation for further validation. 
For the INCA alignment, optimal tolerance parameters were determined on the 20 
standard compounds that had been spiked into an E. coli wild type extract. The 
optimal parameter setting chosen for subsequent analysis of features was 4 s and 
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 0.05 s for 1D and 2D retention time, respectively, and 80 % and 20 % overlap of m/z 
values and relative ion intensities, respectively. The parameters were more stringent 
than in our previous work due to the improved quantification of subpeaks by the new 
ChromaTOF version. With the use of this parameter setting, a total of 4,404 features 
remained. Data reduction resulted in 447 features with a maximum of 17 % zero 
values. The peak areas at m/z 73 for these features were then also normalized 
against the peak area of tridecanoic acid at m/z 271 and log transformed. 
While the initial number of features extracted by INCA had been several-fold greater 
(n=4,404) than that of SC (n=887), data reduction yielded a comparatively similar 
number of features for INCA (n=447) and SC (n=458), respectively. The spike-in 
dataset was used to assess the ability of GC×GC-TOFMS in combination with either 
alignment algorithm to detect fold changes. T-statistics and ROC curves were 
compiled as described in chapter 6.3.1. Briefly, pairwise t-tests of each spike-in level 
with the biological background data were carried out to detect differential features 
assuming equal variance in both groups. After sorting the list of features in 
decreasing order according to the absolute value of the t-statistics, each rank of the t-
statistic was assigned as true positive and negative, and respectively false positive 
and negative by comparing the features up to the respective rank to the actual list of 
spike-ins. The efficiency is shown in ROC curves and their respective AUC. The false 
positive rate is plotted versus the true positive rate for all possible t-statistic ranks. 
ROC curves for both INCA (A) and SC (B) are presented in Figure 7.2.  
Irrespectively of the alignment algorithm used, it proved impossible to discriminate a 
1.1-fold change from the background (AUC for INCA and SC were 0.58 and 0.59, 
respectively). SC (AUC of 0.90) performed better than INCA (AUC of 0.87) in 
distinguishing a 1.25-fold change from the background. For higher fold changes, the 
AUCs improved and became increasingly similar for the algorithms, but did not reach 
1 even at the highest spike-in level. In Figure 7.2C, the AUCs of INCA vs. SC were 
plotted for all possible pairwise fold changes. Overall, SC performed comparable to 
INCA with a small advantage at the lower and a slight disadvantage at the higher fold 
changes. 
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Figure 7.2. ROC curves for different fold changes using (A) INCA and (B) SC alignment, 
both using m/z 73 for quantification, and corresponding AUC values. TPR and FPR improve 
with increasing fold changes. (C) AUC comparison plot between INCA and SC for all 
pairwise fold changes. SC performed comparable to INCA in the spike-in experiment. 
Reproduced from 108. 
7.3.2 SC with m/z 73 versus unique m/z 
To fully exploit the potential of SC, the same peak lists of the GC×GC-TOFMS spike-
in data were used, but the m/z 73 ion trace was replaced by a compound-specific 
unique mass. Here, SC could further capitalize on its access to chromatographic data 
during the alignment procedure. Quant masses could be verified and if necessary 
modified assuring that the same abundant quant m/z ion trace was assigned to an 
identical compound in different samples. In case the quant ion could not be 
extracted, a ratio of the chosen quant ion to the existent unique m/z ion was 
determined, which represented a viable approximation. 
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 Alignment yielded 1,222 features that were reduced to 632 features with a maximum 
of 14 % zero values after elimination of those features that had been detected in less 
than 50 % of the samples. After setting missing values to the minimum area count 
the features´ peak areas were finally normalized with the area integrals of tridecanoic 
acid at m/z 271 and log transformed. 
Representative ROC curves with their respective AUCs making use of unique m/z 
are shown in Figure 7.3A. Analogously, all pairwise fold changes were plotted with 
their respective AUCs to compare the unique m/z with the m/z 73 alignment (Figure 
7.3B). Although it was still impossible to distinguish a 1.1-fold change from the 
background, a 1.25-fold change could be distinguished more effectively by the 
unique m/z alignment with an AUC of 0.92 compared to an AUC of 0.90 for the m/z 
73 alignment. The 2.5-fold and 4-fold changes resulted in nearly ideal AUCs of 0.99. 
However, the use of unique m/z ions as quantifiers still yielded false positives even at 
the highest fold change tested. Overall, the use of unique m/z outperformed m/z 73 in 
the spike-in experiment. 
 
Figure 7.3. (A) ROC curves for different fold changes employing unique m/z ions that were 
extracted automatically by SC as quantifiers and corresponding AUC values. TPR and FPR 
improve with increasing fold changes. (B) AUC comparison plot between unique m/z and m/z 
73 for all pairwise FCs. Unique m/z outperformed m/z 73 in the spike-in experiment. 
Reproduced from 108. 
7.3.3 Evaluation of fold changes 
Genuine changes in metabolite concentration have to be detected against a 
background of numerous features. Therefore, it was determined whether the spiked-
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 in fold changes could be reproduced quantitatively using expected versus observed 
fold change plots. Linear dependencies between expected and observed fold 
changes were observed as exemplified in Figure 7.4 for triethanolamine. 
Corresponding figures for the other spike-ins can be found in Figure S3 in the 
appendix. Triethanolamine quantified via the integral of the m/z 262 (SC) instead of 
the m/z 73 trace (INCA) showed a nearly ideal regression line with a slope of 1 and 
an offset of 0. 
Reproducibility of fold changes was assessed using univariate linear regression on 
the integrals of both the universal m/z 73 fragment ion trace and the analyte-specific 
fragment ion trace extracted from SC for each of the 20 different spike-ins over the 
fold changes investigated. The respective regression equations, regression 
coefficients, and RSDs are given in the figures. The correlation between observed 
and expected fold changes increased when integrating the unique mass trace 
extracted by SC rather than the m/z 73 fragment ion trace used by INCA. The ranges 
of regression coefficients and RSDs improved from 0.827 – 0.992 and 5.8 – 20.7 % 
to 0.882 – 0.994 and 4.2 – 20.7 %, respectively. Interestingly, the highest RSD (20.7 
%) belonged to phenylacetate, for which SC had extracted automatically the m/z 73 
ion trace as quant mass due to the lack of alternative compound-specific m/z ions. 
 
Figure 7.4. Linear dependency between expected and observed fold changes of 
triethanolamine for both (A) the universal m/z 73 fragment ion trace used by INCA and (B) 
the analyte-specific fragment ion trace m/z 262 extracted by Statistical Compare. All possible 
pairwise fold changes are plotted. Reproduced from 108. 
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 A less than optimal performance of SC in the automated extraction of quant ions is 
illustrated by the compound dimethylsuccinate. As evidenced in Figure 7.5, the 
choice of m/z 231 rather than the automatically extracted m/z 147 would have yielded 
a superior linear dependence between expected and observed fold changes. 
 
Figure 7.5. Linear dependency between expected and observed fold changes of 
dimethylsuccinate for (A) the analyte-specific fragment ion trace m/z 147 extracted 
automatically by SC and (B) the manually assigned analyte-specific fragment ion trace m/z 
231. All possible pairwise fold changes are plotted. Reproduced from 108. 
7.3.4 Comparison of E. coli strains – INCA versus SC with m/z U 
Both INCA and SC were applied to the comparative metabolic fingerprinting of a wild 
type versus a double-mutant strain of E. coli. Following exclusion of peaks with a S/N 
<500 and a 2D subpeak S/N <50, peak alignment was carried out with SC and INCA 
according to the parameter settings described in 7.2.2.1 and 7.3.1, respectively, 
using 1D and 2D retention times and the mass spectra as sorting criteria. 
After SC alignment, a total of 809 features remained (Table 7.1). Only features that 
had been detected in at least 50 % of all samples (9 out of 18) were further analyzed. 
This arbitrary cut-off had been selected with respect to the group size of 9 to ensure 
that features present in one group but not the other were not excluded from the list. A 
total of 497 features with a maximum of 15 % zero values remained. Missing values 
were set to the minimum area count; feature integrals were normalized against the 
m/z 271 integral of tridecanoic acid, subjected to log transformation and a PCA 
(Figure 7.6). A clear segregation of the E. coli strains and blanks was obtained. 
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 Table 7.1. Comparison of the performance of SC and INCA in the extraction of features from 
GC×GC-TOFMS data and the identification of metabolites that distinguish a wild type from a 
double-mutant E. coli strain lacking the transhydrogenases UdhA and PntAB. Metabolites 
printed in bold and italic indicate those detected by one of the two alignment algorithms only. 
Reproduced from 108. 
 SC INCA 
Total features 809 2625 
Reduced 
features1 
497 422 
Significant 
features2 
56 53 
Metabolites 
identified that 
distinguished 
the E. coli 
strains 
citrate, cis-aconitate, succinate, 
α-ketoglutarate, fumarate, 
glucose, glucose-6-phosphate, 
myo-inositol, indole, GABA, 
proline, lysine, leucine, 
isoleucine, valine, 
pyroglutamate, aminoadipate, 
tartrate, orotate, mannitol, 
furoate, caproate, sucrose 
pyruvate, citrate, cis-aconitate, 
succinate, α-ketoglutarate, 
fumarate, malate, glucose, 
glucose-6-phosphate, myo-inositol, 
indole, GABA, glycine, proline, 
lysine, leucine, isoleucine, valine, 
pyroglutamate, putrescine, 
itaconate, aminoadipate, tartrate, 
orotate, furoate, caproate, sucrose 
1 Features exceeding S/N ≥500 in 9 out of 18 samples. 
2 Metabolites that differed significantly (FDR <0.05) in abundance between the strains. 
 
 
Figure 7.6. PCA of randomly aligned metabolic fingerprints, using SC, for three biological, 
respectively analytical replicates each of an E. coli mutant and wild type strain. Feature 
reduction yielded 497 features present in at least 50 % of all samples. PC1 accounted for 36 
% of the variance, PC2 for 10 %. Reproduced from 108. 
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 A t-test with equal variances identified a list of 56 features that differed significantly 
between the two strains with an estimated false discovery rate of <0.05, indicating 
significance also after correction for multiple testing. Out of the 56 features, 23 
metabolites were identified accounting for 29 of the 56 features (Table 7.1). A feature 
does not necessarily equal a metabolite (also described in chapter 6.3.2) as partial 
silylation, steric hindrance, degradation or rearrangement reactions can occur and 
cause multiple possible analyte structures of the same metabolite. Further, 
methoximation may yield two signals for certain compounds due to E-Z isomerism of 
methoxyamines.49, 51 Hence, a metabolite can be represented by more than one 
feature and vice versa a feature can represent more than one metabolite. 
With INCA similar results as in chapter 6.3.2 were obtained. INCA alignment yielded 
2,625 features that were reduced to 422 features with a maximum of 17 % zero 
values. Out of the 53 features that significantly distinguished the E. coli strains, 27 
metabolites were identified accounting for 33 of the 53 features. 
Comparing the lists of metabolites identified by the two alignment routines, mannitol 
represented an additional metabolite found by SC only, whereas SC failed to detect 
glycine, itaconate, malate, putrescine, and pyruvate, although their concentrations 
had been verified in chapter 6.3.2 to differ significantly between the two strains. The 
problem here was the failure of SC to extract useful unitized unique quantifiers with 
sufficient intensity across all samples. This is exemplified by putrescine, for which SC 
had extracted the m/z 170 trace as quant ion, yielding RSDs of 56 % and 120 %, 
respectively, for E. coli mutant and wild type strain, while the respective RSDs for m/z 
73 trace were 32% and 39 %. The latter were sufficient to detect a significant 
difference in the intracellular levels of putrescine between the wild type and the 
mutant E. coli strain. Such shortcomings of the current version of SC may be 
overcome in the future by the implementation of an intensity range threshold for the 
automated extraction of suitable quant ions. This way masses can be avoided whose 
intensities are either in saturation or slightly above the noise level, as these masses 
typically yield increased variance. 
7.4 Discussion 
In contrast to INCA, SC operates within the ChromaTOF software and thus has 
access to the raw data during the alignment process. This enables SC to (i) select an 
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 analyte-specific m/z ion rather than the universal m/z 73 trace of the trimethylsilyl ion 
as a quantitative measure for identical compounds across different samples and (ii) 
set a separate S/N for signals that fell initially below the predefined S/N, which 
reduces zero values. These attributes give SC an edge in the detection of changes in 
analyte concentration twofold or less. 
SC fails at times to extract quant ions with adequate intensity. These ions typically 
yield excessive variance in abundance that makes a discriminate analysis 
impossible. Additionally, SC excludes features from the final table if conflicts in the 
peak grouping have occurred. The fact that the user is denied access to these 
conflicts to possibly reconcile them is a clear limitation of the tool. SC also assigns a 
single peak name to a whole group of aligned peaks based on the best quality mass 
spectrum within a group. However, the automatic peak name assignment is not 
always advantageous, because the user loses the ability to reconstruct the correct 
alignment of each metabolite across all samples. Obviously, there is need for 
improvement of SC in certain areas to make it a more efficient tool for comparative 
metabolic fingerprinting. 
INCA, on the other hand, guarantees that no data is lost and the decision about 
further data handling is left to the user. An additional advantage is the capability of 
INCA to automatically select optimal alignment tolerance parameters based on 
spiked-in compounds for any biological matrix. A drawback of INCA certainly is the 
lack of alternative quantification options. The m/z 73 ion is often affected by 
increased variance due to overload or saturation of the detector. Alternatively the TIC 
could be utilized for quantification, but it also tends to be affected by typically 
abundant m/z 73 and 147 ions that derive from TMS derivatives. 
 79
 8 GC×GC-TOFMS quantitative analysis of amino acid 
enantiomers in physiological fluids 
8.1 Introduction 
The enantioselective analysis of amino acids is attracting increasing interest due to a 
better understanding of the biological relevance of D-AAs. 
D-AAs can be found in bacteria, mammalians, plants, and food.175-181 In humans, D-
AAs mainly derive from bacterial metabolism and intake of fermented food.175-177, 182 
D-AA elimination typically proceeds via renal excretion. In addition, enzymes that 
catalyze D-AA decomposition, such as D-AA oxidase and D-aspartate oxidase, have 
been found in brain, liver, and kidney.183, 184 
Separation and quantification of amino acid enantiomers rely primarily on 
chromatographic and electrophoretic strategies.185 Waldhier et al. (2010) developed 
a GC-qMS method based on pre-column methanol/methyl chloroformate 
derivatization and separation on a γ-cyclodextrin based column (Rt-γDEXsa) for the 
quantitative analysis of proteinogenic AAEs.5 Twelve out of the twenty proteinogenic 
amino acids eluted from the Rt-γDEXsa column (Ala, Gly, Val, Leu, Ile, Pro, Thr, Asp, 
Ser, Met, Asn, and Phe). Baseline separation was accomplished for each 
corresponding enantiomer pair (except for Phe enantiomers). Baseline separation of 
D-Ile/L-Leu, L-Thr/L-Asp, and L-Ser/D-Met, respectively, could not be achieved. 
While the use of unique m/z ions enabled the quantification of L-Thr, L-Asp, and D-
Met, it was not possible to quantify the structural isomers D-Ile and L-Leu due to their 
identical m/z ions. Furthermore, a double peak impeded the quantification of L-Ser. 
GC×GC was employed by Junge et al. (2007) for the first time to separate AAEs as 
their ethyl chloroformate derivatives in samples of beer by coupling a 
enantioselective 25 m × 0.25mm ID × 0.16 µm Chirasil-L-Val column to a 3 m × 0.1 
mm ID × 0.1 µm BP-1 column in the second dimension.158 The study presented in 
this chapter widens the scope of GC×GC-based AAE analysis by applying a 
combination of an Rt-γDEXsa chiral 1D column with different 2D columns to the 
separation and also quantification of AAEs as their MeOH/MCF derivatives in 
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 physiological fluids. The performance was compared to that of the previously 
published GC-qMS method.5 
The work in this chapter was published in 126 with Magdalena Waldhier (Institute and 
Chair of Functional Genomics, University of Regensburg), as joint first author. 
8.2 Materials and Methods 
8.2.1 Sample preparation and instrumentation 
Aqueous stock solutions were prepared from the L- and D-AA solids at 
concentrations of 11 – 60 mM. Racemic stock solutions contained enantiomers in the 
range of 7.0 – 46.5 mM. A master mixture was prepared based on these solutions 
containing Gly and all enantiomers at a concentration of 1 mM each. A [U-13C, U-15N] 
cell free amino acid mix served as internal standard. The combined D+L-
concentrations of the 20 proteinogenic AAs contained in the mixture ranged between 
0.37 and 2.58 mM, but no information on D-AA ratios was available. 
A set of 25 serum specimens from patients with liver cirrhosis and 16 control sera 
were analyzed to demonstrate relevance for medical diagnostics. At the time of blood 
drawing, none of the patients had been treated with peptide antibiotics or other drugs 
that might affect D-AA serum levels. Serum specimens were stored at -80°C. 
Specimens were provided by collaborators at the University Hospital of Regensburg 
with approval from the institutional review board. 
Sample and standard solution aliquots of 150 µL and 20 µL of internal standard mix 
were used for quantitative analysis. Derivatization with MeOH/MCF was performed 
as described in chapter 5.2.2 or 5. Sample preparation was carried out by Magdalena 
Waldhier and Nadine Nürnberger (Institute and Chair of Functional Genomics, 
University of Regensburg). 
For analysis, a sample volume of 1.5 µL was injected in splitless mode. GC×GC-
TOFMS instrument settings were used according to chapter 5.3.2. Temperature 
programs (Table 8.1) were optimized by Magdalena Waldhier. Method A was used 
for the Rt®-γDEXsa/Rtx®-1701 column set, whereas method B was applied to the Rt®-
γDEXsa/ZB-AAA column set. 
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 8.2.2 Data processing 
Raw data were processed with the LECO ChromaTOF software version 3.34. For 
compound identification, EI spectra were matched against an in-house generated 
library containing the MeOH/MCF-derivatized D- and L-AAs and compared to the EI 
spectra of the validated GC-qMS method.5 
Table 8.1. Optimized GC temperature programs for the column sets RT®-γDEXsa/Rtx®-1701 
(A) and Rt®-γDEXsa/ZB-AAA (B), respectively. 
Method Temperature program 
A 70°C (1 min) – 2°C/min – 150°C (10 min) – 2°C/min – 180°C (25 min) 
B 70°C (1 min) – 2°C/min – 130°C (12.5 min) – 8°C/min – 150°C (4 min) –
4°C/min – 190°C (6 min) 
8.2.3 Quantification and method validation 
Calibration was performed with the Rt®-γDEXsa/ZB-AAA column set using a 16 point-
serial dilution of the master mixture. It contained all AAs, whose elution from the Rt®-
γDEXsa column as MeOH/MCF-derivatives could be detected, over a concentration 
range of 31 nM to 1 mM each. The applied internal standard solution contained 20 
uniformly 13C-, 15N-labeled AA types at different concentrations between 0.37 and 
2.58 mM. As the labeled AAs had been obtained from algae, they were present in the 
mix at their naturally occurring ratios in algae. Most D-AAs were detected in the 
labeled mix but their abundance was too low (<3.4 % of the respective L-AA area) to 
be suitable as internal standards. Thus, the stable isotope-labeled L-enantiomers of 
Ala, Val, Leu, Ile, Pro, Thr, Asp, Ser, Met, Asn, and Phe were used to correct areas 
of the corresponding D- and L-AA in quantitative measurements. Correspondingly, 
stable isotope-labeled Gly, the only natural nonchiral AA, was used for correcting Gly 
area integrals. Eight aliquots of a human serum specimen were prepared and 
analyzed to test method reproducibility. 
8.3 Results 
Two different column combinations for the GC×GC separation of MeOH/MCF 
derivatives of AAEs were tested. In GC×GC the length of the 2D column is kept short 
to allow the elution of analytes within one modulation period. Length of the 1D 
column, in contrast, is not limited. Therefore, the chiral Rt®-γDEXsa column was 
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 always chosen as 1D stationary phase, as the resolution of enantiomers improves 
with increasing length of the chiral column. Secondly, the Rt®-γDEXsa phase reacted 
sensitive to high temperatures, resulting in reduced enantioselectivity and 
accelerated column degradation as shown previously.5 The increased temperature in 
the 2D separation is thus unfavorable for AAE resolution. 
8.3.1 Rt®-γDEXsa/Rtx®-1701 column set 
Initially, a 2 m midpolarity 14 % cyanopropylphenyl/86 % dimethyl polysiloxane Rtx®-
1701 capillary column served as the 2D column. A characteristic chromatogram of 
the master standard obtained under the optimized temperature program (method A, 
Table 8.1) is shown in Fig. 8.1. The Rtx®-1701 column compensated for the lack of 
selectivity of the Rt®-γDEXsa for L-Thr/L-Asp and L-Ser/D-Met, respectively, and 
allowed their baseline resolution in the second dimension. However, L-Leu and D-Ile 
still coeluted. MCF-Phe enantiomers were not resolved at all by the chiral Rt®-
γDEXsa column and, therefore, could not be separated in the second dimension 
either. 
 
Figure 8.1. Total ion current (TIC) 2D chromatogram of the master mixture using the Rt®-
γDEXsa/Rtx®-1701 column set and GC method A. D-Ile/L-Leu isomers are encircled. 
Reproduced from 126. 
8.3.2 Rt®-γDEXsa/ZB-AAA column set 
Kaspar et al. (2008) had demonstrated the successful separation of Leu and Ile as 
their PCF derivatives on a 15 m ZB-AAA capillary column that reportedly consists of 
50 % phenyl/50 % dimethyl polysiloxane.53, 186 Therefore, the ZB-AAA column was 
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 tested as 2D column. A representative chromatogram of the master mixture obtained 
after optimization of the temperature program (method B, Table 8.1) is pictured in 
Fig. 8.2A. 
 
Figure 8.2. Total ion chromatograms of the master mixture recorded in (A) 2D and (B) 1D 
mode using the Rt®-γDEXsa/ZB-AAA column set and method B. Analytes coeluting from the 
Rt®-γDEXsa column are encircled in both chromatograms. Reproduced from 126. 
As can be seen, baseline separation was achieved for all analytes except for the Phe 
enantiomers. In contrast, 1D-GC-TOFMS yielded 4 unresolved peak pairs (Figure 
8.2B) reflecting the insufficient selectivity of the Rt®-γDEXsa column. Selectivity was 
improved by using thermal modulation and the orthogonal separation properties of 
the 2D ZB-AAA column. Enhanced resolution of enantiomers that were separated by 
a temperature program on the chiral 1D column was achieved due to the fast and 
therewith approximately isothermal separation on the 2D column. It allows additional 
separation of enantiomers even though the 2D selector provides no stereospecific 
retardation. This can be seen for the enantiomers of Leu, Ile, and Pro in Fig. 8.2A. 
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 8.3.3 Quantification and method validation 
Calibration curves were generated for absolute quantification of AAEs. Table 8.2 lists 
fragment ion masses chosen for quantification, as well as values for linear range, R2, 
and reproducibility. For direct comparison, Table 8.2 also includes the values 
obtained for 1D-GC-qMS. The GC-qMS method is specified in 5 (Table 1, E). 
GC×GC-TOFMS calibration curves were linear with the square values of the sample 
correlation coefficient R ranging between 0.9938 and 0.9992, which is comparable, 
albeit inferior to the 1D method, whose R2 values ranged from 0.9956 to 1.0000. 
LLOQs were in the range of 0.03 – 2 µM. Octaplicate analysis of a serum specimen 
yielded RSDs below 5 % except for D-Ala (12.2 %), D-Asp (16.6 %), and D-Asn (9.9 
%), whereas hexaplicate 1D-GC-qMS analysis yielded in general RSDs <4 %. 
Further method validation was exclusively handled by Magdalena Waldhier and can 
be found in her Ph.D. thesis (in preparation) or in 126. 
Table 8.2. Comparison of linear ranges, R2 values, and relative standard deviations for AAE 
analysis in serum by GC×GC-TOFMS and GC-qMS. Reproduced from 126. 
GC×GC-TOFMS GC-qMS AA Quantifier 
analyte + U-
13C,15N-labeled 
IS (m/z) 
LR [µM] R2 RSD 
(%) 
(n=8)
LR [µM] R2 RSD 
(%) 
(n=6)
D-Ala 102 + 105 0.031 -1000 0.9971 12.15 0.031 -500 0.9998 1.10 
L-Ala 102 + 105 0.061 -1000 0.9974 2.16 0.122 -500 0.9996 0.95 
Gly 88 + 90 0.031* -1000 0.9979 3.78 0.977 -500 0.9996 0.87 
D-Val 130 + 135 0.244 -500 0.9971  - 0.244 -500 0.9999  - 
L-Val 130 + 135 0.061* -500 0.9961 3.81 0.244 -500 0.9999 0.81 
D-Leu 144 + 150 0.244 -1000 0.9974  - 0.244 -500 1.0000  - 
L-Leu 144 + 150 0.061 -1000 0.9954 1.28  -  -  - 
D-Ile 144 + 150 0.061 -1000 0.9970  -  -  -  - 
L-Ile 144 + 150 0.061 -1000 0.9973 3.07 0.061 -500 0.9998 0.87 
D-Pro 128 + 133 0.031 -500 0.9988 4.52 0.061 -500 0.9998 1.31 
L-Pro 128 + 133 0.061 -500 0.9970 3.38 0.061 -500 0.9999 0.73 
D-Thr 147 + 149 0.122* -500 0.9986  - 0.977 -1000 0.9996  - 
L-Thr 147 + 149 0.061* -500 0.9980 3.53 1.953 -1000 0.9988 1.62 
D-Asp 160 + 164 0.031* -1000 0.9938 16.64 0.122 -500 0.9998 3.87 
L-Asp 160 + 164 0.061* -1000 0.9990 3.18 0.977 -500 0.9994 0.70 
D-Ser 118 + 121 0.244* -1000 0.9987  - 1.953 -1000 0.9999  - 
L-Ser 118 + 121 0.031* -1000 0.9991 2.37 31.25 -1000 0.9956  - 
D-Met 162 + 167 1.953 -1000 0.9988  - 0.488 -1000 0.9999  - 
L-Met 162 + 167 0.977 -1000 0.9992 2.56 0.244 -1000 0.9996 1.06 
D-Asn 127 + 132 0.061* -1000 0.9973 9.93 0.244 -1000 0.9999  - 
L-Asn 127 +132 0.031* -1000 0.9983 3.43 0.244 -1000 0.9999 1.02 
DL-Phe 162 + 171 0.061 -1000 0.9978 3.41 0.061 -1000 0.9995 1.13 
* At least two additional calibration points were included at the lower end of the GC×GC 
calibration curve compared to the GC-qMS calibration curve. 
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 8.3.4 Application to serum specimens from patients with liver 
cirrhosis 
An exemplary biomedical application of GC×GC-TOFMS was performed by analyzing 
serum specimens from n=16 healthy probands and n=25 patients with liver cirrhosis. 
Data analysis was performed by M. Waldhier. The clear trend of increased serum 
levels of D-AAs in liver cirrhosis patients is visible in Fig. 8.3A. 
 
Figure 8.3. Mean concentrations and SDs of (A) D-AAs and (B) L-AAs in serum specimens 
of n=25 patients suffering from liver cirrhosis compared to the respective values of n=16 
healthy probands (*p <0.05, **p <0.001). Reproduced from 126. 
Only D-Asp concentrations were not increased compared to the respective mean 
concentration of the control group. D-Val, D-Leu, and D-Thr were found above the 
LLOQ only in some of the serum specimens of cirrhosis patients. D-Ile and D-Met 
were detected in none of the samples and D-Ser could not be measured due to the 
interference by a matrix compound. Compared to the controls, significantly elevated 
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 serum concentrations of D-Pro (p=0.013) and D-Ala (p=0.00008) were observed as 
determined by a two-tailed Student’s t-test. Mean D-Asn concentrations were not 
tested because of an insufficient number (n=2) of values above LLOQ in the control 
group. Determined concentrations of D-Ala, D-Pro, and D-Asn + D-Asp in control 
sera were in good agreement with respective serum levels reported previously for 
healthy volunteers.187, 188 L-AA serum levels, on the other hand, were significantly 
decreased in liver cirrhosis specimens as shown in Fig. 8.3B: L-Ala (p=0.0051), L-Ile 
(p=0.036), L-Ser (p=0.0099), L-Asn (p=0.0011), L-Val (p=0.00028), and L-Leu 
(p=0.0003). The increased D-AA serum levels observed for liver cirrhosis reflect the 
loss of intact liver parenchyma and, hence, a reduced enzymatic capacity to catalyze 
D-AA decomposition. 
8.3.5 Comparison of GC×GC-TOFMS and GC-qMS 
In comparison to GC-qMS, GC×GC-TOFMS data analysis was considerably more 
time-consuming. Another problem resulted from the slightly earlier elution of internal 
standards compared to the respective analytes as shown in Fig. 8.4. Since the base 
fraction peak of the labeled AA appeared one modulation prior to the analyte 
maximum, the analyte-to-standard area ratio varied for each fraction. Thus, peaks 
from all modulations had to be integrated to determine the response. 
 
Figure 8.4. Extracted ion chromatogram of L-Val quantification masses. Peak envelopes 
(dashed lines) of L-Val and U-13C, U-15N labeled L-Val are indicated to demonstrate their 
position shift and the varying analyte-to-internal standard area ratio for each fraction. 
Reproduced from 126. 
Numerous fractions had to be integrated manually and summed up, leading to a 
significant increase in data analysis time. These problems were caused by the 
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 spectral match factor that was used to combine all modulated peaks. Due to the 
impact of noise, low abundant modulated peaks suffer from an insufficient spectral 
match and, therefore, are not integrated automatically. Reproducible manual 
inclusion of a great number of sub-fraction integrals is a challenging task and 
contributes to higher RSDs for GC×GC-TOFMS quantitative data as compared to the 
excellent repeatability of chiral GC-qMS analysis (RSDs <4 %). 
As a result of the concentration discrepancy between D- and L-AAs (which may be 
as great as three orders of magnitude) we observed a great number of modulations 
and peak tailing for L-AAs and stable isotope-labeled internal standards. Optimally, 
each first dimension peak should be sampled three to five times, which was the case 
for D-AAs. The correction of the area integral of a D-AA with a stable isotope-labeled 
L-AA that generates ten or more modulations is suboptimal and, consequently, 
lowers repeatability of D-AA quantification results as reflected in comparatively great 
RSDs for D-Asp (16.6 %), D-Ala (12.2 %), and D-Asn (9.9 %), whereas RSDs for the 
other target analytes were <5 %. A set of stable isotope-labeled D-AAs for D-AA area 
integral correction would thus improve precision of quantification results, but is 
unfortunately not available at present. 
The same number of AA types eluted from the Rt®-γDEXsa column in GC×GC 
analysis as in GC-qMS analysis. Reasons for the failure to detect the proteinogenic 
AAs Glu, Gln, Cys, Lys, His, Arg, Tyr, and Trp remain to be elucidated, but may be 
due to chemical or thermal derivative instability as reported for propyl chloroformate 
derivatized arginine 53, or strong interactions with the CD core leading to strong 
retardation and broad peaks that vanish into the baseline. However, due to its higher 
peak capacity the presented GC×GC approach has the potential to be expanded to 
enantiomers of other small organic acids. 
In the end, the optimized GC×GC-TOFMS method presented in this chapter for the 
determination of AAEs in physiological fluids is at present to the best of our 
knowledge the most effective technique for AAE analysis, enabling quantification of 8 
D-AAs in serum or urine in a single chromatographic run. 
8.4 Discussion 
The combination of a γ-CD column (Rt®-γDEXsa) and an AA selective (ZB-AAA) 
column resulted in the baseline separation of 20 AAEs as their MeOH/MCF 
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 derivatives. GC×GC-TOFMS compared to GC-qMS with SIM yielded distinctly lower 
LOQs for Gly, L-Val, and both enantiomers of Thr, Asp, Ser, and Asn. Analytes 
eluting late from the chiral column showed an improved LLOQ in GC×GC-TOFMS, as 
column bleeding could be separated from all analytes in the 2D. In general, LLOQs 
were in the range of 0.03 – 2 µM. Reproducibility of the analysis of a serum specimen 
in octaplicate ranged from 1.3 to 16.6%. The method was applied to the comparison 
of AAE serum concentrations in patients suffering from liver cirrhosis to a control 
group. Significantly increased D-AA concentrations were found for the patient group, 
whereas L-AA levels were decreased. 
Peak resolution was improved by coupling two columns with orthogonal separation 
characteristics. All target analytes were resolved adequately from matrix peaks 
except for D-Ser in serum, a distinct improvement over GC-qMS on an Rt®-γDEXsa 
column that had failed to resolve D-Asn and both enantiomers of Thr and Ser from 
matrix compounds. Separation of D-Met/L-Ser and L-Thr/L-Asp, respectively, which 
had coeluted from the chiral column, was accomplished with the GC×GC approach. 
Separation of D-Ile/L-Leu was possible but required decreased operation 
temperatures for both columns and, as a consequence, increased analysis time from 
44 to 66 min. 
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 9 GC-MS based metabolic fingerprinting and profiling of 
serum versus plasma collection 
9.1 Introduction 
A widely used biological fluid in mammalian studies is blood, as it reflects systemic 
changes in the metabolome. Blood is commonly either sampled as plasma, that still 
contains clotting factors, or as serum. Advantages of plasma over serum are quick 
processing, as there is no need to wait for blood to clot, higher yield, lower risk of 
haemolysis and thrombocytolysis, and virtually no interference from postcentrifugal 
coagulation that can occur in serum.189 On the other hand, disadvantages of plasma 
relative to serum are interferences with analysis caused by anticoagulants, enzyme 
inhibitors, fibrinogen, and cations contained in anticoagulants. For plasma collection 
different anticoagulants and additives are used, including EDTA, heparin, sodium 
fluoride/potassium oxalate (NaF-KOx), and citrate. Anticoagulation occurs by binding 
calcium ions (citrate, EDTA, and oxalate) or by inhibiting thrombin activity 
(heparinates, hirudin). The choice of additive depends on the analysis to be 
performed. 
If heparin is used that contains sodium metabisulfite as a preservative, the 
quantification of cystine and homocystine can be impaired due to the formation of 
sulfocysteine and homosulfocysteine.190 Fluoride inhibits the enzyme enolase in the 
glycolytic pathway and thereby prevents the degradation of glucose, with KOx added 
as an anticoagulant. Waring et al. (2007) compared NaF-KOx and serum gel tubes in 
the determination of blood glucose in humans.191 Serum was promptly separated 
from gel tube samples and refrigerated, whereas NaF-KOx samples were not 
separated until immediately before analysis. A small relative negative bias ranging 
from 3.2 % to 6.3 % was observed for samples collected in NaF-KOx tubes, caused 
by dilution and the onset of glycolysis. Consequently, serum can be used for glucose 
determination if special serum-separating tubes are employed and if the samples are 
immediately frozen after centrifugation. Mikesh et al. (2008) studied human blood 
collected in NaF-KOx tubes and stored at room temperature.192 While fluoride 
prevents lactate production by inhibiting enolase in the glycolytic pathway, glucose is 
still consumed up to 3 hours after blood collection, which is attributed to the 
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 continuing metabolism of glucose to glucose-6-phosphate, as the enzymes upstream 
of enolase remain active. Further, the initial decrease in glucose is the greater the 
higher the white blood cell, red blood cell, or platelet-count in the blood specimen 
under investigation. However, storing the blood samples with or without fluoride 
addition on ice showed only a minimal decrease in glucose and increase in lactate.192 
A drawback of NaF-KOx plasma for metabolic fingerprinting by GC-MS is the excess 
of oxalate that may interfere with the analysis. The same applies for using sodium 
citrate as anticoagulant. Moreover, citrate is an important metabolite of the TCA cycle 
and the use of citrate as an anticoagulant will prevent its accurate analysis. While 
NaF-KOx and citrate plasma are not well suited for general metabolomics 
applications, the question remains, which type of blood sample is preferable for 
metabolomics studies. Deprez et al. (2002) studied the stability of rodent plasma 
collected into heparinized containers for 1H-NMR analysis in toxicology studies.193 
The time elapsing between the drawing of blood and centrifugation to separate 
plasma from blood cells was found not to be critical if less than 35 min, with no 
changes in small metabolites normally associated with cell leakage and haemolysis 
observed. No significant changes were identified in samples, which were snap-frozen 
and stored for up to 9 months at −80 °C. However, storing the samples at 4 °C or 
room temperature led to changes in metabolite concentrations, such as an increase 
in glycerol and choline indicating lipid hydrolysis. Teahan et al. (2006) qualitatively 
compared NMR metabolic profiles of human serum and heparin-plasma. For serum 
and plasma, four different clot contact times up to 180 min and keeping the samples 
during this time on ice or room temperature were investigated.194 The differences 
between NMR profiles of serum and heparin-plasma were found to be minimal. 
Overall, the inter-individual differences were larger than differences in spectra 
caused by increasing clotting time. Nevertheless, changes in metabolite profile were 
smaller when samples had been kept on ice between blood sampling and cell 
separation for periods not exceeding 35 min.194 
Further, lubricants, polymeric surfactants, plasticizers, separator gel components, 
and heparin have been reported as potential sources of interference in mass 
spectrometric analyses.195, 196 Moreover, MS based studies have been performed 
that evaluated the impact of different blood collection tubes on selected analytes 
(aldosterone and testosterone/dihydrotestosterone, respectively).109, 197 However, to 
the best of our knowledge, no comprehensive study has been performed on the 
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 impact on the suitability of plasma versus serum for mass spectrometry based 
metabolic fingerprinting. 
To this end, bovine serum, EDTA-plasma, and EDTA-plasma fortified with 
acetylsalicylic acid (ASA) as antioxidant were compared with regard to their 
applicability for metabolomics studies. Metabolic fingerprints were generated by 
means of GC-TOFMS. For data processing, the LECO ChromaTOF software in 
combination with the in-house developed retention time correction and data 
alignment tool INCA were used. To confirm that the observed signal intensities in the 
GC-TOFMS fingerprints reflected true metabolite abundances, 19 amino acids, 
glucose, and 6 organic acids were quantified using stable isotope-labeled internal 
standards. 
The results presented in this chapter were published with Dr. Katja Dettmer (Institute 
and Chair of Functional Genomics, University of Regensburg) as joint first author in 
198. 
9.2 Material and Methods 
9.2.1 Collection of blood specimens 
Blood specimens were drawn by jugular venipuncture into 7-mL evacuated EDTA-
coated tubes and 7-mL evacuated serum-gel tubes (Vacuette, Greiner Bio-One, 
Kremsmünster, Austria) from 18 lactating Brown Swiss dairy cows held at the 
research farm Veitshof of the Technical University Munich, Freising-Weihenstephan, 
Germany. The tubes were gently inverted 4 times to ensure proper mixing of the 
blood and additive in the specimens. Plasma was separated by centrifugation (15 
min, 2000 xg, 4 °C) immediately after sampling and stored frozen at -80 °C until 
analysis. To prepare EDTA-ASA-plasma blood was also drawn in into 7-mL 
evacuated EDTA-coated tubes, followed by the immediate addition of 200 µL 
stabilization solution prior to sample mixing. The aqueous stabilization solution 
contained 0.3 M Na2EDTA and 1 % (w/v) ASA. Blood serum samples were kept at 
room temperature for blood to clot and centrifuged (15 min, 2000 xg, 4 °C) within 1 
hour after blood collection. 
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 9.2.2 GC-MS analysis 
9.2.2.1 GC-qMS of amino acids 
Quantitative analysis of amino acids was performed in 20-µL sample aliquots using 
GC-qMS after derivatization with propyl chloroformate.162 For details see chapters 
5.2.3 and 5.3.3. 
9.2.2.2 GC-TOFMS for metabolic fingerprinting and quantification of β-
hydroxybutyrate, glucose, glycolysis and citrate cycle intermediates 
Ten-µL serum/plasma aliquots were extracted with 50 µL methanol containing the 
extraction standards [2,2,4,4-2H4]citrate, [U-13C]fumarate, [U-13C]glucose, [U-13C]β-
hydroxybutyrate, [U-13C]lactate, [2,3,3-2H3]malate, [U-13C]pyruvate, [U-2H]succinate, 
[2H7]trans-cinnamate, and unlabeled norvaline. Samples were vortexed and then 
centrifuged at 4 °C and 3,375 xg for 5 min. The supernatant was transferred into a 2-
mL glass vial with a 0.2-mL glass insert. Pellets were re-extracted twice more with 50 
µL of methanol. The extracts were combined, and evaporated and derivatized as 
described in chapter 5.2.1. 
Sample preparation using 10-µL aliquots was repeated for metabolic fingerprinting 
without the addition of the extraction standards due to potential interferences of the 
stable isotope-labeled analogs with the endogenous compounds in data analysis. 
Calibration was performed using metabolite standard solutions in methanol. Hundred 
μL of different calibration levels were transferred into a glass vial with glass insert 
and 10 μL of the surrogate solution containing stable isotope-labeled [2,2,4,4-
2H4]citrate, [U-13C]fumarate, [U-13C]glucose, [U-13C]β-hydroxybutyrate, [U-13C]lactate, 
[2,3,3-2H3]malate, [U-13C]pyruvate, [U-2H]succinate, [2H7]trans-cinnamate, and 
unlabeled norvaline (1 mM each) were added. The standards were dried and 
derivatized as described in chapter 5.2.1. Twelve calibration points were generated 
over a concentration range of 0.5 – 500 μM. 
For metabolic fingerprinting and targeted quantitative analysis of citrate, fumarate, 
glucose, β-hydroxybutyrate, lactate, malate, pyruvate, and succinate, the LECO 
Pegasus GC×GC-TOFMS instrument was used in 1D mode according to chapter 
5.3.1. The modulator was turned off and mass spectra were collected at 50 spectra/s. 
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 Sample preparation of serum, EDTA-plasma and EDTA-ASA-plasma samples was 
performed by Nadine Nürnberger (Institute and Chair of Functional Genomics, 
University of Regensburg). 
9.2.2.3 Data Analysis 
Raw data were processed with the LECO ChromaTOF software version 3.35 
according to chapter 6.2.2. Peaks with an S/N ≥250 were selected. Retention time 
correction and data alignment was performed using INCA as described in chapter 
6.2.3 and 6.2.4. Normalization and testing were performed according to chapter 
6.2.5. INCA was adapted to the analysis of 1D-GC-TOFMS data by simply excluding 
the 2D retention time as a parameter. Quantile plots were generated for data 
visualization. For each feature pairwise quantiles were plotted in different colors to 
visualize the variance in metabolite abundances. 
Quantile plots were generated by Wolfram Gronwald (Institute and Chair of 
Functional Genomics, University of Regensburg). Bland-Altman analyses were done 
by Katja Dettmer. 
9.3 Results and Discussion 
9.3.1 Metabolite fingerprinting 
For an overall comparison of the metabolite fingerprints obtained by GC-TOFMS 
analysis of methanolic extracts of serum, EDTA-plasma and EDTA-ASA-plasma 
samples, peak lists were generated with the LECO ChromaTOF software that 
included all signals with a S/N ≥250. For each peak the area of the m/z 73 fragment 
ion trace, which is shared by all TMS derivatives, was exported as a quantitative 
measure. The peak lists from all samples were aligned into a single data matrix using 
INCA. After alignment a total of 654 features were exported from the GC-TOFMS 
data. 
Not all features were detected in all samples. Therefore, only features present in 10 
or more (>50 %) samples per group were selected for further analysis, which left a 
total of 128 features. The area integral of each feature was normalized by using the 
area integral of tridecanoic acid at m/z 271 to account for variability during 
derivatization and injection. The normalized data was then subjected to a log 
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 transformation. To visualize the variance in metabolite abundances of the aligned 
dataset quantile plots were generated (Figure 9.1). 
Figure 9.1 shows a 1D chromatogram of an EDTA-ASA-plasma sample. For each 
feature of one dataset 0 %- and 100 %- (blue), 10 %- and 90 %- (light blue), 30 %- 
and 70 %- (yellow), and 50 %-quantiles (red) were plotted against the features´ 
median of the other dataset (black). Two quantile plots of this kind are exemplified in 
Figure 9.1B and C.  
 
 
Figure 9.1. TIC chromatogram of an EDTA-ASA-plasma sample using GC-TOFMS (A). 
Several major components are labeled and the added internal standards are italicized. 
Quantile plots of aligned metabolic fingerprints of 18 EDTA-plasma samples (B, C). 0 %- and 
100 %- (blue), 10 %- and 90 %- (light blue), 30 %- and 70%- (yellow), and 50 %-quantiles 
(red) are plotted against the features´ median of 18 bovine serum (B) and EDTA-ASA-
plasma (C) samples (black). Reproduced from 198. 
When comparing the quantiles of EDTA-plasma to the median of EDTA-ASA-plasma 
63 % of the analytes´ medians were located within the 30 %- and 70 %-quantile and 
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 95 % within the 10 %- and 90 %-quantiles. The comparison of EDTA-plasma 
quantiles to the median of serum yielded 65 % of the analytes´ medians within the 30 
%- and 70 %-quantile and 87 % within the 10 %- and 90 %-quantiles. 
A t-test with equal variances was performed for group-wise comparison and the p-
values obtained were corrected for multiple testing according to Benjamini and 
Hochberg (Table 9.1).113 A total of 6, 9, and 21 significant features with a FDR of 
<0.05 were identified when comparing EDTA- versus EDTA-ASA-plasma, EDTA-
plasma versus serum, and EDTA-ASA-plasma versus serum, respectively. Not 
surprisingly, the feature discriminating EDTA-ASA-plasma mostly from EDTA-plasma 
and serum, respectively, was a peak representing acetylsalicylic acid (ASA 
derivative). The comparison of EDTA-plasma with serum yielded citrate and oxalate 
as significantly discriminating features. These compounds also differed significantly 
in concentration between EDTA-ASA-plasma and serum. In addition, a significant 
difference in lactate concentration was found when comparing EDTA-ASA-plasma 
with serum. Also, several unknowns were detected that could not be matched against 
both the custom-made and the NIST 05 library with a minimum similarity of 70 %. 
Table 9.1. Number and identities of the significant features detected in the different sample 
types by means of INCA-based analysis of metabolic fingerprinting GC-TOFMS data. 
Reproduced from 198. 
 EDTA vs. 
EDTA-ASA 
EDTA vs. 
Serum 
EDTA-ASA vs. Serum 
Significant features 
(FDR <0.05) 
6 9 21 
Metabolites identified 
that distinguished the 
sample groups 
Acetyl salicylic 
acid derivative, 
unknowns 
Citrate, 
oxalate, 
unknowns 
Acetyl salicylic acid 
derivative, citrate, lactate, 
oxalate, unknowns 
 
To verify that the variance of the features was not a result of analytical imprecision, 
quantile plots of technical replicates were created (Figure 9.2). One serum, EDTA-
plasma, and EDTA-ASA-plasma sample, respectively, was injected 5 times each. 
The peak lists were processed according to the steps described above. Zero and 100 
%-quantiles are represented by blue, 25 %- and 75 %-quantiles by yellow, and the 50 
%-quantile by red points. The quantile plots for the technical replicates show slight to 
no variance in metabolite abundance. 
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Figure 9.2. Quantile plot of technical replicates. One serum (A), one EDTA-plasma (B), and 
one EDTA-ASA-plasma (C) sample was injected 5 times each. Zero and 100 %-quantiles are 
represented by blue, 25 %- and 75 %-quantiles by yellow, and the 50 %-quantile by red 
points. Reproduced from 198. 
9.3.2 Targeted analysis 
To confirm the results of the metabolic fingerprinting approach a total of 26 
metabolites, including 19 amino acids, glucose, and 7 organic acids, were quantified 
in serum, EDTA-plasma, and EDTA-ASA-plasma samples collected from 18 dairy 
cows, of which 7 were in early and 11 in late lactation. LLOQ, average concentration 
with standard deviation, and concentration range observed for each metabolite in the 
three sample types are listed in Table 9.2. 
The LLOQ of the amino acids and the remaining analytes were determined for 
injection volumes of 20 µL and 10 µL, respectively. With the exception of aspartate, 
all analytes were detected above the LLOQ in all samples. Interestingly, aspartate 
could be detected above the LLOQ in 10 serum samples, but only in 3 and 2 of the 
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 ETDA-plasma and EDTA-ASA-plasma samples, respectively. This indicates that 
overall serum yields slightly higher aspartate values compared to plasma. It should 
be noted that the samples were analyzed in random order to avoid any bias 
introduced by the instrumental analysis. Aspartate was excluded from further 
analysis due to the low number of data points. As expected the highest abundant 
metabolite among the quantified analytes was glucose with an average concentration 
of 2.8 mM in EDTA-plasma and 2.6 mM in EDTA-ASA-plasma and serum. 
Table 9.2. LLOQ, average concentration with SD, and concentration range for the analytes 
quantified in EDTA-plasma, EDTA-ASA-plasma, and serum (n=18 for each). Reproduced 
from 198. 
 LLOQ EDTA-Plasma EDTA-ASA-Plasma Serum 
  Mean ± SD [µM] 
Range 
[µM] 
Mean ± SD 
[µM] 
Range 
[µM] 
Mean ± SD 
[µM] 
Range 
[µM] 
Pyruvate 4.88 a 54 ± 9 44 - 76 49 ± 8 28 - 62 47 ± 11 30 - 70 
Lactate 2.44 a 511 ± 129 310 - 818 508 ± 150 254 - 906 662 ± 105 530 - 842 
β-Hydroxy-
butyrate 4.88
 a 534 ± 297 304 - 1636 517 ± 330 
326 - 
1778 536 ± 300 360 - 1666
Succinate 9.76 a 36 ± 4 28 - 44 33 ± 6 24 - 48 38 ± 5 30 - 46 
Malate 4.88 a 21 ± 3 16 - 26 19 ± 3 14 - 28 20 ± 5 8 - 34 
Citrate 4.88 a 286 ± 61 174 - 398 262 ± 62 164 - 360 212 ± 49 136 - 278 
Glucose 4.88 a 2801 ± 374 2020 - 3276 2623 ± 251 
2076 - 
3038 2661 ± 274 
2050 - 
2970 
Alanine 0.75 b 211 ± 49 128 - 336 201 ± 43 127 - 295 234 ± 57 142 – 353 
Glycine 7.50 404 ± 146 229 - 717 381 ± 134 213 - 639 466 ± 156 284 - 849 
α-Amino- 
butyrate 0.75 24 ± 8 14 - 45 23 ± 7 10 – 34 25 ± 8 14 – 42 
Valine 0.75 183 ± 47 89 - 281 174 ± 43 88 - 262 202 ± 58 112 - 325 
Leucine 0.75 105 ± 24 53 - 158 99 ± 22 53 – 151 117 ± 31 68 – 190 
Isoleucine 2.25 93 ± 20 46 - 134 88 ± 19 44 - 131 103 ± 26 56 - 154 
Proline 0.75 69 ± 13 36 - 90 66 ± 13 35 – 91 79 ± 17 45 - 117 
Asparagine 30.00 35 ± 8 17 - 45 33 ± 8 19 - 44 40 ± 9 23 – 59 
Aspartate c 7.50 9 ± 1 8 - 10 8 ± 1 7.6 - 8.4 9 ± 1 8 - 12 
Methionine 7.50 18 ± 4 10 - 26 18 ± 4 11 – 25 21 ± 5 14 – 32 
Glutamate 7.50 44 ± 10 34 - 66 40 ± 10 25 - 68 51 ± 13 36 - 88 
Phenyl- 
alanine 2.25 46 ± 9 32 - 62 44 ± 9 30 – 60 52 ± 10 39 – 72 
Ornithine 2.25 40 ± 15 17 - 72 36 ± 14 16 - 69 45 ± 17 19 - 76 
Glutamine 75.00 246 ± 46 150 - 307 235 ± 45 140 – 310 281 ± 63 178 – 403 
Lysine 2.25 73 ± 16 43 - 103 66 ± 16 36 - 104 84 ± 21 51 – 127 
Histidine 30.00 44 ± 17 17 - 73 42 ± 15 16 – 61 48 ± 19 19 - 87 
Tyrosine 2.25 45 ± 12 22 - 63 41 ± 11 24 - 59 48 ± 14 25 – 71 
Tryptophan 0.75 50 ± 11 31 - 76 46 ± 9 30 – 65 56 ± 13 35 - 82 
Hippurate 4.50 101 ± 15 81 - 127 96 ± 17 66 - 132 114 ± 20 80 - 141 
a LLOQ was calculated for a sample volume of 10 µL.  
b LLOQ was calculated for a sample volume of 20 µL.  
c Quantified above LLOQ in n=3 for EDTA-plasma, n=2 for EDTA-ASA-plasma, and n=10 for serum. 
 
The three sample types were compared with each other by Bland-Altman plots.164 
Since it is not possible to show all Bland-Altman plots, the mean difference, limits of 
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 agreement, and percentage of the mean difference from the mean concentration are 
listed in Table 9.3 comparing serum versus EDTA-plasma, serum versus EDTA-ASA-
plasma, and EDTA-plasma versus EDTA-ASA-plasma, respectively. An ideal 
agreement between two datasets is observed, if the absolute mean difference is 
almost zero. In order to evaluate the data agreement a cutoff of 15 % was defined to 
be acceptable for the percentage of the mean difference (%đ) from the mean 
concentration. 
Table 9.3. The mean difference (đ), limits of agreement (±1.96 SD of the differences), and 
the percentage of the difference from the mean of the Bland-Altman analyses are presented. 
Calculations were performed with concentrations in µM. Reproduced from 198. 
 Serum vs. EDTA-
plasma 
Serum vs. EDTA-ASA-
plasma 
EDTA plasma vs. 
EDTA-ASA-plasma 
 đ 1.96 
SD 
%đ 
from 
mean
đ 1.96 
SD 
%đ 
from 
mean
%đ 
from 
mean 
corr. 
đ 1.96 
SD 
%đ 
from 
mean
Pyruvate -6.7 11.6 13.3 -2.4 20.9 5.1 13.6 4.2 16.2 8.2 
Lactate 151.3 243.3 25.8 154.6 285.2 26.4 26.7 3.2 241.9 0.6 
β-Hydroxy-
butyrate 
2.1 93.9 0.4 19.7 121.1 3.7 0.5 17.6 111.0 3.3 
Succinate 2.1 12.4 5.7 5.1 14.5 14.5 5.7 3.0 15.3 8.8 
Malate -0.3 11.0 1.6 1.3 12.0 6.7 1.7 1.7 8.7 8.4 
Citrate -74.1 65.2 29.8 -50.9 49.9 21.5 47.8 23.2 60.0 8.5 
Glucose -140.1 430.8 5.1 38.0 479.9 1.4 4.9 178.1 507.1 6.6 
Alanine 22.1 51.7 10.0 32.3 68.1 14.9 10.7 10.2 30.4 4.9 
Glycine 62.1 120.3 14.3 84.8 127.0 20.0 22.3 22.7 62.9 5.8 
α-Amino-
butyrate 
1.8 11.1 7.5 2.8 8.4 11.9 6.9 1.0 9.9 4.4 
Valine 19.5 51.5 10.1 28.3 62.7 15.1 6.9 8.8 21.7 4.9 
Leucine 12.5 32.1 11.2 18.0 38.4 16.6 7.7 5.6 11.8 5.4 
Isoleucine 10.2 27.0 10.5 14.8 31.4 15.5 7.4 4.6 10.3 5.1 
Proline 9.9 18.5 13.5 13.4 22.2 18.6 12.6 3.5 9.5 5.1 
Asparagine 5.5 9.7 14.6 7.0 10.5 19.0 12.3 1.5 5.4 4.5 
Methionine 2.5 5.4 12.6 2.9 6.1 15.1 11.7 0.5 5.2 2.5 
Glutamate 7.3 16.3 15.4 11.0 19.1 23.9 19.1 3.7 12.3 8.6 
Phenyl-
alanine 
5.9 13.5 12.1 7.9 15.4 16.5 10.8 2.0 5.8 4.5 
Ornithine 5.2 12.0 12.2 8.9 14.6 21.8 7.1 3.7 5.7 9.6 
Glutamine 37.5 97.9 14.2 45.9 95.4 17.8 15.5 10.9 40.0 4.5 
Lysine 11.2 25.8 14.3 17.8 26.9 23.7 10.5 6.6 18.3 9.5 
Histidine 3.8 19.1 8.3 6.4 17.7 14.2 8.1 2.5 9.9 5.9 
Tyrosine 3.4 13.8 7.3 7.2 13.8 16.1 5.6 3.8 9.0 8.8 
Tryptophan 6.2 13.4 11.7 9.4 16.0 18.4 9.7 3.2 6.1 6.8 
Hippurate 12.9 27.9 12.0 17.7 35.1 16.8 12.4 4.8 22.1 4.8 
 
When comparing serum to EDTA-plasma the majority of analytes show a positive 
value for the mean difference demonstrating that slightly higher values were 
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 measured in serum. Only pyruvate, malate, citrate, and glucose yielded a negative 
mean difference. However, the %đ was less than 15 % for most analytes. Only 
lactate and citrate featured values of 26 % and 30 %, respectively. 
The comparatively lower values for citrate in serum might be due to the formation of 
complexes with Ca2+ and Mg2+ ions.53 The divalent cation-citrate complexes formed 
will precipitate during methanol extraction of metabolites, resulting in lower citrate 
values. In EDTA-plasma, the EDTA will chelate Ca2+ and Mg2+ ions yielding higher 
citrate values. EDTA-plasma should therefore be favored in studies that focus on the 
quantification of citrate and the related metabolites isocitrate and cis-aconitate, which 
possibly form analogous divalent cation complexes in serum. The discrepancy in 
lactate, on the other hand, is probably due to ongoing glycolysis in the waiting period 
for blood to clot prior to separation of serum from the blood cells by centrifugation, 
resulting in slightly lower glucose values and increased lactate concentrations. 
The representative Bland-Altman plots (Figure 9.3A and B) clearly show that lactate 
levels are significantly (p=0.007) lower in EDTA-plasma than serum, while the 
reverse is true for citrate (p=0.002). Adding ASA to EDTA-plasma did not show any 
major effects on the analytes quantified here. The average concentrations across all 
analytes were approximately 5.2 % lower in EDTA-ASA-plasma in comparison to 
EDTA-plasma, which is attributed to the dilution of the plasma (about 3.5 mL) through 
addition of the aspirin solution (200 µL), which accounts for about 5.7 %. In general 
the data from EDTA-plasma and EDTA-ASA-plasma agreed well with %đ less than 
10 %. However, data were not corrected for the dilution, because the blood volume 
sampled might vary slightly from sample to sample, which makes the collection of 
EDTA-ASA-plasma less accurate. 
The comparison of serum with EDTA-ASA-plasma revealed higher mean differences 
with lower concentrations for most analytes in EDTA-ASA-plasma. Again this can be 
attributed to the dilution of plasma by the Aspirin solution. In order to test this 
hypothesis, the difference in concentration between EDTA-plasma and EDTA-ASA-
plasma found for each analyte in the individual samples was added to the 
concentration determined in the EDTA-ASA-plasma to correct for the dilution and the 
Bland-Altman analysis comparing EDTA-ASA-plasma to serum was performed again 
(Table 9.3, %đ from mean corr.). The resulting %đ values were comparable to the 
%đ values obtained for the comparison of serum versus EDTA-plasma. 
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Figure 9.3. Bland-Altman plots for lactate and citrate comparing serum versus EDTA-
plasma. The mean difference (đ) is indicated in the plots by the centerline, while the outer 
lines represent the limits of agreement corresponding to ±1.96 SD of the differences. 
Reproduced from 198. 
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 10 Conclusions and perspectives 
GC×GC particularly in combination with TOFMS has emerged as a promising and 
powerful analytical tool for metabolomics investigations. Compared to conventional 
1D-GC, GC×GC provides a more comprehensive coverage of metabolomes due to 
increased chromatographic resolution, peak capacity, detection sensitivity, and 
broader dynamic range. In the early stages of the doctoral research work presented 
here, application of GC×GC-TOFMS to metabolomics was impeded by the lack of 
appropriate data processing, alignment, and analysis tools for the comparative 
analysis of metabolic fingerprints taking the entire available, also non-targeted 
information from all experiments into account for statistical analysis and, thereby, the 
identification of novel biomarkers. 
In this thesis, a GC×GC-TOFMS based metabolic fingerprinting strategy is presented 
that was developed in an interdisciplinary collaboration between analytical chemistry 
and bioinformatics. Data preprocessing tools provided by vendor software were used 
in combination with the in-house programmed retention time correction and peak 
alignment module INCA to form a data matrix suitable for multivariate statistical 
analysis. The metabolic fingerprinting routine was validated by a spike-in experiment, 
compared to the later introduced commercial alignment tool Statistical Compare, and 
applied to biomedical studies. 
GC×GC-EI-TOFMS was comprehensively evaluated over various GC-MS techniques 
(GC-EI-TOFMS, GC-CI-qMS, GC-EI-qMS, and GC-APCI-TOFMS) used for 
metabolomics studies employing a standard mixture of 43 compounds. GC×GC-
TOFMS showed the best performance among the tested techniques with linear 
ranges of over three orders of magnitude, LLOQs in the sub-micromolar range, and 
LODs in the nanomolar range. RSDs for calibration replicates (fivefold derivatized) 
were below 10 % and technical replicates (fivefold injected) below 5 % for 80 % of all 
compounds. 
GC×GC-TOFMS was applied to the quantitative analysis of amino acid enantiomers 
as their methyl chloroformate derivatives in physiological fluids. GC×GC-TOFMS 
method was validated by analyzing AAEs in urine and serum specimens, 
respectively, and by comparing the results with those of a previously established GC-
qMS method using single ion monitoring. Peak resolution was enhanced by coupling 
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 a γ-cyclodextrin (Rt®-γDEXsa) with an amino acid selective (ZB-AAA) column. Twenty 
AAEs including the structural isomers L-leucine/D-isoleucine could be baseline 
separated. Except for methionine enantiomers, improved LLOQs were obtained in 
contrast to the GC-qMS method. The analysis of a serum specimen in octaplicate 
yielded RSDs below 5 %, except for D-Ala, D-Asp, and D-Asn. AAE levels in patients 
suffering from liver cirrhosis showed significantly increased D-AA concentrations and 
slightly decreased L-AA levels compared to a control group. 
Despite the progress made, there is still need for improvement in the processing of 
GC×GC-TOFMS metabolic fingerprinting data. Particularly the precision of 
deconvolution algorithms needs to be further optimized to preserve the quality of the 
provided data. Also, data processing strategies need to be refined to enable better 
use of adequate metabolite-specific unique m/z ions for quantification. 
A lingering issue is the computationally intensive handling of GC×GC-TOFMS data. 
As a consequence of high sample throughput, multidimensional separation, and 
increased mass spectral acquisition rates, datasets become extremely large. 
Complete chromatographic analyses can only become more attractive if state-of-the-
art architectures, like 64-bit and multi-core processing, are supported and further 
advances are made by implementing less computationally demanding algorithms. 
Metabolomics aims to determine absolute concentration levels for all metabolites in a 
biological system. However, due to practical limitations, e.g. the absence of standard 
reference material, global GC×GC-TOFMS studies still rely on relative rather than 
absolute concentrations to compare metabolites in different samples. Relative 
quantification tends to have its flaws as metabolite recoveries can vary according to 
differences in matrix composition. 
So far, GC×GC-TOFMS has been mostly used for smaller metabolomics studies. Its 
robustness to run large sample sets over a long period has yet to be determined. In 
this context the development of protocols to correct for batch effects will be of 
uttermost importance. 
The metabolomics field certainly trends towards routine implementation of GC×GC-
TOFMS into a global metabolomic platform that uses complementary tools including 
LC-MS and NMR. Also, combining GC×GC with high-resolution mass analyzers 
should drive future efforts in characterizing unknown components of the metabolome. 
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 In the end, the rapid rate of methodical, hardware and software developments 
promises solutions to many of these problems in years to come. 
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 12 Appendix 
Figure S1. Pseudocode for the peak alignment. Reproduced from 107. 
 
 114
 Figure S2. Linear dependencies between expected and observed fold changes of the 20 
different spike-in metabolites for both the universal m/z 73 and the metabolite-specific m/z 
fragment ion trace investigated over all pairwise fold changes. Reproduced from 107. 
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 Figure S2 continued. 
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 Figure S2 continued. 
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 Figure S2 continued. 
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 Figure S2 continued. 
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 Figure S3. Linear dependencies over all pairwise fold changes between expected and 
observed fold changes of the 20 different spike-in metabolites for both the universal m/z 73 
and the metabolite-specific unique m/z ion trace selected by Statistical Compare. 
Reproduced from 108. 
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 Figure S3 continued. 
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 Figure S3 continued. 
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Figure S3 continued. 
 
 
 
 Table S1. Overview of the GC×GC based metabolomics publications presented in chapter 4.4 and 4.5. Reproduced from 6. 
Authors (Year) 
[Reference] 
Sample 
matrix 
Pretreat-
ment 
Column set [m×mm ID×µm 
film thickness] 
Detection Data  
handling 
Quantification Statistical analysis 
Ahola-Erkkilä et al. 
(2010) 115 
Serum M, S Rtx®-5 (10×0.18×0.2) 
BPX-50 (1.5×0.1×0.1) 
TOFMS ChromaTOF relative t-test 
Allwod et al. (2009) 153 Plant M, S VF-5ms (30×0.25×1.0) 
VF-17ms (2×0.1×0.2) 
TOFMS ChromaTOF - - 
Almstetter et al. (2009 
& 2011) 107, 108 
Bacterium M, S Rxi®-5ms (30×0.25×0.25) 
Rtx®-1701 (2×0.1×0.1) 
TOFMS ChromaTOF/ 
INCA 
relative, 
absolute 
PCA, t-test, FDR, 
ROC, CVal 
Asiago et al. (2010) 117 Serum S DB-5 (30×0.25×0.25) 
DB-17 (1×0.1×0.1) 
TOFMS ChromaTOF relative PLS-DA, t-test, box 
plots, CVal, ROC 
Aura et al. (2010) 161 Feces M, S Rtx®-5 (10×0.18×0.20) 
BPX-50 (1.5×0.1×0.1) 
TOFMS ChromaTOF relative PLS-DA, ANOVA, 
FDR, heatmap 
Beckstrom et al. (2011) 
119 
Plasma M, S Rtx®-5ms (20×0.25×0.5) 
Rtx®-200ms (2×0.18× 0.2) 
TOFMS Fisher ratio/ 
PARAFAC 
relative t-test, PCA, heatmap 
Castillo et al. (2011) 110 Plasma M, S Rtx®-5 (10×0.18×0.2) 
BPX-50 (1.5×0.1×0.1) 
TOFMS ChromaTOF/ 
Guineu 
relative PCA 
Cooper et al. (2010) 145 Yeast M, S Rtx®-5ms (20×0.25×0.5) 
Rtx®-200ms (2×0.18×0.2) 
TOFMS ChromaTOF relative t-test, heatmap  
David et al. (2008) 89 Bacterium Me HP-5ms (30×0.25×0.25) 
BPX-70 (1×0.1× 0.2) 
FID GC Image  - 
Doebbe et al. (2010) 152 Plant M, S Rtx®-5ms (30×0.25×0.25) 
BPX-50 (2×0.1×0.1) 
TOFMS ChromaTOF relative Fisher ratio, t-test 
Gröger and 
Zimmermann (2011) 130 
Plasma M, S SolGel-1ms (30×0.25×0.25) 
BPX-50 (2×0.1×0.1) 
TOFMS MatLab relative PLS-DA, t-test, CVal 
Guo and Lidstrom 
(2008) 140 
Bacterium M, S Rtx®-5 (20×0.25×0.5) 
Rtx®-200 (2×0.18×0.2) 
TOFMS Fisher ratio/ 
PARAFAC 
relative - 
Hoggard and Synovec 
(2008) 93 
Yeast M, S Rtx®-5ms (20×0.25×0.5) 
Rtx®-200ms (2×0.18×0.2) 
TOFMS PARAFAC - - 
Hope et al. (2005) 147 Standards, 
plant 
S DB-5 (10×0.18×0.18) 
DB-17 (2×0.1×0.1) 
TOFMS PARAFAC - - 
Huang and Regnier 
(2008) 127 
Standards, 
serum 
S DB-5 (10×0.18×0.18) 
DB-17 (1×0.1× 0.1) 
TOFMS ChromaTOF relative - 
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 Table S1 continued. 
Authors (Year) 
[Reference] 
Sample 
matrix 
Pretreat-
ment 
Column set [m×mm ID×µm 
film thickness] 
Detection Data  
handling 
Quantification Statistical analysis 
Humston et al. (2008) 
143 
Yeast M, S Rtx®-5ms (20×0.25×0.5) 
Rtx®-200ms (2×0.18×0.2) 
TOFMS S-ratio/ 
PARAFAC 
relative PCA 
Humston et al. (2011) 
144 
Yeast M, S Rtx®-5ms (20×0.25×0.5) 
Rtx®-200ms (2×0.18×0.2) 
TOFMS S-ratio/ 
PARAFAC 
relative PCA, ANOVA, t-test, 
heatmap 
Hyötyläinen et al. 
(2004) 155 
Milk Me Set 1/2: 
CP-7420 (100×0.25×0.25) 
HP-5ms (1.5×0.1×0.1) 
or HP-1 (1×0.1×0.1) 
Set 3/4: HP-1 (30×0.25×0.25) 
Cyano (1×0.1×0.1) 
or DB-WAX (0.35×0.05×0.1) 
FID MatLab relative - 
Johanningsmeier and 
McFeeters (2010) 154 
Plant SPME SolGel-WAX (30×0.25×0.25) 
Rtx®-1701 (1×0.1×0.1) 
TOFMS ChromaTOF relative ANOVA, FDR 
Junge et al. (2007) 158 Standards, 
beer 
MCF, 
ECF, 
TFA-ME 
Chirasil-L-Val (25×0.25×0.16) 
BPX-50 (1 or 3×0.1×0.1) 
or BP-1 (1 or 3×0.1×0.1) 
FID - relative - 
Kajander et al. (2009) 
136 
Mucosa M, S Rtx®-5ms (10×0.18×0.2) 
BPX-50 (1.1×0.1×0.1) 
TOFMS ChromaTOF relative PLS-DA, Wilcoxon 
test, FDR, CVal 
Kempa et al. (2009) 151 Plant M, S VF-5ms (30×0.25×0.25) 
VF-17ms (1×0.1×10) 
TOFMS ChromaTOF/ 
MetMax 
- PCA, ICA 
Kleemann et al. (2010) 
137 
Liver E, S BPX-50 (30×0.25×0.25) 
BPX-5 (2×0.32×0.25) 
TOFMS ChromaTOF relative ANOVA 
 
Koek et al. (2008) 131 Standards, 
bovine 
serum  
E, S BPX-50 (30×0.25×0.25) 
BPX-5 (1×0.1×0.1) 
(2×0.25×0.25) (2×0.32×0.25) 
(2×0.32×0.5) 
TOFMS Chemstation/
ChromaTOF 
relative - 
Koek et al. (2010) 90 Mouse 
liver 
E, S BPX-50 (30×0.25×0.25) 
BPX-5 (2×0.32×0.25) 
TOFMS ChromaTOF relative PCA, PCDA, box 
plots, ANOVA 
Kouremenos et al. 
(2010a) 134 
Standards M, S BPX-5 (30×0.25×0.25) 
BPX-50 (1×0.1×0.1) 
TOFMS ChromaTOF relative - 
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 Table S1 continued. 
Authors (Year) 
[Reference] 
Sample 
matrix 
Pretreat-
ment 
Column set [m×mm ID×µm 
film thickness] 
Detection Data  
handling 
Quantification Statistical analysis 
Kouremenos et al. 
(2010b) 133 
Urine S BPX-5 (30×0.25×0.25) 
BPX-50 (1×0.1×0.1) 
or BPX-50 (30×0.25×0.25) 
BPX-5 (1×0.1×0.1) 
TOFMS ChromaTOF relative - 
Kusano et al. (2007) 148 Plant M, S Rtx®-5Sil MS (30×0.25×0.25) 
Rtx®-50 (1×0.18×0.2) 
TOFMS ChromaTOF relative t-test 
Lankinen et al. (2011) 
118 
Plasma M, S Rtx®-5 (10×0.18×0.2) 
BPX-50 (1.5×0.1×0.1) 
TOFMS ChromaTOF relative t-test, FDR, Spear- 
man correlation 
Li et al. (2009) 120 Plasma S DB-5 (30×0.25×0.25) 
DB-1701 (1.4×0.1×0.1) 
TOFMS GC×GC 
workstation 
relative OSC-PLS-DA, t-test, 
CVal 
May et al. (2008) 150 Plant M, S VF-5ms (30×0.25×0.25) 
VF-17ms (1×0.1×10) 
TOFMS ChromaTOF - - 
Mayadunne et al. 
(2005) 157 
Wine, 
beer, 
honey 
PCF Set 1:BPX-5 (30×0.25×0.25) 
BPX-50 (2×0.1×0.1) 
Set 2: 
SolGel-WAX (30×0.25×0.25) 
BP-1 (1.5×0.1×0.1) 
FID, 
TOFMS 
- absolute - 
McGaw et al. (2010) 125 Plasma S, PCF Rtx®-5 (38×0.18×0.2) 
Rxi®-17 (1×0.1×0.1) 
TOFMS ChromaTOF relative - 
Mervaala et al. (2010) 
138 
Heart M, S Rtx®-5 (10×0.18×0.2) 
BPX-50 (1.5×0.1×0.1) 
TOFMS ChromaTOF relative PLS-DA, ANOVA, 
Wilcoxon test, FDR 
Mohler et al. (2006) 96, 
98, 99 
Yeast M, S Rtx®-5ms (20×0.25×0.5) 
Rtx®-200ms (2×0.18×0.2) 
TOFMS PCA/ 
PARAFAC 
relative - 
Mohler et al. (2007) Yeast M, S Rtx®-5ms (20×0.25×0.5) 
Rtx®-200ms (2×0.18×0.2) 
TOFMS Fisher ratio/ 
PARAFAC 
relative t-test 
Mohler et al. (2008) Yeast M, S Rtx®-5ms (20×0.25×0.5) 
Rtx®-200ms (2×0.18×0.2) 
TOFMS S-ratio/ 
PARAFAC 
relative PCA 
Oh et al. (2008) 106 Standards, 
serum 
E, S DB-5 (10×0.18×0.18) 
DB-17 (1×0.1×0.1) 
TOFMS ChromaTOF/
MSort 
- ROC 
O´Hagan et al. (2007) 
129 
Serum M, S DB-1 (30×0.25×0.25) 
BPX-50 (1.5×0.1×0.1) 
TOFMS ChromaTOF - PCA 
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 Table S1 continued. 
Authors (Year) 
[Reference] 
Sample 
matrix 
Pretreat-
ment 
Column set [m×mm ID×µm 
film thickness] 
Detection Data  
handling 
Quantification Statistical analysis 
Okubo et al. (2010) 142 Bacterium M, S Rtx®-5 (20×0.25×0.5) 
Rtx®-200 (2×0.18×0.2) 
TOFMS S-ratio/ 
PARAFAC 
relative t-test 
Oresic et al. (2008) 121 Serum M, S Rtx®-5 (10×0.18×0.2) 
BPX-50 (1.5×0.1×0.1) 
TOFMS ChromaTOF relative Wilcoxon test, FDR, 
heatmap 
Oresic et al. (2011) 122 Serum M, S Rtx®-5 (10×0.18×0.2) 
BPX-50 (1.5×0.1×0.1) 
TOFMS ChromaTOF relative ANOVA, beanplot, 
CVal, ROC 
Pasikanti et al. (2010) 
135 
Cells M, S DB-1 (30×0.25×0.25) 
Rxi®-17 (1.5×0.1×0.1) 
TOFMS ChromaTOF relative PCA, PLS-DA, 
Welch t-test 
Pierce et al. (2006) 95 Plant M, S DB-5 (20×0.25×0.5) 
Rtx®-200 (2×0.18×0.2) 
TOFMS PCA/ 
PARAFAC 
relative - 
Pierce et al. (2006) 97 Urine M, S DB-1 (20×0.25×0.5) or 
Rtx®-5ms (20×0.25×0.5) 
Rtx®-200 (2×0.18×0.2)  
TOFMS Fisher ratio/ 
PARAFAC 
relative - 
Ralston-Hooper et al. 
(2008) 159 
Inverte-
brates 
E, S Rtx®-5 (10×0.18×0.2) 
DB-17 (1.1×0.18×0.18) 
TOFMS ChromaTOF/
MSort 
relative t-test, FDR, PCA 
Ralston-Hooper et al. 
(2010) 160 
Inverte-
brates 
M, S Rtx®-5 (10×0.18×0.2) 
DB-17 (1.1×0.18×0.18) 
TOFMS ChromaTOF/
MSort 
relative t-test, ANOVA, FDR, 
HCA 
Shellie et al. (2005) 101 Tissue M, S Set 1: PDMS (30×0.25×0.25) 
50% Phenyl polysilphenylene 
siloxane (1.5×0.1×0.1) 
Set 2: 5% Phenyl PDMS 
(30×0.25×0.25) 
50% Phenyl polysilphenylene 
siloxane (2×0.1×0.1) 
TOFMS ChromaTOF relative t-test 
Sinha et al. (2004) 94 Infant urine O, S DB-5 (20×0.25×0.5) 
Rtx®-200 (2×0.18×0.2) 
TOFMS DotMap/ 
PARAFAC 
- - 
Sinha et al. (2004) 91 Plant O, S DB-5 (10×0.18×0.18) 
DB-17 (2×0.1×0.1) 
TOFMS PARAFAC - - 
Snyder et al. (2010) 139 Brain 
tissue 
M, S Rtx®-5 (20×0.25×0.5) 
Rtx®-200 (2×0.18×0.2) 
TOFMS PARAFAC relative - 
Tranchida et al. (2008) 
124 
Plasma Me Equity-1 (30×0.25×0.25) 
Supelcowax™ 10 (0.95×0.1×0.1) 
FID - - - 
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Table S1 continued. 
Authors (Year) 
[Reference] 
Sample 
matrix 
Pretreat-
ment 
Column set [m×mm ID×µm 
film thickness] 
Detection Data  
handling 
Quantification Statistical analysis 
Tyynismaa et al. (2010) 
116 
Muscle M, S Rtx®-5 (10×0.18×0.2) 
BPX-50 (1.5×0.1×0.1) 
TOFMS ChromaTOF relative t-test 
Velagapudi et al. 
(2009) 123 
Serum M, S Rtx®-5 (10×0.18×0.2) 
BPX-50 (1.5×0.1×0.1) 
TOFMS ChromaTOF relative PLS-DA, t-test, 
ANOVA, FDR 
Vlaeminck et al. (2007) 
156 
Milk Me BPX-5 (30×0.25×0.25) 
BPX-20 (0.85×0.1×0.2) 
FID Chemstation relative t-test 
Wachsmuth et al. 
(2011) 171 
Standards, 
bacterium 
M, S Rxi®-5ms (30×0.25×0.25) 
Rtx®-1701 (2×0.1×0.1) 
TOFMS ChromaTOF relative  
Waldhier et al. (2011) 
126 
Serum, 
urine 
MCF Rt®-γDEXsa (30×0.25×0.25) 
Rtx®-1701 (2×0.1×0.1) or 
ZB-AAA (2×0.25×0.1) 
TOFMS ChromaTOF absolute t-test 
Wang et al. (2010) 109 Standards, 
rat plasma 
E, S Rxi®-5ms (30×0.25×0.25) 
BPX-50 (1.2×0.1×0.1) 
TOFMS ChromaTOF/
DISCO 
- ROC 
Welthagen et al. (2005) 
100 
Spleen 
tissue 
M, S Rtx®-1ms (30×0.25×0.25) 
BPX-50 (1.5×0.1×0.1) 
TOFMS ChromaTOF relative t-test 
Wojtowicz et al. (2010) 
132 
Urine S Rxi®-5ms (30×0.25×0.25) 
BPX-50 (2.5×0.1×0.1) 
TOFMS ChromaTOF relative - 
Yang et al. (2009) 141 Bacterium M, S Rtx®-5 (20×0.25×0.5) 
Rtx®-200 (2×0.18×0.2) 
TOFMS Fisher ratio/ 
PARAFAC 
absolute, 
relative 
t-test, Fisher ratio 
Zhang et al. (2008) 105 Standards, 
serum 
E, S DB-5 (10×0.18×0.18) 
DB-17 (1×0.1×0.1) 
TOFMS ChromaTOF - - 
M methoxymation, E ethoxymation, O oxymation, S silylation, Me methylation, TFA-ME N-trifluoroacetyl methyl ester derivatization. 
 
 
 Table S2. Our in-house EI mass spectral library consists of approx. 150 metabolites 
including sugars, alcohols, fatty acids, organic acids, amino acids, and amino acid 
metabolites. Some metabolites yield multiple derivatization products. 
No. Metabolite  54 Hippuric acid, N-TMS, TMS 
1 N-Acetyl glucosamine, MeOx, 4TMS  55 Hippuric acid, TMS 
2 cis-Aconitic acid, 3TMS  56 Histamine, N,1-2TMS 
3 Adenosine, 4TMS  57 Histidine, N,1-2TMS, TMS 
4 Adipic acid, 2TMS  58 Homogentisic acid, TMS 
5 Alanine, N-TMS, TMS  59 Homovanillic acid, 2TMS 
6 α-Aminoadipic acid, N-TMS, 2TMS  60 3-Hydroxyanthranilic acid, N-TMS, 2TMS
7 γ-Aminobutyric acid, 2TMS  61 Hydroxybenzyl alcohol, 2TMS 
8 γ-Aminobutyric acid, 3TMS  62 2-Hydroxybutyric acid, 2TMS 
9 Aminoisobutyric acid, 2TMS  63 3-Hydroxybutyric acid, TMS 
10 Aminoisobutyric acid, 3TMS  64 5-Hydroxyindoleacetic acid, 3TMS 
11 α-Aminopimelic acid, N-TMS, 2TMS  65 3-Hydroxykynurenine, N,N-2TMS, 2TMS 
12 Anthranilic acid, N-TMS, TMS  66 2-Hydroxy-3-methylbutyric acid, 2TMS 
13 Arachidonic acid, TMS  67 Hydroxyphenylacetic acid, TMS 
14 Ascorbic acid, 4TMS  68 Hydroxyphenylpyruvic acid, TMS 
15 Asparagine, N-2TMS, N-TMS, TMS  69 Hydroxyproline, 2TMS 
16 Asparagine, N,N-TMS, 2TMS  70 Hydroxyproline, 3TMS 
17 Aspartic acid, 2TMS  71 Indole-3-pyruvate, MeOx, TMS 
18 Aspartic acid, N-TMS, 2TMS  72 Indole, 1-TMS 
19 Benzoic acid, TMS  73 Indole-1-acetic acid, TMS 
20 Cholesterol, TMS  74 Indole-3-acetic acid, 1-TMS, TMS 
21 Citric acid, 4TMS  75 Indole-3-lactic acid, 1-TMS, 2TMS 
22 Creatinine, N,N-2TMS, TMS  76 Indole-3-propionic acid, 1-TMS, TMS 
23 Cystathionine, N,N-2TMS, 2TMS  77 Isoleucine, N-TMS, TMS 
24 Cysteine, N,S-2TMS, TMS  78 Isoleucine, TMS 
25 Cystine, N,N-2TMS, 2TMS  79 Itaconic acid, 2TMS 
26 Decanoic acid, TMS  80 2-Ketobutyric acid, TMS 
27 Dimethylsuccinic acid, 2TMS  81 α-Ketoglutaric acid, MeOx-TMS 
28 Docosahexaenoic acid, TMS  82 Ketosuccinic acid, 3TMS 
29 Docosanoic acid, TMS  83 Kynurenic acid, 2TMS 
30 Dodecanoic acid, TMS  84 Kynurenine, N-TMS, TMS 
31 Eicosanoic acid, TMS  85 Kynurenine, N,N-2TMS, TMS 
32 Erucic acid, TMS  86 Lactic acid, 2TMS 
33 Erythritol, 4TMS  87 Lactose, 7TMS 
34 Ethanolamine, 3TMS  88 Leucine, N-TMS, TMS 
35 Fructose, MeOx, 5TMS  89 Leucine, TMS 
36 Fructose-6-phosphate, MeOx, 6TMS  90 Linoleic acid, TMS 
37 Fumaric acid, 2TMS  91 α-Linolenic acid, TMS 
38 Galactose, MeOx, 6TMS  92 Lysine, 3TMS 
39 Glucose, MeOx, 5TMS  93 Lysine, N-TMS, N-2TMS, TMS 
40 Glucose-6-phosphate, MeOx, 6TMS   94 Lysine, N,N-2TMS, TMS 
41 Glutamic acid, N-TMS, 2TMS  95 Malic acid, 3TMS 
42 Glutamine, N-TMS, 2TMS  96 Malonic acid, 2TMS 
43 Glutaric acid, 2TMS  97 Maltose, 8TMS 
44 Glyceric acid, 3TMS  98 Mandelic acid, 2TMS 
45 Glycerol, 3TMS  99 Mannitol, 6TMS 
46 Glycerol-1-phosphate, 4TMS  100 Mannose, MeOx, 5TMS 
47 Glycerol-2-phosphate, 4TMS  101 Methionine, N-TMS, TMS 
48 Glycine, N-2TMS, TMS  102 Methionine, TMS 
49 Glycine, N-TMS, TMS  103 Methylhistidine, N-TMS, TMS 
50 Heptadecanoic acid, TMS  104 Methylmalonic acid, 2TMS 
51 Heptanoic acid, TMS  105 3-Methyl-2-oxovaleric acid, TMS 
52 Hexadecanoic acid, TMS  106 4-Methyl-2-oxovaleric acid, TMS 
53 Hexanoic acid, TMS  107 Myo-Inositol-phosphate, 7TMS 
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 Table S2 continued. 
No. Metabolite  163 Tyrosine, N-TMS, 2TMS 
108 Myo-Inositol, 6TMS  164 Undecanoic acid, TMS 
109 Nicotinamide, TMS  165 Valine, N-TMS, TMS 
110 Nicotinic acid, TMS  166 Valine, TMS 
111 Nonadecanoic acid, TMS  167 Vanillic acid, 2TMS 
112 Nonanoic acid, TMS  168 Xanthurenic acid, 3TMS 
113 Norvaline, N-TMS, TMS  169 Xylitol, 5TMS 
114 Octadecanoic acid, TMS  170 Xylose, MeOx, 4TMS 
115 Octanoic acid, TMS    
116 Oleic acid, TMS    
117 Ornithine, N,N-2TMS, TMS    
118 Ornithine, N-TMS, N-2TMS, TMS    
119 Orotic acid, 3TMS    
120 Oxalacetate, MeOx, 2TMS    
121 Oxalic acid, 2TMS    
122 Palmitelaidic acid, TMS    
123 Pantothenic acid, 3TMS    
124 Pentadecanoic acid, TMS    
125 Pentanoic acid, TMS    
126 Phenylacetic acid, TMS    
127 Phenylalanine, N-TMS, TMS    
128 Phenylalanine, TMS    
129 Phenyllactic acid, 2TMS    
130 Phenylpyruvic acid, TMS    
131 Phosphoenolpyruvic acid, MeOx, 3TMS    
132 3-Phosphoglyceric acid, TMS    
133 O-Phosphorylethanolamine, 4TMS    
134 Proline, 1-TMS, TMS    
135 Proline, TMS    
136 Putrescine, N-2TMS, N-2TMS    
137 Pyroglutamate, 1-TMS, TMS    
138 Pyruvate, MeOx, TMS    
138 Quinolinic acid, 2TMS    
139 Ribitol, 5TMS    
140 Ribose, MeOx, 4TMS    
141 Salicylic acid, TMS, acetate    
142 Sarcosine, N-TMS, TMS    
143 Serine, 2TMS    
144 Serine, N-TMS, 2TMS    
145 Serotonine, N,N-2TMS, TMS    
146 Serotonine, N-2TMS, N-TMS, TMS    
147 Shikimic acid, 4TMS    
148 Sorbitol, 6TMS    
149 Suberic acid, TMS    
150 Succinic acid, 2TMS    
151 Sucrose, 8TMS    
152 Tartaric acid, 4TMS    
153 Taurine, N-2TMS, TMS    
154 Taurine, N-TMS, TMS    
155 Tetradecanoic acid, TMS    
156 Threonine, 2TMS    
157 Threonine, N-TMS, 2TMS    
158 Tridecanoic acid, TMS    
159 Triethanolamine, 3TMS    
160 Tryptophan, N,1-2TMS, TMS    
161 Tryptophan, N-TMS, TMS    
162 Tyrosine, 2TMS    
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 Table S3. Comparison of metabolites identified in extracts of the two E. coli strains grown in 
LB medium and harvested in stationary phase using CE-TOFMS and GC×GC-TOFMS 
analysis. Reproduced from 107. 
No. Metabolite CE-TOFMS GC×GC-TOFMS 
 Detected Significant
(p <0.05) 
Detected Significant 
(FDR <0.05) 
1 Aminoadipate x x x x 
2 Caproate x x x x 
3 cis-Aconitate x x x x 
4 Citrate x x x x 
5 Fumarate x x x x 
6 Glucose x x x x 
7 Glucose-6-phosphate x x x x 
8 Isoleucine x x x x 
9 Itaconate x x x x 
10 Leucine x x x x 
11 Lysine x x x x 
12 Malate x x x x 
13 Orotate x x x x 
14 Proline x x x x 
15 Pyruvate x x x x 
16 Succinate  x x x x 
17 Sucrose x x x x 
18 Valine x x x x 
19 Alanine x x x  
20 Aspartate x x x  
21 Benzoate x x x  
22 Glucosamine-6-phosphate x x x  
23 Glucuronate x x x  
24 Glutamate x x  x*  
25 Glycerolphosphate x x x  
26 Octanoate x x x  
27 Pantothenate x x x  
28 Phosphoenolpyruvate x x x  
29 Phosphoglycerate x x x  
30 AMP x x   
31 CMP x x   
32 dTMP x x   
33 Glutathione x x   
34 Maltose x x   
35 UDP x x   
36 UDP-glucose x x   
37 UMP x x   
38 alpha-Ketogluterate x  x x 
39 Tartrate x  x x 
40 Furoate  x1 x x x 
41 GABA 2 x x x 
42 Glycine   x x 
43 Myo-inositol   x x 
44 Indole   x x 
45 Putrescine   x x 
46 Pyroglutamate     x1* x 
47 Caprate x  x  
48 Glutarate x  x  
49 Heptanoic acid x  x  
50 Histidine x  x  
51 Lactate x  x  
52 Phenylalanine x  x  
53 Glycerate  x1 x x  
54 Glycerol  x1 x x  
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 Table S3 continued. 
No. Metabolite CE-TOFMS GC×GC-TOFMS 
 Detected Significant
(p <0.05) 
Detected Significant 
(FDR <0.05)
55 2-Hydroxy-3-methylbutyrate   x  
56 2-Hydroxybutyrate   x  
57 3-Hydroxybutyrate   x  
58 3-Methyl-2-oxovalerate   x  
59 4-Methyl-2-oxovalerate   x  
60 Arachidate   x  
61 Decanoate   x  
62 Dodecanoate   x  
63 Ethanolamine   x  
64 Fructose   x  
65 Glucosamine   x  
66 Hexadecanoate   x  
67 Methionine   x  
68 N-Acetylglucosamine   x  
69 Nicotinamide 3  x  
70 Nicotinate   x  
71 Octadecanoate   x  
72 O-Phosphorylethanolamine   x  
73 Palmitoleate   x  
74 Tetradecanoate   x  
75 Threonine 3  x  
76 Tyrosine   x  
77 Valerate 3  x  
78 Cadaverine    x1  
79 ADP x    
80 CDP x    
81 NAD+/NADH x    
82 UDP-D-glucuronate x    
83 Uridine x    
84 NADP+/NADPH x    
85 Pentose-phosphate x  4  
86 4-Hydroxybenzyl alcohol 3    
87 Adenine 3    
88 Adenosine 3    
89 Arginine 3    
90 cyclic-AMP 3    
91 Cytidine 3    
92 Hypoxanthine 3    
93 Uracil 3    
94 Glutamine 3  *  
95 Nonanoate x  IS5  
96 Cinnamate-d7 -  IS  
97 Glucose-13C6 -  IS  
98 Glutamate-d5 IS  -  
99 Lactate-13C3 IS  IS  
100 Malate-d3 IS  IS  
101 Norvaline -  IS  
102 PIPES IS  -  
103 Pyruvate-13C3 -  IS  
104 Succinate-d4 IS  IS  
105 Uneven numbered fatty acids (C9-C19) -  IS  
* Glutamate and glutamine rearrange to pyroglutamate, 1 not confirmed by a commercial standard, 
2 γ-aminobutyrate was detected, but not confirmed by a commercial standard, 3 Metabolite was not 
detected by CE-TOFMS in E. coli extracts from cells grown in LB medium in the stationary phase, 
but were found in extracts of cells grown with minimal medium, 4 not properly assignable. 
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 Table S4. Comparison of metabolites identified in extracts of two E. coli strains using 
GC×GC-EI-TOFMS and GC-APCI-TOFMS analyses. Reproduced from 171. 
GC×GC-EI-TOFMS (2009) GC-APCI-TOFMS (2010) 
27 identified metabolites out of 
48 features 
25 identified metabolites out of 
45 features 
Detected Detected
Metabolite 
 
Significant (adjusted 
p-valuea <0.05)  
Significant (adjusted 
p-valuea <0.05) 
Citrate x x x x 
Fumarate x x x x 
Succinate x x x x 
α-Ketoglutarate x x x x 
Orotate x x x x 
Itaconate x x x x 
cis-Aconitate x x x x 
Lysine x x x x 
Valine x x x x 
Leucine x x x x 
Myo-inositol x x x x 
Malate x x x x 
Isoleucine x x x x 
Proline x x x  
Putrescine x x x  
Aminoadipate x x x  
Pyroglutamate x x x  
Caproate x x x  
Furoate x x x  
Glucose x x x  
Glucose-6P x x x  
Sucrose x x x  
Pyruvate x x x  
Indole x x x  
Glycine x x x  
Tartrate x x x  
GABA x x x   
Pantothenate x  x x 
Nicotinate x  x x 
Phosphoglycerate x  x x 
Methionine x  x x 
Phosphoenolpyruvate x  x x 
Phenylalanine x   x x 
Dihydroorotate   x x 
N-Acetyl-Aspartate   x x 
N-Acetyl-Neuraminate   x x 
Thymine   x x 
Acetylputrescine   x x 
Ornithine   x x 
Glutamate-5-
phosphateb     x x 
a False discovery rate according to Benjamini and Hochberg.113  
b Tentatively identified without commercial standard. 
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 Table S5. Mastermix compounds, internal standards and uneven numbered fatty acids with 
their respective quantification traces (hard and soft ionization techniques). Modified from 171. 
Compound 
 
Retention 
times 
(1D, 2D) [s] 
m/z 
quantifier EI 
fragment 
ion 
m/z 
quantifier 
[M+H]+ 
ion 
Pyruvate 591, 1.860 174 190 
Lactate 603, 1.800 219 235 
2-Ketobutyrate 643, 1.905 188 204 
Ala-2TMS 647, 1.835 190 234 
2-Hydroxybutyrate 671, 1.835 205 249 
3-Hydroxybutyrate 703, 1.885 233 249 
3-Methyl-2-oxovalerate 727, 1.960 203 232 
4-Methyl-2-oxovalerate 759, 1.965 200 232 
Methylmalonate 759, 2.065 247 263 
Val-2TMS 763, 1.890 218 262 
Leu-2TMS 819, 1.890 232 276 
Glycerol 827, 1.790 218 309 
Ile-2TMS 843, 1.910 232 276 
Nicotinate 843, 2.370 180 196 
Phenylacetate 847, 2.225 193 209 
Pro-2TMS 851, 1.950 216 260 
Gly-3TMS 859, 1.915 276 292 
Succinate 859, 2.145 172 263 
Glycerate 879, 1.910 292 323 
Fumarate 891, 2.125 245 261 
Malate 1035, 2.010 233 351 
Adipate 1039, 2.190 111 291 
Erythritol 1055, 1.790 217 411 
GABA-3TMS 1071, 1.990 304 320 
α-Ketoglutarate 1107, 2.195 198 320 
Phenyllactate 1119, 2.190 193 311 
Phenylpyruvate 1123, 2.260 265 266 
Hydroxyphenylacetate 1163, 2.235 179 297 
Putrescine-4TMS 1251, 1.910 214 377 
cis-Aconitate 1251, 2.220 229 391 
Glycerol-1-phosphate 1271, 2.160 357 461 
Homovanillate 1271, 2.325 326 327 
Phosphoglycerate 1307, 2.280 357 475 
Citrate 1315, 2.140 273 481 
Homogentisate 1323, 2.215 384 385 
Hippurate-1TMS 1331, 3.005 236 252 
Fructose 1371, 1.835 307 570 
Hydroxyphenylpyruvate 1375, 2.255 190 354 
Glucose 1399, 1.870 319 570 
Myo-Inositol 1523, 1.955 305 613 
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Table S5 continued. 
Compound 
 
Retention 
times 
(1D, 2D) [s] 
m/z  
quantifier  
EI fragment  
ion 
m/z  
quantifier 
[M+H]+  
ion 
5-Hydroxyindoleacetate-2TMS 1591, 2.975 335 336 
Glucose-6-phosphate 1691, 2.385 387 722 
Lactose 2043, 3.500 361 948 
 
Surrogates 
[U-13C]pyruvate 591, 1.860 177 193 
[U-13C]lactate 603, 1.800 222 238 
[U-13C]3-hydroxybutyrate 703, 1.885 237 253 
Norvaline-2TMS 787, 1.885 144 262 
[U-2H]succinate 855, 2.125 176 267 
[U-13C]fumarate 891, 2.125 249 265 
[2,3,3-2H3]malate 1031, 2.045 236 354 
[2H7]trans-cinnamate 1079, 2.370 212 228 
[2,2,4,4-2H4]citrate 1315, 2.090 276 485 
[U-13C]glucose 1399, 1.870 323 576 
[4,6,7-2H3]5-hydroxyindole-[2H2]acetate 1587, 2.970 340 341 
[U-13C]lactose 2043, 3.500 367 960 
 
Derivatization standard – uneven numbered fatty acids 
Nonanoic acid 903, 1.980 215 231 
Undecanoic acid 1083, 2.025 243 259 
Tridecanoic acid 1247, 2.040 271 287 
Pentadecanoic acid 1395, 2.075 299 315 
Heptadecanoic acid 1531, 2.160 327 343 
Nonadecanoic acid 1659, 2.285 355 371 
 
 
 Table S6. R² values, LODs and RSDs for technical replicates for evaluated GC-MS approaches. Reproduced from 171. 
Compound GC-APCI-TOFMS GC×GC-EI-TOFMS GC-EI-TOFMS GC-CI-qMS GC-EI-qMS 
 R² 
LOD 
[µM] 
RSDb 
(%)  
R² 
LOD 
[µM] 
RSDb 
(%)  
R² 
LOD 
[µM] 
RSDb 
(%)  
R² 
LOD 
[µM] 
RSDc 
(%) 
R² 
LOD 
[µM] 
RSDc 
(%) 
Ala-2TMS 0.9907 0.98 2.5 0.9979 0.49 4.5 0.9908 1.95 8.3 0.9913 7.81 4.6 0.9955 7.81 2.4 
Val-2TMS 0.9960 0.24 3.8 0.9985 0.03 3.2 0.9944 0.24 8.8 0.9919 1.95 4.5 0.9975 1.95 2.1 
Leu-2TMS 0.9934 0.49 8.1 0.9930 0.98 5.9 0.9932 11.72 8.2 0.9979 3.91 6.7 0.9910 7.81 2.0 
Ile-2TMS 0.9972 0.49 7.0 0.9843 0.98 3.2 0.9907 1.95 5.9 0.9901 3.91 2.3 0.9954 7.81 2.4 
Pro-2TMS 0.9926 1.95 2.7 0.9974 3.91 7.1 0.9906 23.45 7.3 0.9935 7.81 3.8 0.9913 11.72 2.5 
Gly-3TMS 0.9969 0.24 5.0 0.9981 0.03 4.6 0.9905 0.98 7.6 0.9920 1.95 4.4 0.9981 3.91 2.4 
Putrescine-4TMS 0.9981 0.98 3.1 0.9920 7.81 2.3 0.9933 23.45 3.0 0.9908 7.81 6.0 0.9980 0.98 1.0 
GABA-3TMS 0.9910 1.95 1.5 0.9944 0.49 3.8 0.9890 1.95 5.9 0.9900 0.98 5.5 0.9965 0.98 0.4 
Lactatea 0.9949 0.98 0.3 0.9994 0.01 0.7 0.9975 3.91 2.5 0.9958 7.81 8.1 0.9964 1.95 2.3 
2-OH-butyrate 0.9966 0.12 2.5 0.9995 0.01 2.0 0.9958 0.06 1.7 0.9967 23.44 4.8 0.9978 3.91 2.6 
3-OH-butyratea 0.9984 0.06 2.4 0.9992 0.01 0.8 0.9971 0.98 0.2 0.9980 11.72 1.6 0.9990 1.95 3.7 
Me-malonate 0.9956 0.06 3.7 0.9972 0.06 4.2 0.9953 0.24 3.3 0.9968 3.91 4.5 0.9978 7.81 0.9 
Glycerol 0.9903 1.95 4.5d 0.9976 0.01 2.1 0.9978 0.98 3.5 0.9967 3.91 4.0 0.9972 1.95 0.5 
Succinatea 0.9973 0.12 4.0 0.9978 0.02 2.6 0.9940 1.95 3.7 0.9935 11.72 4.8 0.9994 1.95 2.1 
Glycerate 0.9968 0.06 3.3 0.9949 0.02 2.8 0.9969 0.98 4.2 0.9964 15.63 3.0 0.9980 1.95 0.5 
Fumaratea 0.9977 0.24 1.1 0.9997 0.01 1.5 0.9962 0.24 0.6 0.9992 0.98 5.4 0.9991 0.06 0.7 
Malatea 0.9967 0.24 2.9 0.9988 0.01 0.8 0.9955 0.98 0.6 0.9958 7.81 1.4 0.9993 0.24 1.5 
Adipate 0.9973 0.24 4.4 0.9908 0.01 3.0 0.9963 3.91 3.4 0.9934 15.63 3.4 0.9988 0.98 0.8 
Erythritol 0.9948 0.06 2.6 0.9960 0.01 1.7 0.9898 1.95 2.7 0.9925 11.72 1.5 0.9993 0.98 1.0 
cis-Aconitate 0.9969 0.06 1.9 0.9979 0.02 1.8 0.9962 3.91 7.1 0.9929 15.63 10.1 0.9950 0.98 0.6 
Citratea 0.9976 0.49 1.4 0.9994 0.01 0.6 0.9947 1.95 0.3 0.9915 7.81 11.3 0.9993 0.12 1.2 
Pyruvatea 0.9986 0.12 1.3 0.9996 0.004 1.2 0.9981 3.91 3.7 0.9974 7.81 9.1 0.9994 0.98 4.3 
2-Ketobutyrate 0.9969 0.24 4.0 0.9901 0.02 5.1 0.9900 11.72 3.2 0.9913 15.63 6.2 0.9989 3.91 3.0 
3-Me-2-oxovalerate 0.9980 0.12 2.3 0.9979 0.12 2.7 0.9963 0.24 4.1 0.9930 23.44 5.8 0.9933 11.72 6.2 
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Table S6 continued. 
Compound GC-APCI-TOFMS GC×GC-EI-TOFMS GC-EI-TOFMS GC-CI-qMS GC-EI-qMS 
 R² 
LOD 
[µM] 
RSDb 
(%)  
R² 
LOD 
[µM] 
RSDb 
(%)  
R² 
LOD 
[µM] 
RSDb 
(%)  
R² 
LOD 
[µM] 
RSDc 
(%) 
R² 
LOD 
[µM] 
RSDc 
(%) 
4-Me-2-oxovalerate 0.9960 0.24 6.0 0.9928 0.02 4.5 0.9956 0.24 4.3 0.9900 11.72 2.7 0.9976 3.91 1.5 
α-Ketoglutarate 0.9947 0.06 3.1 0.9965 0.03 1.4 0.9901 1.95 2.8 0.9961 15.63 4.4 0.9948 1.95 1.4 
Phenylacetate 0.9970 0.98 3.1 0.9981 0.03 2.9 0.9875 0.03 3.0 0.9948 11.72 3.0 0.9925 7.81 2.5 
Phenylpyruvate 0.9980 0.24 1.8 0.9983 0.49 2.0 0.9901 15.63 1.4 0.9986 7.81 2.8 0.9923 31.25 1.9 
Hydroxyphenylacetate 0.9969 0.24 4.8 0.9973 0.02 2.2 0.9911 0.49 4.5 0.9954 3.91 3.7 0.9984 1.95 0.8 
Homovanillate 0.9969 0.49 0.5 0.9940 0.24 2.8 0.9935 0.98 3.1 0.9974 3.91 2.4 0.9926 0.98 1.3 
Hippurate-1TMS 0.9977 0.49 0.8 0.9963 93.75 nd 0.9930 93.75 nd 0.9984 15.63 5.5 0.9963 31.25 3.0 
Homogentisate 0.9963 0.24 4.6d 0.9968 0.06 2.3 0.9941 3.91 2.7 0.9967 3.91 4.4 0.9985 0.49 1.9 
OH-phenylpyruvate 0.9990 0.24 3.6 0.9935 1.95 4.5 0.9943 7.81 5.3 0.9907 15.63 11.0 0.9924 1.95 2.1 
5-HIAA-2TMSa 0.9987 0.49 2.7 0.9990 0.03 3.9 0.9956 11.72 4.9 0.9959 3.91 4.1 0.9972 11.72 0.7 
Phenyllactate 0.9960 0.49 1.3 0.9986 0.06 5.6 0.9956 0.98 5.3 0.9990 7.81 8.3 0.9975 0.98 2.0 
Nicotinate 0.9976 0.49 1.0 0.9967 0.01 2.1 0.9983 0.49 2.7 0.9980 3.91 1.5 0.9992 0.98 4.1 
Glycerol-1-P 0.9974 0.24 1.8 0.9975 1.95 2.3 0.9931 1.95 2.5 0.9949 7.81 5.6 0.9930 3.91 1.6 
3-P-glycerate 0.9971 0.24 4.0 0.9932 11.72 3.9 0.9934 31.25 3.7 0.9953 7.81 3.7 0.9920 3.91 1.4 
Glucose-6P 0.9965 0.98 2.1 0.9925 7.81 4.2 0.9948 15.63 5.8 0.9904 31.25 2.6 0.9953 0.98 2.5 
Lactosea 0.9920 0.98 6.6 0.9995 0.02 0.3 0.9972 0.49 0.3 0.9981 7.81 7.4 0.9994 1.95 0.6 
Myo-Inositol 0.9980 0.98 2.4 0.9980 0.02 2.5 0.9907 0.06 2.3 0.9920 1.95 7.3 0.9986 0.12 0.9 
Glucosea 0.9984 0.06 0.5 0.9998 0.02 0.2 0.9964 0.49 0.3 0.9949 11.72 3.9 0.9992 1.95 1.9 
Fructose 0.9981 0.12 1.8 0.9985 0.03 0.5 0.9911 0.12 1.0 0.9926 3.91 3.4 0.9983 1.95 1.6 
a Compounds with a corresponding internal standard, b n=5, conc. = 62.5 µM, c n=5, conc. = 500 µM, d Standard conc. above ULOQ.  
nd, not detected. 
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 15 Summary 
The study of cellular metabolite profiles and changes therein due to genetic and 
environmental influences is termed metabolomics. A major, yet to be realized goal is 
the detection and quantification of all metabolites in a single analysis. 
In this work, a comprehensive two-dimensional gas chromatography time-of-flight 
mass spectrometry (GC×GC-TOFMS) method was designed and validated that 
assembles the entire available analytical information from each sample in one data 
matrix for subsequent statistical evaluation. For the purpose of data merging we 
developed and implemented the retention time correction and data alignment tool 
INCA (Integrative Normalization and Comparative Alignment). The INCA module 
capitalized on the characteristic fragmentation behavior of silylated metabolites upon 
EI ionization by using the integral of the m/z 73 ion trace of the trimethylsilyl (TMS) 
group as quantitative measure for all features. The method was applied to reveal 
differences in metabolite composition between (i) an Escherichia coli wild type and a 
double-mutant strain lacking the transhydrogenases UdhA and PntAB and (ii) serum 
and plasma. Subsequently, we evaluated the performance of the Statistical Compare 
alignment function introduced later by LECO for GC×GC-TOFMS data and compared 
it to INCA. 
GC×GC-TOFMS was comprehensively evaluated against various 1D-GC-MS 
techniques using a set of 43 metabolite standards from different chemical classes 
and metabolic pathways. GC×GC-TOFMS proved to be the most powerful method 
with a linear range of more than three orders of magnitude, LLOQs in the sub-
micromolar and LODs in the nanomolar range. 
GC×GC-TOFMS was also employed for absolute quantification of amino acid 
enantiomers (AAEs) as their methyl chloroformate derivatives and results were 
compared to those of a previously established 1D-GC-qMS method with single ion 
monitoring. The coupling of a γ-cyclodextrin (Rt®-γDEXsa) with an amino acid 
selective (ZB-AAA) column resulted in enhanced peak resolution. Twenty AAEs 
including the critcal peak pair L-leucine/D-isoleucine, which exhibited equal 
fragmentation behavior upon EI ionization in 1D-GC-MS, could be baseline 
separated. Except for methionine enantiomers, distinctly improved LLOQs were 
obtained. The method was applied to the analysis of AAE serum concentrations in 
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 patients suffering from liver cirrhosis and showed significantly increased D-AA 
concentrations and slightly decreased L-AA levels compared to a control group. 
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 16 Zusammenfassung 
Die Fachrichtung Metabolomik beschäftigt sich mit der umfassenden Analyse von 
zellulären Stoffwechselprodukten in Abhängigkeit von genetischen und 
umweltbedingten Einflüssen. Ein wesentliches Ziel ist die Detektion und 
Quantifizierung möglichst aller Metabolite in einer einzigen Messung. 
In dieser Arbeit wurde auf Basis der komprehensiven zweidimensionalen 
Gaschromatographie gekoppelt mit der Flugzeitmassenspektrometrie (GC×GC-
TOFMS) ein Verfahren zur Extraktion der gesamten zur Verfügung stehenden 
analytischen Informationen aus einem GC×GC-TOFMS Lauf und der 
Zusammenführung mehrerer Läufe in einer Datenmatrix zur nachfolgenden 
statistischen Auswertung des gesamten Datensatzes entwickelt. Zum Zweck der 
Datenzusammenführung haben wir den INCA (Integrative Normalization and 
Comparative Alignment) Algorithmus zur Retentionszeit-Korrektur und zum 
Datenabgleich entwickelt und implementiert. INCA nutzt das charakteristische 
Fragmentierungsverhalten von silylierten Metaboliten bei vorangehender Elektronen-
Ionisierung (EI) und setzt das Integral der m/z 73 Ionenspur der Trimethylsilylgruppe 
als quantitative Größe für alle Einträge der Peak-Listen ein. Diese vergleichende 
Metabolic Fingerprinting Strategie wurde verwendet, um globale metabolische 
Veränderungen zu detektieren. Zum einen wurde mittels GC×GC-TOFMS ein E. coli 
Wildtypstamm im Vergleich mit der entsprechenden Deletionsmutante UdhA-PntAB 
untersucht, in der beide Nikotinamidnukleotid-Transhydrogenasen fehlen. Zum 
anderen wurden Unterschiede zwischen Serum- und Plasma-Proben analysiert. In 
einem separaten Verfahren wurde die später entwickelte Statistical Compare (SC) 
Funktion von LECO zur Datenanordnung in die Datenprozessierungs-Strategie mit 
eingebunden. Diverse Vor- und Nachteile von SC wurden im direkten Vergleich zu 
INCA ermittelt. 
Das Leistungsvermögen der GC×GC-TOFMS im Vergleich zu anderen GC-MS 
Techniken wurde anhand von 43 Metaboliten von unterschiedlichen chemischen 
Klassen und metabolischen Stoffwechselwegen evaluiert. GC×GC-TOFMS erwies 
sich als die leistungsfähigste Methode mit linearen Bereichen von mehr als drei 
Größenordnungen, unteren Bestimmungsgrenzen im sub-mikromolaren und 
Nachweisgrenzen im nanomolaren Bereich. 
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Desweiteren wurde GC×GC-TOFMS zur absoluten Quantifizierung von Aminosäure 
Enantiomeren als deren Methylchloroformat Derivate angewendet. Die Resultate 
wurden mit denen einer im Vorfeld etablierten 1D-GC-qMS Methode mit Einzelionen-
Nachweis verglichen. Die Kopplung einer γ-Cyclodextrin (Rt®-γDEXsa) mit einer 
Aminosäure-selektiven (ZB-AAA) Säule führte zu einer deutlich verbesserten 
Auflösung. Zwanzig Aminosäure Enantiomere konnten bis zur Grundlinie 
voneinander getrennt werden, einschließlich des kritischen Peakpaares L-Leucin/D-
Isoleucin, das in der 1D-GC-MS zur gleichen Retentionszeit eluierte und dasselbe 
Fragmentierungsmuster zeigte. Es wurden, mit Ausnahme der Methionin 
Enantiomere, im Allgemeinen verbesserte untere Bestimmungsgrenzen erzielt. Die 
Methode wurde zur Bestimmung der Konzentrationen von Aminosäure Enantiomeren 
in Serumproben von Leberzirrhose-Patienten angewandt. Im Vergleich zu einer 
Kontroll-Gruppe wurden erhöhte D- und leicht verminderte L-Aminosäure 
Konzentrationen festgestellt. 
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